var title_f34_5_34896="Cavernous malformation bleed";
var content_f34_5_34896=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F68000&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F68000&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    MRI of a cerebral cavernous malformation with old hemorrhage",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 283px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A dark hemosiderin ring around the cavernous malformation is evident on this T-2 weighted MR image, suggestive of old hemorrhage.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Guy Rordorf, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_5_34896=[""].join("\n");
var outline_f34_5_34896=null;
var title_f34_5_34897="Contents: Geriatric medicine";
var content_f34_5_34897=[" <script type=\"text/javascript\">",
"  $$.inlineInitCustomer(",
"	false);",
"	var quirksmode = document.compatMode == \"CSS1Compat\";",
"	if (quirksmode) {",
"		$(\"html\").addClass(\"ie-standards\");",
"	}",
" </script>",
" <div id=\"message-wrap\">",
"  <div id=\"message-bg\">",
"  </div>",
"  <iframe id=\"message-bk\">",
"  </iframe>",
"  <dl id=\"message-container\">",
"   <dt id=\"message-title\">",
"   </dt>",
"   <dd id=\"message-body\">",
"   </dd>",
"   <dd id=\"message-controls\">",
"   </dd>",
"  </dl>",
" </div>",
" <div id=\"topPanel\">",
"  <div id=\"header\">",
"   <div id=\"header_container\">",
"    <h2 id=\"logo\">",
"     <a href=\"./toc\">",
"      Wolters Kluwer Health UpToDate",
"     </a>",
"    </h2>",
"    <div id=\"header_right\">",
"     <div id=\"searchpanel\">",
"      <a href=\"/login\" id=\"loginbutton\">",
"       Log in",
"      </a>",
"      <div id=\"cmsSearchBox\">",
"       <div class=\"header-search\">",
"        <form action=\"./search\" id=\"cmssearch\" method=\"get\" name=\"SearchForm\">",
"         <div class=\"header-search-left\">",
"          <input autocomplete=\"off\" class=\"searchfield\" id=\"cmsTxtBox\" name=\"search\" placeholder=\"Search UpToDate\" type=\"text\"/>",
"         </div>",
"         <div class=\"header-search-right\">",
"          <input alt=\"Search\" id=\"cmsSearchSubmit\" src=\"/sites/all/themes/uptodate/images/search_button.png\" type=\"image\"/>",
"         </div>",
"         <div class=\"clear\">",
"         </div>",
"        </form>",
"       </div>",
"      </div>",
"      <div id=\"cms_lang_dropdown\">",
"       <form accept-charset=\"UTF-8\" action=\"/\" id=\"lang-dropdown-form\" method=\"post\">",
"        <div class=\"form-item form-type-select form-item-lang-dropdown-select\">",
"         <select class=\"lang-dropdown-select-element form-select\" id=\"edit-lang-dropdown-select\" name=\"lang_dropdown_select\" style=\"width:100px\">",
"          <option selected=\"selected\" value=\"en\">",
"           English",
"          </option>",
"          <option value=\"ja\">",
"           ���������������������������",
"          </option>",
"         </select>",
"        </div>",
"        <input name=\"lang_dropdown_type\" type=\"hidden\" value=\"language\">",
"         <input name=\"en\" type=\"hidden\" value=\"/\">",
"          <input name=\"ja\" type=\"hidden\" value=\"/ja\">",
"           <noscript>",
"            <div>",
"             <input class=\"form-submit\" id=\"edit-submit\" name=\"op\" type=\"submit\" value=\"Go\"/>",
"            </div>",
"           </noscript>",
"           <input name=\"form_build_id\" type=\"hidden\" value=\"form-on4lUWpxHun_wp6revUkjCG6rK2IBuCGME9Cw0HXeok\">",
"            <input name=\"form_id\" type=\"hidden\" value=\"lang_dropdown_form\">",
"            </input>",
"           </input>",
"          </input>",
"         </input>",
"        </input>",
"       </form>",
"      </div>",
"      <div class=\"clear\">",
"      </div>",
"     </div>",
"     <ul id=\"utility\">",
"      <li class=\"first\">",
"       <a href=\"/home/about-us\">",
"        About Us",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/news-events\">",
"        News &amp; Events",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/contact-us\">",
"        Contact Us",
"       </a>",
"      </li>",
"      <li class=\"last\">",
"       <a href=\"/help\">",
"        Help",
"       </a>",
"      </li>",
"     </ul>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"nav\">",
"    <ul>",
"     <li id=\"productTab\">",
"      <a href=\"/home/product\">",
"       Product",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"editoralTab\">",
"      <a href=\"/home/editorial\">",
"       Editorial",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"whyUptodateTab\">",
"      <a href=\"/home/why-uptodate\">",
"       Why UpToDate",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"supscriptionOptionsTab\">",
"      <a href=\"/home/subscription-options\">",
"       Subscription Options",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"/store\">",
"       Subscribe",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"wkhcsTab\">",
"      <a href=\"/home/wolters-kluwer-health-clinical-solutions\">",
"       Wolters Kluwer Health Clinical Solutions",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"    </ul>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"greyBar\">",
"    <div id=\"greyBarTitle\">",
"     <span class=\"emphasis\">",
"      <a href=\"mobipreview.htm?3/3/3134\">",
"       Contents",
"      </a>",
"     </span>",
"     <img src=\"./../images/space_arrows.myextg\">",
"      <a href=\"mobipreview.htm?1/34/1568\">",
"       Family Medicine and General Practice",
"      </a>",
"      <img src=\"./../images/space_arrows.myextg\">",
"       Geriatric medicine",
"      </img>",
"     </img>",
"    </div>",
"    <div id=\"greyBarButtons\">",
"     <div id=\"printGB\">",
"      <a class=\"icontxt\" href=\"?view=print\">",
"       <img align=\"middle\" alt=\"Print this page\" border=\"0\" height=\"20\" src=\"./../images/icn_print.myextg\" width=\"24\"/>",
"      </a>",
"      <a class=\"icontxt\" href=\"?view=print\" title=\"Print this page\">",
"       Print",
"      </a>",
"     </div>",
"    </div>",
"   </div>",
"   <!-- menuMessage.jsp -->",
"   <!-- /menuMessage.jsp -->",
"  </div>",
"  <!-- header -->",
" </div>",
" <!-- topPanel -->",
" <div id=\"leftPanel\">",
"  <ul>",
"   <li>",
"    <a href=\"mobipreview.htm?3/45/3806\">",
"     Specialties",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"mobipreview.htm?18/22/18798\">",
"     Patient Information",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"mobipreview.htm?3/13/3294\">",
"     What's New",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"mobipreview.htm?0/37/606\">",
"     Calculators",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"mobipreview.htm?0/40/654\">",
"     Authors and Editors",
"    </a>",
"   </li>",
"  </ul>",
" </div>",
" <!-- leftPanel -->",
" <div id=\"rightPanel\">",
"  <noscript>",
"   <div id=\"javascriptDisabled\">",
"    It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"   </div>",
"  </noscript>",
"  <div id=\"printHeader\">",
"   <div id=\"printHeaderLogo\">",
"    <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"    </img>",
"   </div>",
"   <div id=\"printHeaderText\">",
"    Official reprint from UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"    <a href=\"file://www.uptodate.com\">",
"     www.uptodate.com",
"    </a>",
"    <br>",
"     &copy;2013 UpToDate",
"     <sup>",
"      &reg;",
"     </sup>",
"    </br>",
"   </div>",
"   <div id=\"printHeaderLinks\">",
"    <a href=\"#\" id=\"printHeaderPrint\" rel=\"\" title=\"Click here to print\">",
"     Print",
"    </a>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"     Back",
"    </a>",
"   </div>",
"  </div>",
"  <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" id=\"tocTable\" width=\"100%\">",
"   <trs>",
"    <tds>",
"     <h1>",
"      Contents:",
"			Geriatric medicine",
"     </h1>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds valign=\"top\">",
"     <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">",
"      <trs>",
"       <tds>",
"        <strong>",
"         Abuse",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?17/27/17850\">",
"           Elder mistreatment: Abuse, neglect, and financial exploitation",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Cardiovascular disease",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?13/17/13592\">",
"           Clinical evaluation of lower extremity chronic venous disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?15/59/16314\">",
"           Coronary reperfusion for acute myocardial infarction in older adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?10/32/10760\">",
"           Treatment of dyslipidemia in the older adult",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?33/36/34377\">",
"           Valvular heart disease in elderly adults",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Dementia",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?1/55/1913\">",
"           Cholinesterase inhibitors in the treatment of dementia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?1/55/1914\">",
"           Clinical features and diagnosis of dementia with Lewy bodies",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?11/61/12249\">",
"           Dementia and delirium in HIV-infected patients",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?33/41/34455\">",
"           Epidemiology, pathology, and pathogenesis of dementia with Lewy bodies",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?36/57/37786\">",
"           Etiology, clinical manifestations, and diagnosis of vascular dementia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?27/25/28057\">",
"           Evaluation of cognitive impairment and dementia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?12/20/12618\">",
"           Frontotemporal dementia: Clinical features and diagnosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?0/25/408\">",
"           Frontotemporal dementia: Treatment",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?15/36/15946\">",
"           Parkinson disease dementia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?40/25/41369\">",
"           Prevention of dementia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?20/34/21031\">",
"           Prognosis and treatment of dementia with Lewy bodies",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?35/22/36202\">",
"           Risk factors for dementia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?4/28/4552\">",
"           Safety and societal issues related to dementia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?9/55/10104\">",
"           Treatment and prevention of vascular dementia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?26/48/27402\">",
"           Treatment of behavioral symptoms related to dementia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?33/4/33865\">",
"           Treatment of dementia",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         End of life care",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?40/13/41178\">",
"           Approach to symptom assessment in palliative care",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?37/60/38858\">",
"           Assessment and management of depression in palliative care",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?2/37/2650\">",
"           End of life considerations for heart failure patients",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?19/1/19477\">",
"           Ethical considerations in effective pain management at the end of life",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?42/63/44024\">",
"           Ethical issues near the end of life",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?24/12/24778\">",
"           Euthanasia and physician assisted suicide",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?31/16/32008\">",
"           Hospice: Philosophy of care and appropriate utilization in the United States",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?14/8/14473\">",
"           Legal aspects of end of life care",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?27/52/28490\">",
"           Overview of comprehensive patient assessment in palliative care",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?35/7/35962\">",
"           Overview of managing common non-pain symptoms in palliative care",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?12/37/12890\">",
"           Pain assessment and management in the last weeks of life",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?29/6/29801\">",
"           Palliative care: Benefits, services, and models of care",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?20/23/20855\">",
"           Palliative care: Issues specific to geriatric patients",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?27/25/28058\">",
"           Pediatric palliative care",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?29/4/29769\">",
"           Psychosocial issues at the end of life",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?40/15/41208\">",
"           Religion, spirituality, and end of life care",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?4/11/4280\">",
"           Sexuality in palliative care",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?38/6/39015\">",
"           Survival estimates in advanced cancer",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Endocrine disease",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?39/56/40842\">",
"           Bisphosphonates in the management of osteoporosis in postmenopausal women",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?42/10/43173\">",
"           Calcitonin in the prevention and treatment of osteoporosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?11/56/12170\">",
"           Calcium and vitamin D supplementation in osteoporosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?35/53/36696\">",
"           Clinical manifestations and diagnostic evaluation of benign prostatic hyperplasia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?35/23/36213\">",
"           Clinical manifestations, diagnosis, and evaluation of osteoporosis in men",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?21/33/22040\">",
"           Denosumab for osteoporosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?10/55/11128\">",
"           Diagnosis and evaluation of osteoporosis in postmenopausal women",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?12/22/12650\">",
"           Endocrine changes with aging",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?31/45/32473\">",
"           Epidemiology and etiology of osteoporosis in men",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?6/25/6553\">",
"           Epidemiology and etiology of premenopausal osteoporosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?33/19/34104\">",
"           Epidemiology and pathogenesis of benign prostatic hyperplasia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?41/35/42553\">",
"           Evaluation and treatment of premenopausal osteoporosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?8/31/8698\">",
"           Medical treatment of benign prostatic hyperplasia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?28/55/29561\">",
"           Osteoporosis after solid organ or stem cell transplantation",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?36/19/37178\">",
"           Osteoporosis in patients with chronic kidney disease: Diagnosis, evaluation, and management",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?4/13/4314\">",
"           Overview of testosterone deficiency in elderly men",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?13/60/14279\">",
"           Overview of the clinical manifestations of hyperthyroidism in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?38/52/39754\">",
"           Overview of the management of osteoporosis in postmenopausal women",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?15/26/15786\">",
"           Parathyroid hormone therapy for osteoporosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?3/53/3929\">",
"           Pathogenesis of osteoporosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?41/54/42855\">",
"           Pathogenesis, clinical features, and evaluation of glucocorticoid-induced osteoporosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?17/26/17831\">",
"           Postmenopausal hormone therapy in the prevention and treatment of osteoporosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?17/36/17994\">",
"           Prevention and treatment of glucocorticoid-induced osteoporosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?32/21/33113\">",
"           Prevention of osteoporosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?39/28/40393\">",
"           Screening for osteoporosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?40/32/41481\">",
"           Selective estrogen receptor modulators for osteoporosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?30/58/31657\">",
"           Treatment of osteoporosis in men",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?0/42/682\">",
"           Treatment of type 2 diabetes mellitus in the elderly patient",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?43/28/44487\">",
"           Use of biochemical markers of bone turnover in osteoporosis",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         General",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?15/34/15913\">",
"           Accidental hypothermia in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?3/19/3385\">",
"           Approach to the evaluation of older drivers",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?22/43/23223\">",
"           Approach to the patient with dizziness",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?2/35/2617\">",
"           Approach to the patient with weight loss",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?42/38/43624\">",
"           Comprehensive geriatric assessment",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?30/0/30730\">",
"           Drug prescribing for older adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?11/32/11786\">",
"           Etiology and clinical manifestations of vitamin B12 and folate deficiency",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?33/26/34215\">",
"           Failure to thrive in elderly adults: Evaluation",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?41/29/42455\">",
"           Failure to thrive in elderly adults: Management",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?22/4/22602\">",
"           Falls in older persons: Risk factors and patient evaluation",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?28/7/28792\">",
"           Frailty",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?9/12/9417\">",
"           Gait disorders of elderly patients",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?37/18/38186\">",
"           Geriatric health maintenance",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?31/12/31946\">",
"           Geriatric nutrition: Nutritional issues in older adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?18/31/18937\">",
"           Hip fractures in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?14/61/15322\">",
"           Hospital management of older adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?11/9/11417\">",
"           Managing multiple comorbidities",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?41/9/42138\">",
"           Medical care of the nursing home patient in the United States",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?32/58/33706\">",
"           Medical consultation for patients with hip fracture",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?37/24/38282\">",
"           Normal aging",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?32/22/33130\">",
"           Overview of geriatric rehabilitation: Program components and settings for rehabilitation",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?8/60/9161\">",
"           Physical activity and exercise in older adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?33/20/34120\">",
"           Pressure ulcers: Epidemiology, pathogenesis, clinical manifestations, and staging",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?8/12/8393\">",
"           Prevention of falls and complications of falls in community-dwelling older persons",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?30/59/31673\">",
"           Prevention of falls in nursing care facilities and the hospital setting",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?1/1/1049\">",
"           Prevention of pressure ulcers",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?36/10/37034\">",
"           Screening for colorectal cancer: Strategies in patients at average risk",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?36/12/37064\">",
"           Treatment of pressure ulcers",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Gynecologic disease",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?20/8/20618\">",
"           Differential diagnosis of vulvar lesions",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Hematologic disease",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?22/0/22538\">",
"           Anemia in the older adult",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?1/14/1258\">",
"           Anticoagulation in older adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?28/29/29146\">",
"           Treatment of acute myeloid leukemia in older adults",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Infectious disease",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?41/19/42295\">",
"           Approach to the adult with asymptomatic bacteriuria",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?31/54/32618\">",
"           Evaluation of infection in the older adult",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?25/34/26152\">",
"           Important sites and pathogens causing infections in long-term care facilities",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?21/12/21705\">",
"           Pneumococcal vaccination in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?0/30/489\">",
"           Principles of infection control in long-term care facilities",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?36/8/37002\">",
"           Seasonal influenza vaccination in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?43/24/44422\">",
"           Urinary tract infection associated with urethral catheters",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Malignancy",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?34/0/34826\">",
"           Adjuvant systemic therapy for older women with early stage breast cancer",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?10/51/11066\">",
"           Adjuvant therapy for resected colon cancer in elderly patients",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?40/56/41864\">",
"           Comprehensive geriatric assessment for patients with cancer",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?14/43/15029\">",
"           Management of malignant gliomas in elderly patients",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?23/55/24441\">",
"           Prostate cancer in elderly patients",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?10/42/10922\">",
"           Systemic chemotherapy for cancer in elderly persons",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?35/38/36455\">",
"           Systemic therapy for advanced non-small cell lung cancer in elderly patients and patients with a poor performance status",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?40/31/41466\">",
"           Therapy for metastatic colorectal cancer in elderly patients and those with a poor performance status",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?39/60/40903\">",
"           Treatment of metastatic breast cancer in older women",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Neurologic disease",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?14/13/14554\">",
"           Clinical manifestations of Parkinson disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?39/56/40841\">",
"           Seizures and epilepsy in the elderly patient: Etiology, clinical presentation, and diagnosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?17/6/17512\">",
"           Treatment of seizures and epilepsy in the elderly patient",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Ophthalmic disease",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?6/52/6986\">",
"           Age-related macular degeneration: Clinical presentation, etiology, and diagnosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?2/19/2362\">",
"           Cataract in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?14/59/15289\">",
"           Open-angle glaucoma: Epidemiology, clinical presentation, and diagnosis",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Psychiatric disease",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?38/37/39514\">",
"           Diagnosis and management of late-life depression",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?38/10/39081\">",
"           Diagnosis of delirium and confusional states",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?15/60/16330\">",
"           Geriatric bipolar disorder: Acute treatment",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?7/23/7545\">",
"           Geriatric bipolar disorder: Epidemiology, clinical features, assessment, and diagnosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?22/4/22601\">",
"           Geriatric bipolar disorder: Maintenance treatment and prognosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?30/29/31190\">",
"           Grief and bereavement",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?40/21/41305\">",
"           Overview of electroconvulsive therapy (ECT) for adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?27/33/28185\">",
"           Prevention and treatment of delirium and confusional states",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?10/8/10377\">",
"           Suicidal ideation and behavior in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?40/28/41416\">",
"           Unipolar major depression in adults: Indications for and efficacy of electroconvulsive therapy (ECT)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Pulmonary disease",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?5/43/5818\">",
"           Diagnosis and management of asthma in older adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?10/48/11014\">",
"           Emergency airway management in the geriatric patient",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?7/31/7671\">",
"           Sleep apnea and other causes of impaired sleep in older adults",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Renal disease and hypertension",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?28/31/29174\">",
"           Hemodialysis in the elderly patient",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?42/29/43480\">",
"           Renal transplantation and the elderly patient",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?24/27/25018\">",
"           Treatment of hypertension in the elderly patient, particularly isolated systolic hypertension",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Rheumatologic disease",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?13/32/13832\">",
"           Clinical manifestations and diagnosis of polymyalgia rheumatica",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?18/33/18969\">",
"           Clinical manifestations of giant cell (temporal) arteritis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?11/49/12056\">",
"           Clinical manifestations of osteoarthritis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?32/32/33287\">",
"           Diagnosis and classification of osteoarthritis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?33/50/34599\">",
"           Diagnosis of giant cell (temporal) arteritis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?26/0/26630\">",
"           Glenohumeral osteoarthritis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?9/29/9687\">",
"           Investigational approaches to the pharmacologic therapy of osteoarthritis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?2/30/2538\">",
"           Nonpharmacologic therapy of osteoarthritis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?34/59/35769\">",
"           Overview of hyperkyphosis in older persons",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?18/42/19114\">",
"           Pathogenesis of osteoarthritis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?40/2/40994\">",
"           Patient guidelines for weight-resistance training in osteoarthritis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?14/23/14714\">",
"           Pharmacologic therapy of osteoarthritis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?28/43/29370\">",
"           Risk factors for and possible causes of osteoarthritis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?12/9/12440\">",
"           Surgical therapy of osteoarthritis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?33/26/34217\">",
"           Treatment of giant cell (temporal) arteritis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?39/41/40598\">",
"           Treatment of polymyalgia rheumatica",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?7/28/7621\">",
"           Weight-resistance exercises in patients with osteoarthritis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?5/19/5427\">",
"           Weight-resistance training in patients with osteoarthritis",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Surgery",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?35/60/36810\">",
"           Estimation of cardiac risk prior to noncardiac surgery",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?10/4/10314\">",
"           Preoperative medical evaluation of the healthy patient",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Urinary incontinence",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?29/14/29929\">",
"           Clinical presentation and diagnosis of urinary incontinence",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?7/1/7192\">",
"           Epidemiology, risk factors, and pathogenesis of urinary incontinence",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?27/29/28122\">",
"           Nocturia: Clinical presentation, diagnosis, and treatment",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?1/32/1546\">",
"           Pelvic organ prolapse and stress urinary incontinence in women: Combined surgical treatment",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?42/10/43177\">",
"           Stress urinary incontinence in women: Choosing a primary surgical procedure",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?15/43/16055\">",
"           Stress urinary incontinence in women: Choosing a type of midurethral sling",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?43/23/44409\">",
"           Stress urinary incontinence in women: Persistent/recurrent symptoms after surgical treatment",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?16/58/17319\">",
"           Stress urinary incontinence in women: Preoperative evaluation for a primary procedure",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?32/49/33562\">",
"           Stress urinary incontinence in women: Retropubic midurethral slings",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?32/4/32842\">",
"           Treatment of urinary incontinence",
"          </a>",
"         </li>",
"        </ul>",
"       </tds>",
"      </trs>",
"     </div>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"     <img height=\"10\" src=\"./../images/spacer.myextg\" width=\"1\"/>",
"    </tds>",
"   </trs>",
"  </div>",
"  <div id=\"footer\">",
"   <div id=\"footerNav\">",
"    <ul>",
"     <li>",
"      <a href=\"file://www.wolterskluwerhealth.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Wolters Kluwer Health",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.factsandcomparisons.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Facts &amp; Comparisons&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medispan.com\" rel=\"nofollow\" target=\"_blank\">",
"       Medi-Span&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationordersets.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Order Sets",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationmedical.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Medical",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://pharmacyonesource.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Pharmacy OneSource&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medicom.com.cn/\" rel=\"nofollow\" target=\"_blank\">",
"       Medicom",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.lexi.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Lexicomp",
"      </a>",
"     </li>",
"     <li class=\"last\">",
"      <a href=\"/home/privacy-policy\">",
"       Privacy Policy",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"   <div id=\"footerLogo\">",
"    <a href=\"./toc\">",
"     Wolters Kluwer Health | UpToDate",
"    </a>",
"   </div>",
"   <div id=\"supportFooter\">",
"    <span class=\"sfInfo\">",
"     &copy; 2013 UpToDate, Inc. All rights reserved.",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Release: 21.3 - C21.34",
"    </span>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <span class=\"sfInfo\">",
"     <a href=\"/home/terms-use\">",
"      Terms of Use",
"     </a>",
"    </span>",
"    <br/>",
"    <span class=\"sfInfo\">",
"     Licensed to:",
"     <span class=\"emphasis\">",
"      UpToDate Marketing Professional",
"     </span>",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Support Tag: [0505-95.154.198.148-6529EC8A95-14]",
"     <br/>",
"    </span>",
"   </div>",
"  </div>",
" </div>",
" <!-- rightPanel -->",
"</body>"].join("\n");
var script_f34_5_34897=[""].join("\n");
var outline_f34_5_34897=null;
var title_f34_5_34898="Lupus pernio - nasal tip";
var content_f34_5_34898=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F76184&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F76184&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Lupus pernio in sarcoidosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    An erythematous to violaceous plaque is present on the nose of this patient with cutaneous sarcoidosis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_5_34898=[""].join("\n");
var outline_f34_5_34898=null;
var title_f34_5_34899="Neomycin and polymyxin B: Patient drug information";
var content_f34_5_34899=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Neomycin and polymyxin B: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/7/9332?source=see_link\">",
"     see \"Neomycin and polymyxin B: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?4/14/4324?source=see_link\">",
"     see \"Neomycin and polymyxin B: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F200576\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Neosporin&reg; G.U. Irrigant",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F200577\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Neosporin&reg; Irrigating Solution",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10015820\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691634",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to rinse the bladder.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10015819\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702591",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to neomycin, polymyxin B, or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701080",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are pregnant or may be pregnant.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10015824\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696934",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not use this drug for more than 10 days unless told to do so by your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10015825\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697898",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Bladder irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698344",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Skin irritation.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10015827\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699009",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad bladder irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10015822\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694770",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take this drug by mouth. It is for use as a bladder rinse only.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694871",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Follow what your doctor has told you to do.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10015823\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696583",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696485",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not use 2 doses or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10015828\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699394",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a refrigerator. Throw away any part of the solution not used after 2 days.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10015829\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11804 Version 32.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-200.131.240.2-C7EAEF3114-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_5_34899=[""].join("\n");
var outline_f34_5_34899=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F200576\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F200577\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10015820\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10015819\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10015824\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10015825\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10015827\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10015822\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10015823\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10015828\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10015829\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?9/7/9332?source=related_link\">",
"      Neomycin and polymyxin B: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?4/14/4324?source=related_link\">",
"      Neomycin and polymyxin B: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f34_5_34900="Uvular edema tonsillectomy";
var content_f34_5_34900=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F83871&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F83871&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Uvular edema after tonsillectomy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 392px; height: 504px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Glenn C Isaacson, MD, FAAP, FACS.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_5_34900=[""].join("\n");
var outline_f34_5_34900=null;
var title_f34_5_34901="Ethosuximide: Patient drug information";
var content_f34_5_34901=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Ethosuximide: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/54/13158?source=see_link\">",
"     see \"Ethosuximide: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?2/34/2598?source=see_link\">",
"     see \"Ethosuximide: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F168739\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Zarontin&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F168740\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Zarontin&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10884524\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700454",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug comes with an extra patient fact sheet called a Medication Guide. Read it with care. Read it again each time this drug is refilled.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10011326\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2692054",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat seizures.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10011325\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702084",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to ethosuximide or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10011330\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696820",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not run out of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697780",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Wear disease medical alert ID (identification).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696966",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Follow laws about driving with a seizure problem.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697179",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have been taking this drug for many weeks, talk with your doctor before stopping. You may want to slowly stop this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697282",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have kidney disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697290",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have liver disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697307",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have mental illness, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698465",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood work checked. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696900",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take St John's wort with this drug. This drug may not work as well.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696611",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid beer, wine, mixed drinks, or other drugs and natural products that slow your actions.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s4128402",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you drink grapefruit juice or eat grapefruit often, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10011331\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698060",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling lightheaded, sleepy, having blurred eyesight, or a change in thinking clearly. Avoid driving and doing other tasks or actions that call for you to be alert or have clear eyesight until you see how this drug affects you.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698011",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Trouble moving around.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697998",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698984",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not hungry.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697875",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Anemia, low white blood cell count, and low platelet count may rarely happen.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697880",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Arthritis-like health problem may rarely happen.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10011333\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699077",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of infection. These include a fever of 100.5&deg;F (38&deg;C) or higher, chills, very bad sore throat, ear or sinus pain, cough, more sputum or change in color of sputum, pain with passing urine, mouth sores, wound that will not heal, or anal itching or pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699075",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of low mood (depression), thoughts of killing yourself, nervousness, emotional ups and downs, thinking that is not normal, anxiety, or lack of interest in life.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699058",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in thinking clearly and with logic.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699019",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699038",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad muscle pain or weakness.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699033",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad joint pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699105",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any bruising or bleeding.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698999",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Pinpoint red spots on your skin.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699049",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad skin irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698972",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Mouth sores.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698670",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       For women, if you get pregnant while taking this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698512",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If seizures are worse or not the same after starting this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10011328\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695786",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take as you have been told, even if you feel well.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695913",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with or without food.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2696421",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Liquid:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696107",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Those who have feeding tubes may also use the liquid. Flush the feeding tube before and after this drug is given.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10011329\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696460",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. This could cause seizures. Talk with your doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10011334\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699278",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Protect liquid (solution) from light.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10011335\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12454 Version 36.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-200.167.4.114-2B3BC00349-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_5_34901=[""].join("\n");
var outline_f34_5_34901=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F168739\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F168740\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10884524\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10011326\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10011325\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10011330\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10011331\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10011333\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10011328\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10011329\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10011334\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10011335\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?12/54/13158?source=related_link\">",
"      Ethosuximide: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?2/34/2598?source=related_link\">",
"      Ethosuximide: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f34_5_34902="Ciclesonide (oral inhalation): Drug information";
var content_f34_5_34902=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Ciclesonide (oral inhalation): Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?34/34/35365?source=see_link\">",
"    see \"Ciclesonide (oral inhalation): Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?22/26/22949?source=see_link\">",
"    see \"Ciclesonide (oral inhalation): Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F8002707\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Alvesco&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F8002711\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Alvesco&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F8007866\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Corticosteroid, Inhalant (Oral)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F8002780\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Asthma:",
"     </b>",
"     Oral inhalation (Alvesco&reg;):",
"     <b>",
"      Note:",
"     </b>",
"     Titrate to the lowest effective dose once asthma stability is achieved:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <i>",
"      U.S. labeling:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Prior therapy with bronchodilators alone: Initial: 80 mcg twice daily (maximum dose: 320 mcg/day)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Prior therapy with inhaled corticosteroids: Initial: 80 mcg twice daily (maximum dose: 640 mcg/day)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Prior therapy with oral corticosteroids: Initial: 320 mcg twice daily (maximum dose: 640 mcg/day)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <i>",
"      Canadian labeling:",
"     </i>",
"     Initial: 400 mcg once daily; maintenance: 100-800 mcg/day (1-2 puffs once daily; more severe asthma may require 400 mcg twice daily).",
"     <b>",
"      Note:",
"     </b>",
"     Canadian Thoracic Society 2010 Asthma Management guidelines recommendation: Doses &gt;200 mcg/day may provide minimal additional benefit while increasing risks for adverse events; add-on therapy should be considered prior to dose increases &gt;200 mcg/day (Lougheed, 2010).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <i>",
"      Global Strategy for Asthma Management and Prevention, 2011:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &ldquo;Low&rdquo; dose: 80-160 mcg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &ldquo;Medium&rdquo; dose: &gt;160-320 mcg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &ldquo;High&rdquo; dose: &gt;320 mcg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">",
"     <b>",
"      Conversion from oral to orally-inhaled steroid:",
"     </b>",
"     Initiation of oral inhalation therapy should begin in patients who have previously been stabilized on oral corticosteroids (OCS). A gradual dose reduction of OCS should begin ~7-10 days after starting inhaled therapy. U.S. labeling recommends reducing prednisone dose no more rapidly than &le;2.5 mg/day on a weekly basis. The Canadian labeling recommends decreasing the daily dose of prednisone by 1 mg (or equivalent of other OCS) every 7 days in closely monitored patients, and every 10 days in patients whom close monitoring is not possible. In the presence of withdrawal symptoms, resume previous OCS dose for 1 week before attempting further dose reductions.",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F8002779\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?22/26/22949?source=see_link\">",
"      see \"Ciclesonide (oral inhalation): Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Asthma:",
"     </b>",
"     Oral inhalation (Alvesco&reg;):",
"     <b>",
"      Note:",
"     </b>",
"     Titrate to the lowest effective dose once asthma stability is achieved:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <i>",
"      U.S. labeling:",
"     </i>",
"     Children &ge;12 years: Refer to adult dosing.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <i>",
"      Canadian labeling:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Children 6-11 years: Initial: 100-200 mcg once daily; maintenance: 100-200 mcg/day (1-2 puffs once daily).",
"     <b>",
"      Note:",
"     </b>",
"     Canadian Thoracic Society 2010 Asthma Management guidelines recommend dose titration in children 6-11 years who fail to achieve an adequate response in spite of adherence to therapy and/or lack of alternative factors (eg, environmental triggers) which might impair response (Lougheed, 2010).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Children &ge;12 years: Refer to adult dosing.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <i>",
"      Global Strategy for Asthma Management and Prevention, 2011:",
"     </i>",
"     Children &gt;5 years: Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F8002781\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F14080402\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no dosage adjustments provided in the manufacturer labeling (has not been studied); however, dose adjustments may not be necessary as  &le;20% of drug is eliminated renally.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F14080403\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Dosage adjustments are not necessary.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F8002812\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Aerosol, for oral inhalation:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Alvesco&reg;: 80 mcg/inhalation (6.1 g); 160 mcg/inhalation (6.1 g) [contains ethanol; 60 metered actuations]",
"    </p>",
"   </div>",
"   <div class=\"block foccan drugH1Div\" id=\"F8002813\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: Canada",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aerosol for oral inhalation:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Alvesco&reg;: 100 mcg/inhalation [30-, 60-, and 120 metered actuations]; 200 mcg/inhalation [30-, 60-, and 120 metered actuations]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F8002712\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F8002790\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;margin-left:0em;display:inline\">",
"     Remove mouthpiece cover, place inhaler in mouth, close lips around mouthpiece, and inhale slowly and deeply. Press down on top of inhaler after slow inhalation has begun. Remove inhaler while holding breath for approximately 10 seconds. Breathe out slowly and replace mouthpiece on inhaler. Rinse mouth with water (and spit out) after inhalation. Do not wash or place inhaler in water. Clean mouthpiece using a dry cloth or tissue once weekly. Discard after the \"discard by\" date or after labeled number of doses has been used, even if container is not completely empty.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Shaking is not necessary since drug is formulated as a solution aerosol. Prime inhaler prior to initial use or if not in use for &ge;7-10 days by releasing 3 puffs into the air.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F8002713\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;margin-left:0em;display:inline\">",
"     Prophylactic management of bronchial asthma",
"    </p>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F8002729\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Central nervous system: Headache (&le;11%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Respiratory: Nasopharyngitis (&le;11%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Cardiovascular: Facial edema (&ge;3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Central nervous system: Dizziness (&ge;3%), fatigue (&ge;3%), dysphonia (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Dermatologic: Urticaria (&ge;3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Gastrointestinal: Gastroenteritis (&ge;3%), oral candidiasis (&ge;3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Neuromuscular &amp; skeletal: Arthralgia (&ge;3%), musculoskeletal chest pain (&ge;3%), back pain (&ge;3%), extremity pain (&ge;3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Ocular: Conjunctivitis (&ge;3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Otic: Ear pain (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Respiratory: Upper respiratory infection (&le;9%),  nasal congestion (&le;6%), pharyngolaryngeal pain (&le;5%), hoarseness (&ge;3%), pneumonia (&ge;3%), sinusitis (&ge;3%), paradoxical bronchospasm (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Miscellaneous: Influenza (&ge;3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     &lt;1% (Limited to important or life-threatening): ALT increased, angioedema (with swelling of lip/pharynx/tongue), bruising, candidiasis (pharyngeal), cataract, chest discomfort, cough, dry throat, dysgeusia, dyspepsia, GGT increased, intraocular pressure increased, nausea, palpitation, pharyngitis, rash, throat irritation,  weight gain, xerostomia",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F8002718\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to ciclesonide or any component of the formulation; primary treatment of acute asthma or status asthmaticus",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">",
"     Canadian labeling: Additional contraindications (not in U.S. labeling): Untreated fungal, bacterial, or tuberculosis infections of the respiratory tract; moderate-to-severe bronchiectasis",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F8002719\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Adrenal suppression: May cause hypercorticism or suppression of hypothalamic-pituitary-adrenal (HPA) axis, particularly in younger children or in patients receiving high doses for prolonged periods. HPA axis suppression may lead to adrenal crisis. Withdrawal and discontinuation of a corticosteroid should be done slowly and carefully. Particular care is required when patients are transferred from systemic corticosteroids to inhaled products due to possible adrenal insufficiency or withdrawal from steroids, including an increase in allergic symptoms. Patients receiving &gt;20 mg per day of prednisone (or equivalent) may be most susceptible. Fatalities have occurred due to adrenal insufficiency in asthmatic patients during and after transfer from systemic corticosteroids to aerosol steroids; aerosol steroids do",
"     <b>",
"      not",
"     </b>",
"     provide the systemic steroid needed to treat patients having trauma, surgery, or infections.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Bronchospasm: May occur with wheezing after inhalation; if this occurs, stop steroid and treat with a fast-acting bronchodilator.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Immunosuppression: Prolonged use of corticosteroids may also increase the incidence of secondary infection, mask acute infection (including fungal infections), prolong or exacerbate viral infections, or limit response to vaccines. Exposure to chickenpox and measles should be avoided; use caution in patients with active or quiescent TB infections (contraindicated in Canada) or in patients with ocular herpes.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Kaposi's sarcoma: Prolonged treatment with corticosteroids has been associated with the development of Kaposi's sarcoma (case reports); if noted, discontinuation of therapy should be considered.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Psychiatric disturbances: Corticosteroid use may cause psychiatric disturbances, including depression, euphoria, insomnia, mood swings, and personality changes. Pre-existing psychiatric conditions may be exacerbated by corticosteroid use.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Thrush:",
"     <i>",
"      Candida albicans",
"     </i>",
"     infections (mostly mild-to-moderate) of the mouth and pharynx may occur with orally inhaled corticosteroid use; interruption of therapy may be necessary at times while antifungal therapy is employed; advise patients to rinse mouth after use.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull;	Vasculitis: Rare cases of vasculitis (Churg-Strauss syndrome) or other eosinophilic conditions (eg, vasculitic rash, decreased pulmonary function, cardiac complications) can occur.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Asthma: Supplemental steroids (oral or parenteral) may be needed during stress or severe asthma attacks. Not to be used in status asthmaticus or for the relief of acute bronchospasm.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Cardiovascular disease: Use with caution following acute myocardial infarction (MI); corticosteroids have been associated with myocardial rupture. Use with caution in patients with HF; long-term use has been associated with fluid retention and hypertension.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Diabetes: Use with caution in patients with diabetes mellitus; may alter glucose production/regulation leading to hyperglycemia.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Hepatic impairment: Systemic exposure to the active metabolite is increased in moderate-to-severe impairment; however, dosage adjustments are not recommended in hepatic impairment; monitor for increased systemic effects, particularly in patients with severe hepatic impairment, including cirrhosis.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Myasthenia gravis: Use with caution in patients with myasthenia gravis; exacerbation of symptoms has occurred with corticosteroids especially during initial treatment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Ocular disease: Use with caution in patients with cataracts and/or glaucoma; increased intraocular pressure, open-angle glaucoma, and cataracts have occurred with prolonged use. Consider routine eye exams in chronic users.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Osteoporosis: Use with caution in patients with osteoporosis; high doses and/or long-term use of corticosteroids have been associated with increased bone loss and osteoporotic fractures.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Renal impairment: Use in renally-impaired patients has not been studied; however, &le;20% of drug is eliminated renally.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Seizure disorders: Use with caution in patients with a history of seizure disorder; seizures have been reported with adrenal crisis.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Thyroid disease: Changes in thyroid status may necessitate dosage adjustments; metabolic clearance of corticosteroids increases in hyperthyroid patients and decreases in hypothyroid ones.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull;	 Elderly: Because of the risk of adverse effects, systemic corticosteroids should be used cautiously in the elderly in the smallest possible effective dose for the shortest duration.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull;	 Pediatrics: Orally inhaled corticosteroids may cause a reduction in growth velocity in pediatric patients (~1 cm per year [range: 0.3-1.8 cm per year] and related to dose and duration of exposure). To minimize the systemic effects of orally inhaled corticosteroids, each patient should be titrated to the lowest effective dose. Growth should be routinely monitored in pediatric patients.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull;	 Discontinuation of therapy: Withdraw systemic therapy with gradual tapering of dose. There have been reports of systemic corticosteroid withdrawal symptoms (eg, joint/muscle pain, lassitude, depression) when withdrawing oral inhalation therapy.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F8002758\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP3A4 (major);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F8002759\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aldesleukin: Corticosteroids may diminish the antineoplastic effect of Aldesleukin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticorelin: Corticosteroids may diminish the therapeutic effect of Corticorelin. Specifically, the plasma ACTH response to corticorelin may be blunted by recent or current corticosteroid therapy.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Moderate): May decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dasatinib: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: Corticosteroids may enhance the adverse/toxic effect of Deferasirox. Specifically, the risk for GI ulceration/irritation or GI bleeding may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hyaluronidase: Corticosteroids may diminish the therapeutic effect of Hyaluronidase.  Management: Patients receiving corticosteroids (particularly at larger doses) may not experience the desired clinical response to standard doses of hyaluronidase.  Larger doses of hyaluronidase may be required.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivacaftor: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May increase the serum concentration of CYP3A4 Substrates. Management: Minimize doses of CYP3A4 substrates, and monitor for increased concentrations/toxicity, during and 2 weeks following treatment with mifepristone. Avoid cyclosporine, dihydroergotamine, ergotamine, fentanyl, pimozide, quinidine, sirolimus, and tacrolimus.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Telaprevir: Corticosteroids may decrease the serum concentration of Telaprevir. Telaprevir may increase the serum concentration of Corticosteroids.  Management: Concurrent use of telaprevir and systemic corticosteroids is not recommended.  When possible, consider alternatives.  If used together, employ extra caution and monitor closely for excessive corticosteroid effects and diminished telaprevir effects.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F8002714\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F8002715\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Teratogenic effects were reported following subcutaneous administration of ciclesonide in animal reproduction studies.  Hypoadrenalism may occur in infants born to mothers receiving corticosteroids during pregnancy. Inhaled corticosteroids are recommended for the treatment of asthma during pregnancy (ACOG, 2008; NAEPP, 2005).",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F8002717\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/use caution",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F13766078\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Systemic corticosteroids are excreted in human milk. It is not known if sufficient quantities of ciclesonide are absorbed following oral inhalation to produce detectable amounts in breast milk; however, oral absorption is limited (&lt;1%). The use of inhaled corticosteroids is not considered a contraindication to breast-feeding (NAEPP, 2005).",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F8002815\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Aerosol solution",
"     </b>",
"     (Alvesco Inhalation)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     80 mcg/ACT (6.1 g): $191.11",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     160 mcg/ACT (6.1 g): $191.11",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F8002793\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Growth (adolescents) and signs/symptoms of HPA axis suppression/adrenal insufficiency; ocular effects (eg, cataracts, increased intraocular pressure, glaucoma)",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F11390225\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Alvesco (AR, AU, BE, BG, BR, CH, CO, CZ, DE, EE, FI, GB, GR, HK, HN, IE, IL, KP, MY, NL, NO, NZ, PL, PT, SE, SG, TW, VE);",
"     </li>",
"     <li>",
"      Cicletex (AR);",
"     </li>",
"     <li>",
"      Disbronc (CN)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F8002765\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Ciclesonide is a nonhalogenated, glucocorticoid prodrug that is hydrolyzed to the pharmacologically active metabolite des-ciclesonide following administration. Des-ciclesonide has a high affinity for the glucocorticoid receptor and exhibits anti-inflammatory activity. The mechanism of action for corticosteroids is believed to be a combination of three important properties &minus; anti-inflammatory activity, immunosuppressive properties, and antiproliferative actions.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F8002767\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Absorption: 52% (lung deposition)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Protein binding: &ge;99%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metabolism: Ciclesonide hydrolyzed to its active metabolite, des-ciclesonide via esterases in nasal mucosa and lungs; des-ciclesonide undergoes further hepatic metabolism primarily via  CYP3A4 and to a lesser extent via CYP2D6",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bioavailability: 63% (active metabolite)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Half-life elimination: ~6-7 hours (active metabolite)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Time to peak: ~1 hour (active metabolite)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Excretion: Feces (66%); urine (&le;20% as active metabolite)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      &ldquo;Asthma In Pregnancy,&rdquo; ACOG Practice Bulletin No. 90. American College of Obstetricians and Gynecologists,",
"      <i>",
"       Obstet Gynecol",
"      </i>",
"      , 2008, 111(2 Pt 1):457-64.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/5/34902/abstract-text/18238988/pubmed\" id=\"18238988\" target=\"_blank\">",
"        18238988",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Bateman E, Karpel J, Casale T, et al, &ldquo;Ciclesonide Reduces the Need for Oral Steroid Use in Adult Patients With Severe, Persistent Asthma,&rdquo;",
"      <i>",
"       Chest",
"      </i>",
"      , 2006, 129(5):1176-87.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/5/34902/abstract-text/16685007/pubmed\" id=\"16685007\" target=\"_blank\">",
"        16685007",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Derendorf H, &ldquo;Pharmacokinetic and Pharmacodynamic Properties of Inhaled Ciclesonide,&rdquo;",
"      <i>",
"       J Clin Pharmacol",
"      </i>",
"      , 2007, 47(6):782-9",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/5/34902/abstract-text/17412829/pubmed\" id=\"17412829\" target=\"_blank\">",
"        17412829",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      <i>",
"       Global Strategy for Asthma Management and Prevention",
"      </i>",
"      , Global Initiative for Asthma (GINA) 2011. Available at file://www.ginasthma.org",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Goedert JJ, Vitale F, Lauria C, et al, &ldquo;Risk Factors for Classical Kaposi's Sarcoma,&rdquo;",
"      <i>",
"       J Natl Cancer Inst",
"      </i>",
"      , 2002, 94(22):1712-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/5/34902/abstract-text/12441327/pubmed\" id=\"12441327\" target=\"_blank\">",
"        12441327",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lougheed MD, Lemi&egrave;re C, Dell SD, et al, &ldquo;Canadian Thoracic Society Asthma Management Continuum - 2010 Consensus Summary for Children Six Years of Age and Over, and Adults,&rdquo;",
"      <i>",
"       Can Respir J",
"      </i>",
"      , 2010, 17(1):15-24.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/5/34902/abstract-text/20186367/pubmed\" id=\"20186367\" target=\"_blank\">",
"        20186367",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      NAEPP Working Group Report on &ldquo;Managing Asthma During Pregnancy: Recommendations for Pharmacologic Treatment,&rdquo; National Institutes of Health, National Heart, Lung, and Blood Institute, NIH Publication No. 05-5236, March 2005. Available at",
"      <a href=\"file://www.nhlbi.nih.gov/health/prof/lung/asthma/astpreg/astpreg_full.pdf\" target=\"_blank\">",
"       file://www.nhlbi.nih.gov/health/prof/lung/asthma/astpreg/astpreg_full.pdf",
"      </a>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Pearlman DS, Berger WE, Kerwin E, et al, &ldquo;Once-Daily Ciclesonide Improves Lung Function and is Well Tolerated by Patients With Mild-to-Moderate Persistent Asthma,&rdquo;",
"      <i>",
"       J Allergy Clin Immunol",
"      </i>",
"      , 2005, 116(6):1206-12.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/5/34902/abstract-text/16337447/pubmed\" id=\"16337447\" target=\"_blank\">",
"        16337447",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Pedersen S, Engelst&auml;tter R, Weber HJ, et al, &ldquo;Efficacy and Safety of Ciclesonide Once Daily and Fluticasone Propionate Twice Daily in Children With Asthma,&rdquo;",
"      <i>",
"       Pulm Pharmacol Ther",
"      </i>",
"      , 2009, 22(3):214-20.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/5/34902/abstract-text/19141327/pubmed\" id=\"19141327\" target=\"_blank\">",
"        19141327",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Pedersen S, Garcia Garcia ML, Manjra A, et al, &ldquo;A Comparative Study of Inhaled Ciclesonide 160 mcg/day and Fluticasone Propionate 176 mcg/day in Children With Asthma,&rdquo;",
"      <i>",
"       Pediatr Pulmonol",
"      </i>",
"      , 2006, 41(10):954-61.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/5/34902/abstract-text/16868976/pubmed\" id=\"16868976\" target=\"_blank\">",
"        16868976",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9045 Version 36.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-199.231.185.123-63BADDD788-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_5_34902=[""].join("\n");
var outline_f34_5_34902=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8002707\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8002711\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8007866\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8002780\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8002779\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8002781\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14080402\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14080403\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8002812\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8002813\">",
"      Dosage Forms: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8002712\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8002790\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8002713\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8002729\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8002718\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8002719\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8002758\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8002759\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8002714\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8002715\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8002717\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13766078\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8002815\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8002793\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11390225\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8002765\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8002767\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9045\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9045|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?34/25/35220?source=related_link\">",
"      Ciclesonide (nasal): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?26/37/27221?source=related_link\">",
"      Ciclesonide (nasal): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?3/33/3604?source=related_link\">",
"      Ciclesonide (nasal): Pediatric drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?34/34/35365?source=related_link\">",
"      Ciclesonide (oral inhalation): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?22/26/22949?source=related_link\">",
"      Ciclesonide (oral inhalation): Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f34_5_34903="Atelectasis in children";
var content_f34_5_34903=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Atelectasis in children",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?34/5/34903/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/5/34903/contributors\">",
"     Jonathan D Finder, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?34/5/34903/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/5/34903/contributors\">",
"     Gregory Redding, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?34/5/34903/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/5/34903/contributors\">",
"     Alison G Hoppin, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?34/5/34903/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 16, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The word atelectasis is of Greek origin and means lack of stretch; in current medical usage, the term refers to collapse or loss of lung volume. Atelectasis is also defined as collapse of alveolar spaces, generally of a magnitude severe enough to appear on a plain chest radiograph. Atelectasis is a common problem in pediatric patients. The three main types of atelectasis noted in children include obstructive atelectasis, resorptive atelectasis, and compressive atelectasis. In almost all cases, atelectasis is acquired and referred to as secondary; rarely, primary atelectasis caused by congenital abnormalities may be present from birth. An overview of atelectasis in children is presented here. The radiographic appearance of atelectasis and an overview of atelectasis in adults are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/5/7255?source=see_link\">",
"     \"Radiologic patterns of lobar atelectasis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/61/35795?source=see_link\">",
"     \"Atelectasis: Types and pathogenesis in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PATHOPHYSIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;In order to understand the pathophysiology of atelectasis, a review of the normal mechanisms that prevent lung collapse is required. Elastin fibers within alveolar walls result in a tendency for the alveoli to recoil inwards. This is balanced by the outward recoil of the chest wall and the interaction between the parietal and visceral pleura. In addition, the primary mechanism that keeps the lung from collapsing at low volumes is surfactant.",
"   </p>",
"   <p>",
"    Surfactant is a complex phospholipid and protein mixture produced by type II alveolar epithelial cells. It functions to lower surface tension, which is defined by the law of Laplace:",
"   </p>",
"   <p>",
"    &nbsp;Pressure = 2 x (surface tension)",
"    <span class=\"nowrap\">",
"     /",
"    </span>",
"    radius",
"   </p>",
"   <p>",
"    As alveolar volume decreases with expiration, surface tension increases to the degree that, without surfactant, the alveolus would collapse completely. This adhesive atelectasis becomes clinically relevant in diseases that result in absent or deficient surfactant production and homeostasis, including neonatal respiratory distress syndrome, congenital surfactant protein B deficiency, and pulmonary alveolar proteinosis. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/49/31511?source=see_link\">",
"     \"Overview of neonatal respiratory distress: Disorders of transition\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/62/8168?source=see_link\">",
"     \"Clinical manifestations and etiology of pulmonary alveolar proteinosis in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In the normal lung, surfactant functions to keep alveoli open during expiration. Despite this, even a person with normal surfactant eventually will develop areas of micro-atelectasis that can progress to macro-atelectasis if coughing is prevented. In addition, it is suspected that we sigh in sleep to protect against the development of atelectasis. Yawning also may be a physiologic mechanism that prevents atelectasis.",
"   </p>",
"   <p>",
"    Children are at increased risk for development of atelectasis because their lungs lack the collateral ventilation of adults. Specifically, the lungs of children do not have pores of Kohn and canals of Lambert, which allow collateral ventilation of obstructed alveoli. Thus, following airway obstruction, air in the alveolar space is reabsorbed, and collapse occurs more readily than in adult patients. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/61/35795?source=see_link\">",
"     \"Atelectasis: Types and pathogenesis in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Infants and young children are also prone to atelectasis as compared with adults, because their chest wall is compliant and, thus, provides less outward force to oppose the elastic recoil of the lung.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Obstructive atelectasis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most common type of atelectasis in children is obstructive atelectasis, due to complete or partial large airway obstruction. Obstructive atelectasis can be further classified on the basis of anatomy as intraluminal, intrinsic to the airway wall, or extramural. Examples of intraluminal causes of atelectasis include airway foreign body, blood clot, mucus plug, and tumor (eg, carcinoid).",
"   </p>",
"   <p>",
"    Mucus plugging is the most common cause of atelectasis in the pediatric population (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef51657 graphicRef63366 \" href=\"mobipreview.htm?23/26/23974\">",
"     image 1A-B",
"    </a>",
"    ). The \"right middle lobe syndrome\" is seen in asthmatics who develop collapse of the right middle lobe (RML) in the midst of an exacerbation of asthma. It is theorized that a combination of mucus plugging, a small orifice and long segmental bronchus to this lobe, and compression from adjacent hyperinflated upper and lower lobes leads to this condition. Treatment of atelectasis in this setting is directed at controlling the underlying asthma. RML atelectasis also has been described in other diseases, primarily in the setting of mycobacterial infection; this usually is caused by extrinsic airway compression from enlarged hilar lymph nodes. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/11/24759?source=see_link\">",
"     \"Overview of nontuberculous mycobacterial infections in HIV-negative patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Airway wall disorders that can cause atelectasis include bronchomalacia and bronchial stenosis. Primary bronchomalacia is caused by a lack of structural integrity within the airway wall and usually is",
"    <strong>",
"     not",
"    </strong>",
"    associated with atelectasis. In contrast, secondary bronchomalacia can be caused by vascular compression and frequently results in atelectasis. Bronchial stenosis can impair mucociliary clearance and predispose to atelectasis and postobstructive pneumonia. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/27/29114?source=see_link\">",
"     \"Congenital anomalies of the intrathoracic airways and tracheoesophageal fistula\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Extramural bronchial compression can lead to atelectasis, especially in combination with increased airway secretions. Vascular compression can be caused by dilated pulmonary arteries in children with pulmonic valve disease, pulmonary hypertension, or cardiomegaly. Atelectasis caused by cardiomegaly can be difficult to manage and may ultimately require a surgical approach to separate the bronchus from contiguous vascular structures.",
"   </p>",
"   <p>",
"    Bronchogenic cysts or other space-occupying lesions (tumors) can also compress and obstruct bronchi and lead to obstructive atelectasis. Computed tomography (CT) and magnetic resonance imaging (MRI) are useful modalities to employ when one is attempting to determine the cause of bronchial compression. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/27/29114?source=see_link\">",
"     \"Congenital anomalies of the intrathoracic airways and tracheoesophageal fistula\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Infants and children with cystic fibrosis are especially prone to atelectasis. This is likely due to inspissated mucus within the airway leading to post obstructive atelectasis (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef53555 graphicRef66266 \" href=\"mobipreview.htm?34/59/35766\">",
"     image 2A-B",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Resorptive atelectasis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Resorptive atelectasis results from an alveolar space-filling lesion, typically pneumonia. It is especially common in patients with neuromuscular weakness who lack the ability to reinflate the collapsed area of lung. It differs from post-obstructive atelectasis in that the primary lesion is at the level of the alveolar space rather than the airway. Resorptive atelectasis can also occur in normal children. Resorptive atelectasis is especially common in patients with chest wall pain who limit their lung expansion and coughing; this is referred to as splinting. Splinting appears to be a risk factor for pneumonia, because patients avoid both deep breaths and forceful coughing. Prior to the development of antibiotics, pneumonia following rib fracture was a common cause of death. Impaired cough and splinting can also be problematic in patients with abdominal pain, particularly following laparotomy.",
"   </p>",
"   <p>",
"    Patients with respiratory muscle weakness (eg, those with muscular dystrophy, spinal muscular atrophy, or spinal cord injury) are at increased risk for mucus plugging, atelectasis, and pneumonia. The atelectasis that develops in these patients is multifactorial, but the main problem is an inability to inhale deeply and reinflate areas of collapse. This is compounded by a weak cough that prevents the expulsion of mucus plugs. It is extremely common for children with respiratory muscle weakness to develop a prolonged period of atelectasis following pneumonia. This resorptive atelectasis is perpetuated by the individual's inability to fully reinflate the lobe or segment and to expel any mucus plugs. In the absence of aggressive airway clearance treatment (eg, mechanical insufflation-exsufflation), atelectasis may persist for years.",
"   </p>",
"   <p>",
"    Postanesthetic atelectasis is a special form of resorptive atelectasis. Individuals undergoing general anesthesia are at particularly high risk for developing atelectasis for complex reasons, which include the characteristics of the anesthesia gases (use of 100 percent oxygen), the lack of sighing breaths, prolonged positioning, and reduction of end-expiratory lung volume (functional residual capacity) due to relaxation of thoracic musculature [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/5/34903/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Relaxation atelectasis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Relaxation or passive atelectasis develops when contact between the parietal and visceral pleurae is eliminated by a pleural effusion or pneumothorax [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/5/34903/abstract/2\">",
"     2",
"    </a>",
"    ]. In general, the uniform elasticity of normal lungs leads to preservation of shape even when volume is decreased, a quality called form elasticity. However, the different lobes will behave independently of each other on occasion. For example, the middle and lower lobes may shrink more than the upper lobe in the presence of a pleural effusion, while the upper lobe may be affected more by a pneumothorax [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/5/34903/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Compressive atelectasis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The final type of atelectasis seen in the pediatric population is caused by space-occupying masses within the chest. Examples include large cysts or overinflated lobes that can compress and collapse adjacent lung tissue. Cardiomegaly is another common cause of compressive atelectasis. It is common to see compressive atelectasis of adjacent lung tissue in children with congenital lobar emphysema and cystic congenital adenomatoid malformation. Compressive atelectasis is one of the indications for surgery in children with these conditions, and resolves completely after surgical correction. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/27/29114?source=see_link\">",
"     \"Congenital anomalies of the intrathoracic airways and tracheoesophageal fistula\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     PHYSICAL FINDINGS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The physical findings of atelectasis in children tend to be minimal. In most cases, there are no changes in the physical exam. As an example, in the setting of asthma and compressive right middle lobe atelectasis, the upper and lower lobes will fill the space occupied by the collapsed lobe so that breath sounds can be normal in the right axilla. Crackles",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    wheezes may be heard over areas of obstructive atelectasis if the airway obstruction is incomplete and allows some airflow. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/36/38471?source=see_link&amp;anchor=H5#H5\">",
"     \"The pediatric physical examination: Chest and abdomen\", section on 'Lungs'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    When larger areas of the lung are atelectatic, there are generally physical findings. Atelectasis of a lower lobe may result in absent breath sounds. Compensatory hyperinflation of the remaining lobes might allow the perception of some breath sounds at the lung base, but when compared to the unaffected base, the amplitude will be decreased. As noted above, if atelectasis is caused by intrabronchial mucus plug or foreign body, crackles distal to the obstruction may be audible.",
"   </p>",
"   <p>",
"    Dullness to percussion also may be noted in the setting of extensive collapse. Complete atelectasis of one lung is unusual in children but can cause tracheal deviation as well as greatly diminished or absent breath sounds in the affected hemithorax (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef73236 \" href=\"mobipreview.htm?25/11/25791\">",
"     image 3",
"    </a>",
"    ). In long-standing atelectasis, particularly that associated with an airway foreign body, post-obstructive pneumonia and localized bronchiectasis may occur and result in inspiratory (and occasional expiratory) crackles. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/33/2585?source=see_link\">",
"     \"Airway foreign bodies in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     RADIOLOGIC ASSESSMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Atelectasis is generally diagnosed on the basis of compatible radiographic findings. Pulmonary opacification, with or without associated adjacent compensatory signs, typically is evident. The atelectatic features are determined by the size of the area of volume loss and by the imaging modality utilized. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/5/7255?source=see_link\">",
"     \"Radiologic patterns of lobar atelectasis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Plain films",
"    </span>",
"    &nbsp;&mdash;&nbsp;Plain film findings include nonspecific small areas of opacity, subsegmental opacities with linear or angular margins, lobar opacities, or unilateral whole lung opacity with signs of compensatory hyperinflation, pulmonary fissural shift, mediastinal shift, or bilateral pulmonary opacification (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef80883 graphicRef59863 \" href=\"mobipreview.htm?1/57/1941\">",
"     image 4A-B",
"    </a>",
"    ). Etiologies may or may not be suggested based on the film findings.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Ultrasound",
"    </span>",
"    &nbsp;&mdash;&nbsp;Atelectasis can be diagnosed as an incidental finding on ultrasonography, such as basilar atelectasis noted on abdominal ultrasound. Normally aerated lung cannot be visualized because ultrasound waves do not penetrate gas. Atelectatic lung, however, appears as a solid, hyperechoic structure. The clinical role of ultrasound in the diagnosis of atelectasis is limited.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Other modalities",
"    </span>",
"    &nbsp;&mdash;&nbsp;Atelectatic change may appear as localized or diffuse regions of increased parenchymal attenuation on computed tomographic scans. Signs of compensatory hyperinflation and mediastinal shift may be seen. Contrast-enhanced images reveal diffuse, homogeneous enhancement in the areas of opacity.",
"   </p>",
"   <p>",
"    Atelectatic change frequently is seen in children who undergo thoracic imaging with computed tomography. When the atelectasis is seen in posterior locations in a patient scanned in the supine position (dependent atelectasis), this finding is clinically unimportant (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef57564 \" href=\"mobipreview.htm?20/4/20544\">",
"     image 5",
"    </a>",
"    ). In children intubated and anesthetized for CT scanning, higher inspiratory pressures decrease the incidence of dependent atelectasis, demonstrating the transient nature of this finding [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/5/34903/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     LABORATORY ABNORMALITIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Aside from the chest radiograph, there are few laboratory abnormalities associated with most cases of atelectasis. Indeed, one of the means of differentiating pneumonia from atelectasis is the absence of changes on complete blood count in the latter condition. Leukocytosis with a preponderance of immature forms is suggestive of pneumonia rather than atelectasis. Arterial blood gases and hemoglobin saturation usually are normal because of the protective mechanism of hypoxic vasoconstriction, which directs blood flow away from the unventilated lung to the areas of normal ventilation. However, sudden development of lobar atelectasis (such as in the post-operative patient) generally will result in some degree of hypoxemia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment of atelectasis should be directed at the underlying cause of collapse. A single approach to the radiographic finding of atelectasis cannot be applied given the spectrum of underlying causes. The literature on the treatment of atelectasis remains largely retrospective and anecdotal without many prospective, randomized trials [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/5/34903/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Chest physiotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most common treatment of atelectasis in the hospital setting is manual chest physiotherapy (percussion and drainage, deep insufflation, and saline lavage) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/5/34903/abstract/6\">",
"     6",
"    </a>",
"    ]. There are limited data supporting the efficacy of this approach [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/5/34903/abstract/5,7\">",
"     5,7",
"    </a>",
"    ]. In patients with cystic fibrosis, short-term trials suggest some efficacy of airway clearance therapies, but long-term efficacy has not been demonstrated. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/22/39274?source=see_link&amp;anchor=H9#H9\">",
"     \"Cystic fibrosis: Overview of the treatment of lung disease\", section on 'Chest physiotherapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Mechanical insufflation-exsufflation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with neuromuscular weakness and atelectasis benefit from mechanical insufflation-exsufflation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/5/34903/abstract/8\">",
"     8",
"    </a>",
"    ]. Mechanically assisted coughing greatly improves secretion clearance in the setting of respiratory infection in the patient with neuromuscular disease and should be first-line therapy for this patient population [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/5/34903/abstract/9\">",
"     9",
"    </a>",
"    ]. This modality is greatly aided by simultaneous manual augmentation of cough with either a thoracic squeeze or abdominal thrust during the expiratory phase. A 2004 American Thoracic Society consensus statement supported the use of this modality for patients with Duchenne muscular dystrophy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/5/34903/abstract/10\">",
"     10",
"    </a>",
"    ]. The use of this technique for children with neuromuscular disease has gained widespread acceptance in the United States and internationally [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/5/34903/abstract/11,12\">",
"     11,12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Intrapulmonary percussive ventilation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intrapulmonary percussive ventilation (IPV) uses a device that mobilizes secretions by rapidly oscillating a column of air via mouthpiece. Aerosolized medications can be delivered simultaneously. The use of IPV for the treatment of atelectasis has been described in case series and prospective controlled trials, as illustrated below:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one case series of four patients (three with neuromuscular disease) with atelectasis refractory to conventional therapy, three of four patients had clinical and radiographic improvement within 48 hours of initiation of IPV [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/5/34903/abstract/13\">",
"       13",
"      </a>",
"      ]. The fourth patient experienced third-degree atrioventricular block and hypoxemia during two IPV treatments but was subsequently able to tolerate IPV without these adverse effects.",
"     </li>",
"     <li>",
"      In another report, IPV was retrospectively compared to conventional chest physiotherapy in 46 children and found to be safe and efficacious [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/5/34903/abstract/14\">",
"       14",
"      </a>",
"      ]. These authors then studied IPV prospectively in mechanically ventilated children and found that those who received IPV showed greater clinical improvement in atelectasis than those who received conventional chest physiotherapy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/5/34903/abstract/14\">",
"       14",
"      </a>",
"      ]. In a small randomized controlled trial of outpatients with neuromuscular weakness, IPV resulted in a decreased rate of hospitalization and need for antibiotics [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/5/34903/abstract/15\">",
"       15",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    IPV has also been studied as a means to mobilize secretions in tracheotomized patients with Duchenne muscular dystrophy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/5/34903/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Intermittent positive pressure breathing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intermittent positive pressure breathing (IPPB) has long been used in the intensive care setting in non-intubated patients. Although widely accepted, few studies have validated its efficacy. The related technology IPV has supplanted IPPB in its role in the inpatient setting. In a Respiratory Care Clinical Practice Guideline [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/5/34903/abstract/17\">",
"     17",
"    </a>",
"    ], IPPB is suggested for patients who have impaired airway clearance, and for delivery of aerosolized medications to patients with neuromuscular weakness who are incapable of inhaling deeply. IPPB should be used with caution in patients with severe, uncontrolled bronchospasm or severe airway obstruction.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Mucolytic therapies",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     DNase",
"    </span>",
"    &nbsp;&mdash;&nbsp;Recombinant human",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?25/35/26163?source=see_link\">",
"     DNase",
"    </a>",
"    (dornase alpha) was developed for the treatment of cystic fibrosis. Clinical trials have established efficacy, particularly for patients with moderate or severe disease, and it is a recommended component of cystic fibrosis care. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/22/39274?source=see_link&amp;anchor=H5#H5\">",
"     \"Cystic fibrosis: Overview of the treatment of lung disease\", section on 'Inhaled DNase I (dornase alfa)'",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p>",
"    Considerably less information is available about the use of",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?25/35/26163?source=see_link\">",
"     DNase",
"    </a>",
"    in patients with atelectasis who do not have cystic fibrosis, and results are variable. In a retrospective descriptive study of 30 patients who received DNase (either nebulized or endotracheally instilled) for atelectasis of various causes, 25 had rapid clinical and radiographic response [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/5/34903/abstract/18\">",
"     18",
"    </a>",
"    ]. Several case reports have suggested that bronchoscopic instillation of DNase rapidly and completely treated atelectasis in the setting of mucus plugging [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/5/34903/abstract/19-21\">",
"     19-21",
"    </a>",
"    ]. In contrast, a separate case series suggested that delivery of DNase via endotracheal tube did not lead to radiographic or clinical improvement in seven mechanically ventilated children with atelectasis and without cystic fibrosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/5/34903/abstract/22\">",
"     22",
"    </a>",
"    ]. Use of this modality in RSV has been suggested [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/5/34903/abstract/23\">",
"     23",
"    </a>",
"    ] but is not widely accepted. A case report describes four neonates with respiratory failure and atelectasis who were treated with DNase, of whom three experienced clinical improvement; this suggests that this therapy also may be useful in the neonatal intensive care setting [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/5/34903/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The success of",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?25/35/26163?source=see_link\">",
"     DNase",
"    </a>",
"    for mucus plugs likely depends upon the DNA content of the plug. As most mucus plugs have little DNA content, DNase should not be considered standard therapy for this indication. A small pathological study of the composition of bronchial casts suggests that two broad categories are present: inflammatory and acellular [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/5/34903/abstract/25\">",
"     25",
"    </a>",
"    ]. Inflammatory casts are made primarily of fibrin with a dense eosinophilic infiltrate. In contrast, acellular casts are comprised of mucin with little cellular content. The nature and cause of the cast or plug may determine whether mucolytic therapy is effective.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28543338\">",
"    <span class=\"h3\">",
"     N-acetylcysteine",
"    </span>",
"    &nbsp;&mdash;&nbsp;N-acetylcysteine acts by cleaving disulfide bonds in mucus. Although it has long been used clinically as a mucolytic, both via direct instillation with a bronchoscope and via nebulizer, but no well-designed studies suggest efficacy in patients with atelectasis, with or without cystic fibrosis. A solution of 10 percent N-acetylcysteine is mucolytic in vitro, but this concentration is sufficient to induce bronchospasm in some patients. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/22/39274?source=see_link&amp;anchor=H8#H8\">",
"     \"Cystic fibrosis: Overview of the treatment of lung disease\", section on 'Inhaled N-acetylcysteine'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Invasive approaches",
"    </span>",
"    &nbsp;&mdash;&nbsp;In cases of compressive atelectasis, surgical intervention is often necessary. Compression secondary to lymphadenopathy is best treated by management of the underlying disease. Bronchoscopic examination is indicated if a foreign body is present or suspected. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/33/2585?source=see_link\">",
"     \"Airway foreign bodies in children\"",
"    </a>",
"    .) In general, bronchoscopy is considered a \"last resort\" in atelectasis management, to be used only when non-invasive therapies have failed. The literature on this approach has been largely uncontrolled and retrospective, so any benefit of bronchoscopy over non-invasive approaches has not been established [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/5/34903/abstract/26\">",
"     26",
"    </a>",
"    ]. When a mucus plug or bronchial cast is suspected, bronchoscopy may be indicated to aid in removal of the obstructing lesion. Case reports have described plastic bronchitis and atelectasis requiring bronchoscopy associated with the 2009 H1N1 virus epidemic [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/5/34903/abstract/27,28\">",
"     27,28",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?32/1/32785?source=see_link\">",
"       \"Patient information: Atelectasis (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Atelectasis is also defined as collapse of alveolar spaces, generally of a magnitude severe enough to appear on a plain chest radiograph. The three main types of atelectasis seen in children are obstructive, resorptive, and compressive atelectasis.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Obstructive atelectasis is the most common type of atelectasis in children, and is caused by complete or partial obstruction of large airways. This is typically caused by mucus plugging, particularly in children with asthma in whom it often involves the right middle lobe. Other causes of obstructive atelectasis include cystic fibrosis, bronchial stenosis, bronchogenic cyst, or compression of the airway from external structures such as vascular malformations or cardiac disease. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Obstructive atelectasis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Resorptive atelectasis results from an alveolar space-filling lesion such as pneumonia. It is especially common in patients with neuromuscular weakness who lack the ability to reinflate the collapsed area of lung or in patients with chest wall pain who limit their lung expansion and coughing. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Resorptive atelectasis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Relaxation or passive atelectasis develops when contact between the parietal and visceral pleurae is eliminated by a pleural effusion or pneumothorax. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Relaxation atelectasis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Compressive atelectasis is caused by space-occupying masses within the chest, such as large cysts or cardiomegaly. The compression also may be caused by overinflated lobes, as in congenital lobar emphysema or cystic congenital adenomatoid malformation. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Compressive atelectasis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Atelectasis in children may be associated with few or no physical findings. Crackles or wheezes may be heard if the airway obstruction is incomplete. If larger areas of the lung are affected, breath sounds may be absent. Dullness to percussion may be noted in the setting of extensive collapse. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Physical findings'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      On plain chest radiographs, findings suggestive of atelectasis include nonspecific small areas of opacity, subsegmental opacities with linear or angular margins, lobar opacities, or unilateral whole lung opacity with signs of compensatory hyperinflation, pulmonary fissural shift, mediastinal shift, or bilateral pulmonary opacification. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Plain films'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Treatment of atelectasis should be directed at the underlying cause of collapse. In patients with asthma the most important treatment is to optimize asthma therapy. The most common treatment of atelectasis in the hospital setting is manual chest physiotherapy, but little clinical evidence supports the efficacy of this approach. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Chest physiotherapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In cases of compressive atelectasis, surgical intervention is often necessary, unless the compression is due to lymphadenopathy, which is best treated by management of the underlying disease. Bronchoscopic examination is indicated if a foreign body is present or suspected, but otherwise is rarely used. (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Invasive approaches'",
"      </a>",
"      above.) &nbsp; &nbsp; &nbsp; &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/5/34903/abstract/1\">",
"      Kaditis AG, Motoyama EK, Zin W, et al. The effect of lung expansion and positive end-expiratory pressure on respiratory mechanics in anesthetized children. Anesth Analg 2008; 106:775.",
"     </a>",
"    </li>",
"    <li>",
"     Muller NL, Fraser RS, Colman NC, et al. Radiologic diagnosis of diseases of the chest, Saunders, Philadelphia, 2001.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/5/34903/abstract/3\">",
"      Stark P, Leung A. Effects of lobar atelectasis on the distribution of pleural effusion and pneumothorax. J Thorac Imaging 1996; 11:145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/5/34903/abstract/4\">",
"      Sargent MA, Jamieson DH, McEachern AM, Blackstock D. Increased inspiratory pressure for reduction of atelectasis in children anesthetized for CT scan. Pediatr Radiol 2002; 32:344.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/5/34903/abstract/5\">",
"      Schindler MB. Treatment of atelectasis: where is the evidence? Crit Care 2005; 9:341.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/5/34903/abstract/6\">",
"      Galvis AG, Reyes G, Nelson WB. Bedside management of lung collapse in children on mechanical ventilation: saline lavage--simulated cough technique proves simple, effective. Pediatr Pulmonol 1994; 17:326.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/5/34903/abstract/7\">",
"      Stiller K. Physiotherapy in intensive care: towards an evidence-based practice. Chest 2000; 118:1801.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/5/34903/abstract/8\">",
"      Miske LJ, Hickey EM, Kolb SM, et al. Use of the mechanical in-exsufflator in pediatric patients with neuromuscular disease and impaired cough. Chest 2004; 125:1406.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/5/34903/abstract/9\">",
"      Bach JR. Mechanical insufflation-exsufflation. Comparison of peak expiratory flows with manually assisted and unassisted coughing techniques. Chest 1993; 104:1553.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/5/34903/abstract/10\">",
"      Finder JD, Birnkrant D, Carl J, et al. Respiratory care of the patient with Duchenne muscular dystrophy: ATS consensus statement. Am J Respir Crit Care Med 2004; 170:456.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/5/34903/abstract/11\">",
"      Fauroux B, Guillemot N, Aubertin G, et al. Physiologic benefits of mechanical insufflation-exsufflation in children with neuromuscular diseases. Chest 2008; 133:161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/5/34903/abstract/12\">",
"      Birnkrant DJ, Bushby KM, Amin RS, et al. The respiratory management of patients with duchenne muscular dystrophy: a DMD care considerations working group specialty article. Pediatr Pulmonol 2010; 45:739.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/5/34903/abstract/13\">",
"      Birnkrant DJ, Pope JF, Lewarski J, et al. Persistent pulmonary consolidation treated with intrapulmonary percussive ventilation: a preliminary report. Pediatr Pulmonol 1996; 21:246.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/5/34903/abstract/14\">",
"      Deakins K, Chatburn RL. A comparison of intrapulmonary percussive ventilation and conventional chest physiotherapy for the treatment of atelectasis in the pediatric patient. Respir Care 2002; 47:1162.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/5/34903/abstract/15\">",
"      Reardon CC, Christiansen D, Barnett ED, Cabral HJ. Intrapulmonary percussive ventilation vs incentive spirometry for children with neuromuscular disease. Arch Pediatr Adolesc Med 2005; 159:526.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/5/34903/abstract/16\">",
"      Toussaint M, De Win H, Steens M, Soudon P. Effect of intrapulmonary percussive ventilation on mucus clearance in duchenne muscular dystrophy patients: a preliminary report. Respir Care 2003; 48:940.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/5/34903/abstract/17\">",
"      Sorenson HM, Shelledy DC, AARC. AARC clinical practice guideline. Intermittent positive pressure breathing--2003 revision &amp; update. Respir Care 2003; 48:540.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/5/34903/abstract/18\">",
"      Hendriks T, de Hoog M, Lequin MH, et al. DNase and atelectasis in non-cystic fibrosis pediatric patients. Crit Care 2005; 9:R351.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/5/34903/abstract/19\">",
"      Durward A, Forte V, Shemie SD. Resolution of mucus plugging and atelectasis after intratracheal rhDNase therapy in a mechanically ventilated child with refractory status asthmaticus. Crit Care Med 2000; 28:560.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/5/34903/abstract/20\">",
"      Gershan WM, Rusakow LS, Chetty A, Splaingard ML. Resolution of chronic atelectasis in a child with asthma after aerosolized recombinant human DNase. Pediatr Pulmonol 1994; 18:268.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/5/34903/abstract/21\">",
"      Greally P. Human recombinant DNase for mucus plugging in status asthmaticus. Lancet 1995; 346:1423.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/5/34903/abstract/22\">",
"      Boeuf B, Prouix F, Morneau S, et al. Safety of endotracheal rh DNAse (Pulmozyme) for treatment of pulmonary atelectasis in mechanically ventilated children. Pediatr Pulmonol 1998; 26:147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/5/34903/abstract/23\">",
"      Merkus PJ, de Hoog M, van Gent R, de Jongste JC. DNase treatment for atelectasis in infants with severe respiratory syncytial virus bronchiolitis. Eur Respir J 2001; 18:734.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/5/34903/abstract/24\">",
"      MacKinnon R, Wheeler KI, Sokol J. Endotracheal DNase for atelectasis in ventilated neonates. J Perinatol 2011; 31:799.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/5/34903/abstract/25\">",
"      Seear M, Hui H, Magee F, et al. Bronchial casts in children: a proposed classification based on nine cases and a review of the literature. Am J Respir Crit Care Med 1997; 155:364.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/5/34903/abstract/26\">",
"      Wu KH, Lin CF, Huang CJ, Chen CC. Rigid ventilation bronchoscopy under general anesthesia for treatment of pediatric pulmonary atelectasis caused by pneumonia: A review of 33 cases. Int Surg 2006; 91:291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/5/34903/abstract/27\">",
"      Deng J, Zheng Y, Li C, et al. Plastic bronchitis in three children associated with 2009 influenza A(H1N1) virus infection. Chest 2010; 138:1486.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/5/34903/abstract/28\">",
"      Terano C, Miura M, Fukuzawa R, et al. Three children with plastic bronchitis associated with 2009 H1N1 influenza virus infection. Pediatr Infect Dis J 2011; 30:80.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6378 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-122.72.76.133-0B08567BAA-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_5_34903=[""].join("\n");
var outline_f34_5_34903=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H21\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PATHOPHYSIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Obstructive atelectasis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Resorptive atelectasis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Relaxation atelectasis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Compressive atelectasis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      PHYSICAL FINDINGS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      RADIOLOGIC ASSESSMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Plain films",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Ultrasound",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Other modalities",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      LABORATORY ABNORMALITIES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Chest physiotherapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Mechanical insufflation-exsufflation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Intrapulmonary percussive ventilation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Intermittent positive pressure breathing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Mucolytic therapies",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - DNase",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H28543338\">",
"      - N-acetylcysteine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Invasive approaches",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/6378\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/6378|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?2/35/2609\" title=\"diagnostic image 1A\">",
"      Left upper lobe atelectasis A",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?19/20/19777\" title=\"diagnostic image 1B\">",
"      Left upper lobe atelectasis B",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?7/26/7585\" title=\"diagnostic image 2A\">",
"      CF atelectasis1",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?34/38/35425\" title=\"diagnostic image 2B\">",
"      CF atelectasis2",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?25/11/25791\" title=\"diagnostic image 3\">",
"      Right mainstem intubation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?17/53/18258\" title=\"diagnostic image 4A\">",
"      Right upper lobe atelectasis A",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?31/4/31822\" title=\"diagnostic image 4B\">",
"      Right upper lobe atelectasis B",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?20/4/20544\" title=\"diagnostic image 5\">",
"      Dependent atelectasis CT",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/33/2585?source=related_link\">",
"      Airway foreign bodies in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/61/35795?source=related_link\">",
"      Atelectasis: Types and pathogenesis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/62/8168?source=related_link\">",
"      Clinical manifestations and etiology of pulmonary alveolar proteinosis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/27/29114?source=related_link\">",
"      Congenital anomalies of the intrathoracic airways and tracheoesophageal fistula",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/22/39274?source=related_link\">",
"      Cystic fibrosis: Overview of the treatment of lung disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/49/31511?source=related_link\">",
"      Overview of neonatal respiratory distress: Disorders of transition",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/11/24759?source=related_link\">",
"      Overview of nontuberculous mycobacterial infections in HIV-negative patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?32/1/32785?source=related_link\">",
"      Patient information: Atelectasis (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/5/7255?source=related_link\">",
"      Radiologic patterns of lobar atelectasis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/36/38471?source=related_link\">",
"      The pediatric physical examination: Chest and abdomen",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f34_5_34904="Constrictive bronchiolitis High";
var content_f34_5_34904=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F62630&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F62630&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1040px;\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Constrictive bronchiolitis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 237px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    High power view of constrictive bronchiolitis in a patient with severe progressive airflow obstruction following toxic fume exposure. There is complete obliteration of the bronchiole by submucosal scarring. The surrounding alveolar spaces are spared. Pentachrome stain.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Talmadge E King Jr, MD.",
"    </div>",
"   </div>",
"  </div>",
"  <div class=\"figure\" style=\"width: 450px\">",
"   <div class=\"ttl\">",
"    Section through a bronchiole",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 220px; height: 251px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Bronchioles are distinguished from bronchi by a lack of glands and cartilage. Hematoxylin and eosin stain.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     From: Corrin, B. Development and structure of the normal lung. In: Clinical Atlas Respiratory Diseases, Turner-Warwick, M, Hodson, ME, Corrin, B, Kerr, IH (Eds), JB Lippincott, London, 1989.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_5_34904=[""].join("\n");
var outline_f34_5_34904=null;
var title_f34_5_34905="Subacute and chronic low back pain: Surgical treatment";
var content_f34_5_34905=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Subacute and chronic low back pain: Surgical treatment",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?34/5/34905/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/5/34905/contributors\">",
"     Roger Chou, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?34/5/34905/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/5/34905/contributors\">",
"     Steven J Atlas, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?34/5/34905/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/5/34905/contributors\">",
"     Fenny H Lin, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?34/5/34905/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 31, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The long-term outcome of acute low back pain is generally favorable. Rapid improvement in pain and disability and return to work are the norm in the first month [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/5/34905/abstract/1\">",
"     1",
"    </a>",
"    ]. Further improvement generally occurs over three months. However, given how common low back pain is, persistent symptoms affect millions of individuals. Subacute low back pain is commonly defined as back pain lasting between 4 and 12 weeks and chronic low back pain as pain that persists for 12 or more weeks. For those with chronic symptoms, few achieve the complete resolution they seek, but rather treatment focuses on controlling pain and improving activity.",
"   </p>",
"   <p>",
"    This topic will address indications and outcomes of surgery for patients with subacute and chronic back pain who do not respond to more conservative treatment. Conservative and nonsurgical interventional therapies for patients with subacute and chronic low back pain are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/24/19850?source=see_link\">",
"     \"Subacute and chronic low back pain: Pharmacologic and noninterventional treatment\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/52/39753?source=see_link\">",
"     \"Subacute and chronic low back pain: Nonsurgical interventional treatment\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A summary of the multiple interventions for subacute and chronic low back pain discussed in these topics is presented in a set of tables (",
"    <a class=\"graphic graphic_table graphicRef72902 \" href=\"mobipreview.htm?7/38/7789\">",
"     table 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef61982 \" href=\"mobipreview.htm?38/46/39661\">",
"     table 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef77165 \" href=\"mobipreview.htm?15/17/15646\">",
"     table 3",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef63348 \" href=\"mobipreview.htm?43/23/44412\">",
"     table 4",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Two related issues, surgical treatment for patients with lumbar stenosis and the initial management of patients with acute low back pain, are also discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/15/22776?source=see_link\">",
"     \"Lumbar spinal stenosis: Treatment and prognosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/21/13658?source=see_link\">",
"     \"Treatment of acute low back pain\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     INDICATIONS FOR SPINAL SURGERY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Only a small minority of patients suffering from low back pain ever require surgery. However, rates of surgical procedures are rising in the US, particularly for spinal fusion in patients with nonspecific back pain [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/5/34905/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Urgent evaluation by a neurosurgeon or orthopedic surgeon with experience in back surgery is indicated for the small minority of low back pain patients with severe or progressive motor weakness, or signs and symptoms of cauda equina syndrome (see",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/27/6585?source=see_link\">",
"     \"Clinical features and diagnosis of neoplastic epidural spinal cord compression, including cauda equina syndrome\"",
"    </a>",
"    ). In patients without urinary retention, the probability of cauda equina syndrome is approximately 1 in 10,000 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/5/34905/abstract/3\">",
"     3",
"    </a>",
"    ]. The presence of mild foot drop or other minor motor deficits due to lumbar disc prolapse with radiculopathy is",
"    <strong>",
"     not",
"    </strong>",
"    an absolute indication for surgery, because many such patients will recover with non-surgical treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/5/34905/abstract/4,5\">",
"     4,5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the absence of severe or progressive weakness, or signs of cauda equina syndrome, surgery is an option for patients with chronic low back pain and significantly impaired quality of life who have not responded to adequate trials of non-surgical approaches.",
"   </p>",
"   <p>",
"    There is no evidence that early referral for surgery, in the absence of severe or progressive neurologic deficits, improves outcomes for lumbar disc prolapse and radiculopathy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/5/34905/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]. Referral for surgery is an elective option for patients with persistent disabling symptoms after at least four to six weeks of standard nonsurgical therapies.",
"   </p>",
"   <p>",
"    Surgical interventions fall into two broad treatment categories: radicular pain conditions, most commonly due to disc herniation or spinal stenosis with or without degenerative spondylolisthesis; and non-specific low back pain (often presumed to be related to degenerative changes in the intervertebral discs or facet joints).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     NONSPECIFIC LOW BACK PAIN WITH DEGENERATIVE DISC CHANGES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most patients with subacute and chronic low back pain and degenerative lumber disc disease do not have radicular symptoms or symptoms attributable to a specific condition, and are categorized as having non-specific low back pain [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/5/34905/abstract/6\">",
"     6",
"    </a>",
"    ]. There is ongoing debate about the role for surgery in the treatment of chronic nonspecific low back pain. Surgery is not recommended for patients with non-specific subacute low back pain. Regardless of treatment (disc replacement, fusion, or nonsurgical), few patients report complete symptom resolution.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Spinal fusion",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most common surgery for chronic nonspecific low back pain with lumbar disc degenerative changes is vertebral fusion, a procedure that unites (fuses) two or more vertebral bodies together. The goal is to restrict spinal motion and remove the degenerated disc (the presumed pain generator) in order to relieve symptoms. A variety of fusion techniques are practiced. All involve the placement of a bone graft between the vertebrae. Fusion can be performed with or without supplemental hardware (instrumentation), such as plates, screws, or cages, that serve as an internal splint while the bone graft heals. Fusion alters the normal mechanics of the spine and is associated with an increase in long-term degenerative changes in adjacent spine segments.",
"   </p>",
"   <p>",
"    A systematic review of four randomized trials found that disability outcomes between lumbar vertebral fusion and nonsurgical treatment did not meet US Food and Drug Administration (FDA) criteria for clinically meaningful differences [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/5/34905/abstract/7\">",
"     7",
"    </a>",
"    ]. Enrolled patients had at least one year of low back pain that did not respond to standard nonsurgical therapy. Patients with significant psychiatric or somatic illness, ongoing compensation issues, or other chronic pain conditions were generally excluded. One randomized trial of 289 patients found fusion superior to unstructured nonsurgical therapy at two year follow-up for decrease in pain (33 versus 7 percent), reduction in disability (25 versus 6 percent), return to work (36 versus 13 percent) and self perception of improvement (63 versus 29 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/5/34905/abstract/8\">",
"     8",
"    </a>",
"    ]. Three trials found no clear or clinically relevant difference between surgery and nonsurgical treatment, but two trials were underpowered and a third trial had a high crossover rate between groups [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/5/34905/abstract/9-11\">",
"     9-11",
"    </a>",
"    ]. Four-year follow-up of two of these randomized trials again failed to demonstrate any benefit of spinal fusion surgery compared with cognitive intervention and exercises [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/5/34905/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    One factor for the inconsistent results between trials may be the nonsurgical treatment chosen as the comparator. In trials that showed no, or only modest, differences, the nonsurgical treatment was an intensive rehabilitation program incorporating a cognitive behavioral component [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/5/34905/abstract/9-11\">",
"     9-11",
"    </a>",
"    ]. In the trial that reported better results with surgery, the nonsurgical treatment intervention was less intensive and more heterogeneous [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/5/34905/abstract/8\">",
"     8",
"    </a>",
"    ]. The systematic review concluded that although methodologic flaws limit firm conclusions, surgery may be more effective than unstructured nonsurgical care, but may not be more effective than intense rehabilitation with cognitive behavioral therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/5/34905/abstract/7\">",
"     7",
"    </a>",
"    ]. A subsequent systematic review came to a similar conclusion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/5/34905/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Practice guidelines from the American Pain Society, based on this subsequent review, recommend that surgery be presented as an option to patients with persistent (&gt;1 year) disabling nonradicular low back pain with discussion of its risks and benefits and with interdisciplinary rehabilitation discussed as similarly effective [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/5/34905/abstract/14\">",
"     14",
"    </a>",
"    ]. Shared decision making with regard to surgery should take into account that most patients who undergo surgery will have some residual symptoms.",
"   </p>",
"   <p>",
"    A Medicare advisory committee reviewed lumbar fusion surgery in older patients with low back pain related to degenerative disc disease. The report noted flaws in existing studies (poorly defined clinical conditions and outcomes, lack of standardization for control populations, few elderly patients, few randomized studies) and concluded that there was uncertainty regarding the effectiveness of lumbar fusion for older patients with chronic back pain [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/5/34905/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A small (n = 41) trial published subsequent to the above reviews differed from previous studies in that it only enrolled patients with chronic low back pain who had single level degenerative disc disease at",
"    <span class=\"nowrap\">",
"     L4/L5",
"    </span>",
"    or",
"    <span class=\"nowrap\">",
"     L5/S1,",
"    </span>",
"    positive provocative discography, and positive response to a local anesthetic disc block. It allocated patients based on a minimization technique to surgery (anterior interbody fusion or posterolateral fusion with screws) versus a minimal exercise intervention (walking and stretching). Like the earlier trial that compared fusion to standard rehabilitation, this trial found that both surgical procedures were associated with lower pain scores and improved function [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/5/34905/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Randomized trials that directly compare different fusion techniques are inconsistent and do not permit reliable judgment about comparative benefits. The use of instrumentation is popular with some surgeons. A systematic review found that instrumentation was associated with improved fusion rates without a clear difference in clinical outcome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/5/34905/abstract/17\">",
"     17",
"    </a>",
"    ]. The use of bone morphogenetic proteins to speed bone fusion has significantly increased between 2002 and 2006 in the United States [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/5/34905/abstract/18\">",
"     18",
"    </a>",
"    ]. In a large database sampling 20 percent of community hospitals in the US, use of bone morphogenetic proteins for spinal fusion was associated with greater hospital costs, a longer hospital stay (3.2 percent increase after multivariable adjustment), but no difference in complication rates for lumbar procedures [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/5/34905/abstract/18\">",
"     18",
"    </a>",
"    ]. Additionally, a review raised concerns about potential underreporting of harms from industry-sponsored studies of bone morphogenetic proteins for spine surgery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/5/34905/abstract/19\">",
"     19",
"    </a>",
"    ]; additional analyses with access to all industry held data are in progress [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/5/34905/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    No operative deaths were reported in any of the trials comparing fusion to nonsurgical therapy. A systematic review that included observational data estimated the following complication rates for spinal fusion: in-hospital mortality, 0.2 percent; deep wound infection, 1.5 percent; deep vein thrombosis, 1.6 percent; pulmonary embolus, 2.2 percent; and nerve injury, 2.8 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/5/34905/abstract/21\">",
"     21",
"    </a>",
"    ]. One trial found that more technically difficult procedures were associated with higher rates of complications, but did not result in better overall outcome at two years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/5/34905/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Lumbar disc replacement",
"    </span>",
"    &nbsp;&mdash;&nbsp;Artificial disc replacement is a newer alternative to fusion. A theoretic advantage of lumbar disc replacement compared to fusion is that a prosthetic disc could help preserve normal range of motion and spine mechanics. This could reduce the long-term degenerative changes in adjacent vertebral segments that have been observed following spinal fusion. However, the evidence to date suggests that the efficacy of this approach is similar to that of spinal fusion.",
"   </p>",
"   <p>",
"    A 2012 systematic review of seven randomized trials evaluated the use of disc replacement for chronic low back pain [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/5/34905/abstract/23\">",
"     23",
"    </a>",
"    ]. Five trials (n = 1301) specifically compared disc replacement versus fusion for improvement of pain (visual analog score) and function (Oswestry Disability Index) outcomes at two years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/5/34905/abstract/24-28\">",
"     24-28",
"    </a>",
"    ]. All studies had risk of bias due to lack of blinding and industry sponsorship. Pooled results demonstrated no significant difference in pain scores between the two groups. There was a statistically, but not clinically, significant difference in improvement in function in the disc replacement group compared to the fusion group (4.3 points, 95% CI 1.9-6.7).",
"   </p>",
"   <p>",
"    Only one trial has compared lumbar disc replacement versus a multidisciplinary rehabilitation program [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/5/34905/abstract/29\">",
"     29",
"    </a>",
"    ]. This study included 173 patients with chronic pain, disability, and L4-5",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    L5-S1 degenerative disc disease. Those randomly assigned to disc replacement had a statistically, but not clinically, significant improvement in disability score (difference of 8 points on a 100 point scale) at two year follow-up, and lower pain scores (difference 12 points on a 100 point scale) compared to the rehabilitation arm. Six patients in the surgery group had complications resulting in physical impairment, with one patient requiring a lower leg amputation following revision surgery. No major complications were reported for the rehabilitation arm.",
"   </p>",
"   <p>",
"    A key limitation of existing evidence for the role of lumbar disc replacement is the lack of longer-term follow-up to assess efficacy and failure rates necessitating device removal and potential conversion to a fusion procedure. Regardless of treatment (disc replacement, fusion, or nonsurgical), few patients report complete symptom resolution.",
"   </p>",
"   <p>",
"    Disc replacement is approved by the FDA for patients who are in good health, &le;60 years old, with disease limited to one disc between L3 and S1 and no associated deformity, spondylolisthesis, or neurologic deficit. Patients should be treated by surgeons experienced in performing disc replacement, to minimize complications and length of hospitalization [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/5/34905/abstract/30\">",
"     30",
"    </a>",
"    ]. Guidelines from the American Pain Society found insufficient evidence regarding long-term benefits and harms of disc replacement to support recommendations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/5/34905/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Other disc prostheses and nucleus pulposus prostheses are under development, but have not yet been approved by the FDA.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     LUMBAR DISC PROLAPSE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The purpose of surgery for symptomatic lumbar disc prolapse is to relieve symptoms due to inflammation of, or pressure on, affected nerve roots by removing part of, or the entire, disc.",
"   </p>",
"   <p>",
"    A variety of discectomy techniques are available:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The traditional open discectomy is performed with a standard surgical incision, often with the aid of eyepiece (loupe) magnification. It frequently involves a laminectomy (removal of the vertebral lamina to relieve pressure on nerve roots).",
"     </li>",
"     <li>",
"      Microdiscectomy, a refinement of open discectomy, has become the most common procedure and can be performed on an outpatient basis. It involves a smaller incision in the back, with visualization through an operating microscope, followed by a hemilaminectomy (removal of part of the lamina in order to adequately visualize the disc) and removal of the disc fragment compressing the affected nerve or nerves.",
"     </li>",
"     <li>",
"      Minimally invasive techniques include percutaneous manual nucleotomy, automated percutaneous lumbar discectomy, laser discectomy, endoscopic discectomy, microendoscopic discectomy, coblation nucleoplasty, and the disc DeKompressor [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/5/34905/abstract/31\">",
"       31",
"      </a>",
"      ]. Tubular or trochar discectomy is a less invasive technique in which a tubular retractor is inserted over a guidewire, gaining access to the disc by muscle splitting rather than muscle incision and detachment [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/5/34905/abstract/32\">",
"       32",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Minimally invasive techniques involve smaller incisions and surgery with the aid of indirect visualization; some techniques employ lasers to vaporize parts of the disc or automated techniques for removing portions of the disc. They have the potential advantage of quicker recovery from surgery compared to standard open discectomy or microdiscectomy.",
"   </p>",
"   <p>",
"    Major post-operative complications are rare for any of the discectomy procedures [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/5/34905/abstract/33-35\">",
"     33-35",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Standard open discectomy or microdiscectomy",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Compared to no surgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;Randomized trials comparing surgery to nonsurgical management for lumbar disc prolapse with persistent radiculopathy indicate that patients who undergo surgery experience faster and larger improvements, though substantial improvements are observed regardless of whether patients undergo surgery or not and in some studies outcomes appear similar within two years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/5/34905/abstract/5,33,34,36,37\">",
"     5,33,34,36,37",
"    </a>",
"    ]. The available randomized trials have not been blinded (which can only be accomplished by performing sham surgical procedures) and thus are likely to be influenced by a patient's expectations of treatment results.",
"   </p>",
"   <p>",
"    An early trial comparing surgery to nonsurgical therapy for lumbar disc prolapse with nerve root compression found one-year outcome superior for standard open discectomy, with a lower likelihood of poor results (OR 0.37, 95% CI 0.14-0.99); differences were no longer present after 4 to 10 years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/5/34905/abstract/5\">",
"     5",
"    </a>",
"    ]. One-quarter of patients randomized to nonsurgical therapy eventually underwent surgery, making longer-term results difficult to interpret.",
"   </p>",
"   <p>",
"    The Spine Patient Outcomes Research Trials (SPORT) are multicenter, randomized trials, with associated prospective cohort studies, evaluating surgery versus non-surgical therapy for three spinal conditions: lumbar disc herniation, spinal stenosis without degenerative spondylolisthesis, and spinal stenosis with degenerative spondylolisthesis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/5/34905/abstract/38\">",
"     38",
"    </a>",
"    ]. The SPORT trial of surgery for prolapsed lumbar disc found standard open discectomy or microdiscectomy (technique left to discretion of the surgeon) no better than nonoperative treatment for pain relief and improvement in function after three months, in an intention-to-treat analysis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/5/34905/abstract/34\">",
"     34",
"    </a>",
"    ]. Patients in both groups improved an average of 20 to 30 points (on a 100 point scale) on pain and functional status scores. Results up to four years showed persistent, comparable benefits for surgical and nonoperative treatment in an intention-to-treat analysis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/5/34905/abstract/39\">",
"     39",
"    </a>",
"    ]. These results likely underestimate the relative benefit of surgical treatment since about half of patients assigned to either arm crossed over to the other intervention.",
"   </p>",
"   <p>",
"    A concurrent prospective cohort study of SPORT patients who met eligibility criteria but declined randomization reported moderate benefits at three months through two years for surgical treatment, compared to nonoperative treatment (10 to 15 points on the 0 to 100 SF-36 bodily pain scale; 12 to 15 points on the 0 to 100 SF-36 physical function scale; 2 to 4 points on the 0 to 24 Sciatica Bothersomeness Index), after adjusting for potential confounders [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/5/34905/abstract/40\">",
"     40",
"    </a>",
"    ]. These results were similar to those of an on-treatment analysis of the randomized trial [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/5/34905/abstract/34\">",
"     34",
"    </a>",
"    ]. A combined analysis at four years included all patients from the randomized trial and observation cohort who underwent surgery and compared them with patients who had nonsurgical care [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/5/34905/abstract/39\">",
"     39",
"    </a>",
"    ]. Patients who had surgery for lumbar disc herniation, compared to those who did not undergo surgery, had greater improvement for all outcomes evaluated (pain, functional status, and disability indices) other than work status.",
"   </p>",
"   <p>",
"    An earlier long-term (up to 10 years) cohort study also found early benefits from discectomy that became attenuated with longer follow-up [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/5/34905/abstract/36\">",
"     36",
"    </a>",
"    ]. As with all observational studies, interpretation of these results should take into account the possibility of confounding due to factors contributing to the patients' choice of treatment, expectations from treatment, and perception of symptoms.",
"   </p>",
"   <p>",
"    A cost effectiveness analysis using SPORT data from 775 surgical patients and 416 nonoperative patients (on-treatment analysis of randomized trial and observational cohorts) found that surgery, compared to nonoperative care, resulted in higher costs but better health outcomes at two years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/5/34905/abstract/41\">",
"     41",
"    </a>",
"    ]. The cost per QALY gained with surgery ranged from $34,000 to $69,000, depending on imputed surgical costs, and is comparable with other commonly accepted health care interventions. The cost per QALY gained with surgery decreased when reevaluated at four years, indicating increasing value for surgery, compared to nonoperative management with longer follow-up [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/5/34905/abstract/42\">",
"     42",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Two randomized trials compared outcomes for early microdiscectomy or initial non-surgical treatment in patients with lumbar disc herniation and radicular pain lasting 6 to 12 weeks [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/5/34905/abstract/33,37\">",
"     33,37",
"    </a>",
"    ]. In both trials, about 40 percent of patients assigned to initial nonsurgical treatment underwent surgery.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the larger trial (n = 283), 125 patients underwent microdiscectomy at a mean of 2.2 weeks; 55 of the 142 patients assigned to conservative therapy had surgery at a mean of 19 weeks [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/5/34905/abstract/33\">",
"       33",
"      </a>",
"      ]. There was no difference in disability scores after one year between the group assigned to early surgery or conservative treatment. Patients assigned to surgery reported a faster rate of perceived recovery (HR 1.97, 95% CI 1.72-2.22). A concurrent cost utility analysis found surgery likely to be cost-effective from a societal perspective [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/5/34905/abstract/43\">",
"       43",
"      </a>",
"      ]. Early surgery was associated with increased quality adjusted life years (QALY) and negligible costs compared to nonsurgical therapy after factoring in costs saved by early productivity.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Perceived recovery at one year for both groups was 95 percent. Patient satisfaction decreased for both groups with longer term follow-up. At two-year follow-up, there was no difference in patient reports of unsatisfactory outcomes (20 percent) or disability scores between the two groups [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/5/34905/abstract/44\">",
"     44",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A smaller (n = 58) randomized trial found no difference between microdiscectomy and nonsurgical therapy (isometric exercises) on any outcome after two years; microdiscectomy was moderately superior for leg pain at six weeks and trends favored microdiscectomy at two years [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/5/34905/abstract/37\">",
"       37",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Guidelines from the American Pain Society recommend that clinicians discuss risks and benefits of surgery with patients who have persistent, disabling radiculopathy due to a herniated lumbar disc [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/5/34905/abstract/14\">",
"     14",
"    </a>",
"    ]. Shared decision-making regarding surgery should be based on understanding that benefits are moderate on average, and decrease over time compared to patients who do not choose to have surgery.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Comparing open discectomy to microdiscectomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Four trials found no clear differences between standard open discectomy and microdiscectomy in patients with lumbar disc herniation and radiculopathy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/5/34905/abstract/45-48\">",
"     45-48",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Minimally invasive procedures",
"    </span>",
"    &nbsp;&mdash;&nbsp;Unlike standard discectomy and microdiscectomy, fewer randomized trials have evaluated minimally invasive techniques.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      One small (n = 62) trial compared percutaneous disc decompression to conservative therapy (medications, physical therapy, education, counseling) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/5/34905/abstract/49\">",
"       49",
"      </a>",
"      ]. Percutaneous disc decompression was associated with higher pain scores at three months (3.0 versus 0.9 on a 0 to 10 scale), but lower pain scores at year one (1.6 versus 4.0) and at year two (1.7 versus 4.0). Challenges in interpreting this trial are that it used an inadequate randomization method (alternate allocation), and it is unclear why decompression would have a delayed effect, as most trials have shown that benefits of discectomy are most pronounced at short-term follow-up.",
"     </li>",
"     <li>",
"      Several randomized trials have compared percutaneous tubular discectomy with conventional microdiscectomy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/5/34905/abstract/32,50-52\">",
"       32,50-52",
"      </a>",
"      ]. The largest and the only double blind trial found that one-year disability scores were slightly better with conventional microdiscectomy compared to tubular discectomy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/5/34905/abstract/32\">",
"       32",
"      </a>",
"      ]. Additionally, contrary to previous reports, tubular discectomy did not result in faster recovery and patient reported leg and back pain intensity were marginally better with the conventional procedure.",
"     </li>",
"     <li>",
"      Two trials compared microdiscectomy to percutaneous discectomy, but evaluated different percutaneous discectomy techniques and reported inconsistent outcomes [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/5/34905/abstract/53,54\">",
"       53,54",
"      </a>",
"      ]. One trial (n = 71) found a lower rate of satisfactory results for patients undergoing percutaneous discectomy with automated nucleotome compared to microdiscectomy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/5/34905/abstract/53\">",
"       53",
"      </a>",
"      ]. Another trial (n = 40) found no clear difference between microdiscectomy and automated percutaneous discectomy with modified forceps and an automated cutter with suction, but estimated that only 10 to 15 percent of patients needing surgery would be eligible for the percutaneous method [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/5/34905/abstract/54\">",
"       54",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      One trial compared endoscopic discectomy and microdiscectomy with two year follow-up; 200 patients were entered into the study and 178 followed-up at two years [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/5/34905/abstract/55\">",
"       55",
"      </a>",
"      ]. The endoscopic technique used either transforaminal or interlaminar approaches as indicated by patient anatomy; all procedures were performed by one of two experienced surgeons. Disability and pain outcomes were similar for the two procedures, though return-to-work was significantly faster in the endoscopic surgery group (25 versus 49 days). However, results are difficult to interpret because of several methodological shortcomings, including lack of intention-to-treat analysis and unclear presentation of randomization, blinding, and exclusion criteria.",
"     </li>",
"     <li>",
"      A randomized but unblinded trial in one center compared standard microdiscectomy and simple fragment excision (microscopic sequestrectomy, a procedure in which disc fragments are removed without entering the disc space itself) in 84 patients with single-level disc herniation and no prior surgery [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/5/34905/abstract/56\">",
"       56",
"      </a>",
"      ]. Both groups improved substantially immediately following surgery. At two year follow-up, rates of reherniation between the groups did not differ, while self-reported motor function improved over time for the sequestrectomy group, and worsened for the microdiscectomy group. Longer term outcomes and confirmation of these findings by additional studies are needed before the limited procedure can be routinely recommended.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    There are no published trials comparing laser-assisted discectomy, coblation nucleoplasty, or minimally invasive techniques (other than the percutaneous disc decompression) versus open discectomy, microdiscectomy, or nonsurgical therapy.",
"   </p>",
"   <p>",
"    Until more definitive evidence is available showing clear advantages for alternative surgical techniques, our preference is for microdiscectomy or standard open discectomy for patients with lumbar disc herniation and radiculopathy who are appropriate surgical candidates.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Postoperative physiotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is no evidence that patients need to have activity restricted following first-time lumbar surgery. Although commonly prescribed following surgery, the effectiveness of formal postoperative physiotherapy is uncertain.",
"   </p>",
"   <p>",
"    A systematic review, including literature published through 2001, found a lack of high quality studies, and insufficient evidence that physiotherapy immediately following lumbar disc surgery is effective, although it did not cause harm [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/5/34905/abstract/57\">",
"     57",
"    </a>",
"    ]. On the other hand, intensive exercise programs started four to six weeks after surgery were more effective than mild exercise programs for short-term improvement in function and return to work, with no difference in long-term outcomes. The components and intensity of physiotherapy ranged widely in the included trials, and an optimal post-operative rehabilitation regimen could not be identified.",
"   </p>",
"   <p>",
"    A single blind randomized study of 120 patients with uncomplicated lumbar disc surgery evaluated a twelve week course of immediate physiotherapy, compared to sham therapy (neck massage) or no therapy; all patients received education on ergonomics, lifestyle changes and back exercises [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/5/34905/abstract/58\">",
"     58",
"    </a>",
"    ]. Scores for low back pain at twelve weeks were better for physiotherapy than no treatment, but were not significantly different for physiotherapy or sham therapy, suggesting that psychological factors and patient expectations may have influenced outcome. There were no differences between outcomes for any group at long-term (1.5 years) follow-up.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     SPINAL STENOSIS OR DEGENERATIVE SPONDYLOLISTHESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Spondylolisthesis refers to anterior slippage of one vertebral body over another. Degenerative spondylolisthesis, usually caused by degenerative changes at the facet joints and intervertebral discs, is a common cause of spinal stenosis. Degenerative spondylolisthesis leads to a loss of normal structural supports and subluxation of the affected vertebral body, and can cause pain and neurologic deficits due to spinal stenosis or tension on nerve roots. The most common site for degenerative spondylolisthesis is L4.",
"   </p>",
"   <p>",
"    Surgery may be beneficial in patients with persistent symptoms related to spinal stenosis (narrowing of the spinal canal), although the benefit of surgery, compared to nonsurgical therapy, declines over time. Decompressive laminectomy, with or without fusion, is the most common surgery for spinal stenosis and symptomatic degenerative spondylolisthesis. Surgical options and outcomes for spinal stenosis and degenerative lumbar spondylolisthesis are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/15/22776?source=see_link&amp;anchor=H7#H7\">",
"     \"Lumbar spinal stenosis: Treatment and prognosis\", section on 'Surgical treatment'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     SPONDYLOLYSIS AND ISTHMIC SPONDYLOLISTHESIS",
"    </span>",
"   </p>",
"   <p>",
"    Spondylolysis refers to a defect in the pars interarticularis (a bone connecting one facet joint to another) (",
"    <a class=\"graphic graphic_figure graphicRef51358 \" href=\"mobipreview.htm?27/40/28303\">",
"     figure 1",
"    </a>",
"    ). Spondylolysis is often asymptomatic and detected incidentally as a radiologic finding, although it may also be associated with low back pain. Approximately 90 percent of spondylolysis occurs at L5 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/5/34905/abstract/59\">",
"     59",
"    </a>",
"    ]. It is seen in about 6 percent of the adult population [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/5/34905/abstract/59\">",
"     59",
"    </a>",
"    ], but may be more frequent among adolescent athletes. Symptoms resolve spontaneously in many persons with symptomatic spondylolysis. Treatment is controversial as there are no randomized trials to guide treatment options. Treatment options for symptomatic spondylolysis include bracing, activity restriction, and physical therapy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/45/19162?source=see_link&amp;anchor=H7#H7\">",
"     \"Back pain in children and adolescents: Overview of causes\", section on 'Spondylolysis and spondylolisthesis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Isthmic spondylolisthesis differs from degenerative spondylolisthesis in that a lytic defect in the pars interarticularis (lytic spondylolysis) results in anterior subluxation (slippage) of the affected vertebral body (",
"    <a class=\"graphic graphic_figure graphicRef76454 \" href=\"mobipreview.htm?22/15/22768\">",
"     figure 2",
"    </a>",
"    ). The subluxation may also place stress on the adjacent intervertebral disc, resulting in degenerative disc disease. The most common site of isthmic spondylolisthesis, L5, can cause back pain or radicular symptoms due to tension or compression on the L5 nerve root. Initial treatment for symptomatic isthmic spondylolisthesis is similar to treatment for spondylolysis. Surgical treatment is reserved for patients who do not respond to non-surgical therapies. Potential indications for surgery include progressive slip, development of neurological deficits, and segmental instability associated with pain. Segmental instability is typically diagnosed using a combination of imaging (dynamic slippage with extension or flexion) and clinical findings (frequent exacerbations of back symptoms with minimal provocation). The most common surgical procedure for isthmic spondylolisthesis is posterolateral (transpedicular) fusion, with or without decompressive laminectomy.",
"   </p>",
"   <p>",
"    Evidence on efficacy of surgery versus nonsurgical therapy for isthmic spondylolisthesis is limited to one randomized trial (n = 114). In patients with low back pain and sciatica for at least one year, posterolateral fusion was associated with moderately decreased pain (mean score 37 versus 56 on a 0 to 100 scale) and disability (mean Disability Rating Index 29 versus 44 on a 0 to 100 scale) and superior patient-reported overall outcomes (74 versus 43 percent better or much better) after two years compared to an exercise program [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/5/34905/abstract/60\">",
"     60",
"    </a>",
"    ]. After an average of nine years follow-up, however, differences were small and no longer significant for pain or function [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/5/34905/abstract/61\">",
"     61",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Evidence on efficacy of different surgical techniques for isthmic spondylolisthesis is also limited. One trial (n = 42) found fusion plus decompressive laminectomy associated with worse outcomes compared to fusion alone [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/5/34905/abstract/62\">",
"     62",
"    </a>",
"    ], and another (n = 77) found no difference in clinical outcomes between instrumented and non-instrumented fusion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/5/34905/abstract/63\">",
"     63",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     INTRACTABLE LOW BACK PAIN",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients may have persistent disabling low back pain despite use of several standard therapies or following back surgery (ie, failed back surgery syndrome). Chronic opioids may be used in such patients to manage pain, but responses are incomplete, long-term outcome unknown, and side effects can be serious. Opioids should only be used after adequate risk assessment and with appropriate monitoring and supervision. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/49/42778?source=see_link\">",
"     \"Overview of the treatment of chronic pain\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Spinal cord stimulation involves the placement of electrodes in the epidural space adjacent to the spinal area presumed to be the source of pain. An electric current is then applied to achieve sympatholytic and other neuromodulatory effects. The number and type of electrode leads and parameters of electrical stimulation can vary. Electrodes may be implanted percutaneously or by laminectomy, and power for the spinal cord stimulator is supplied by an implanted battery or transcutaneously through an external radiofrequency transmitter.",
"   </p>",
"   <p>",
"    Spinal cord stimulation has been evaluated in randomized trials:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      One randomized trial (n = 50) of patients with persistent low back pain after surgery found spinal cord stimulation superior to reoperation for achieving &gt;50 percent pain relief compared to patients randomized to reoperation after a mean of 2.9 years (38 versus 12 percent) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/5/34905/abstract/64\">",
"       64",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A second randomized trial (n =100) of patients with persistent radicular pain following surgery for herniated disc found spinal cord stimulation associated with greater likelihood of experiencing &gt;50 percent pain relief compared with conventional medical management (48 versus 9 percent) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/5/34905/abstract/65\">",
"       65",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In the randomized trials, 26 to 32 percent of patients experienced a complication following spinal cord stimulator implantation, including electrode migration, infection or wound breakdown, generator pocket-related complications, and lead problem. A prospective cohort study of patients with radicular symptoms and low back pain who were receiving worker&rsquo;s compensation found that, outside the setting of a research environment, outcomes at 12 and 24 months were not significantly better for spinal cord stimulation compared with pain clinic management or usual care [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/5/34905/abstract/66\">",
"     66",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Guidelines from the American Pain Society suggest that clinicians discuss spinal cord stimulation as an option in patients with persistent and disabling radicular pain following surgery for herniated disc, being sure that patients are aware of the relatively high rate of complications following stimulator implantation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/5/34905/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Other therapies include intrathecal opioids or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/55/38773?source=see_link\">",
"     ziconotide",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/5/34905/abstract/67\">",
"     67",
"    </a>",
"    ] and adhesiolysis (injection of isotonic saline, hypertonic saline, or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?41/33/42512?source=see_link\">",
"     hyaluronidase",
"    </a>",
"    into the epidural space in order to facilitate lysis of adhesions); randomized trials for these interventions are not available or inconclusive.",
"   </p>",
"   <p>",
"    Referral to clinicians experienced in treating intractable back pain should be considered when standard interventions have failed. Many tertiary care centers offer interdisciplinary pain treatment clinics that may not be available in the primary care setting.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?36/7/36978?source=see_link\">",
"       \"Patient information: Low back pain in adults (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?8/47/8950?source=see_link\">",
"       \"Patient information: Low back pain in adults (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      We suggest not performing surgery for most patients with chronic symptoms attributed to nonspecific low back pain (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). Decisions regarding surgery should be based on shared decision-making. We suggest that surgery be limited to patients with nonspecific low back pain who meet the following criteria: persistent symptoms with associated disability for at least one year despite nonsurgical interventions; appropriate surgical candidate; and intensive rehabilitation with a cognitive behavioral therapy component is either not available or has not been effective (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Nonspecific low back pain with degenerative disc changes'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Vertebral fusion is the most common surgery for chronic, nonspecific low back pain. Surgical instrumentation (use of pedicle screws or other hardware) increases fusion rates, but it is not known if instrumentation improves clinical outcomes. More research with longer follow-up is needed to determine the appropriate role of artificial disc replacement versus fusion. We suggest that vertebral fusion be performed for patients who undergo surgical intervention for chronic low back pain (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      In patients with lumbar disc prolapse and radiculopathy who do not have severe or progressive neurologic deficits, there is no evidence that early referral for surgery improves outcomes. Outcomes for patients who undergo discectomy, compared to nonsurgical therapy, favor surgery at short-term follow-up but are equivalent at one to two years. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Lumbar disc prolapse'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Minimally invasive discectomy techniques have not been demonstrated to be superior to traditional discectomy methods and may not be applicable for many patients. For patients with lumbar radicular symptoms of at least 6 to 12 weeks who are good surgical candidates and desire surgery based on shared decision-making, we suggest either open discectomy or microdiscectomy (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). Earlier surgery may be indicated for patients with severe and disabling pain related to lumbar disc prolapse that is unresponsive to medical therapy. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Lumbar disc prolapse'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Surgery may be beneficial in patients with persistent symptoms related to spinal stenosis. For patients who undergo laminectomy compared to nonsurgical therapy, outcomes favor surgery at short-term follow-up but not at longer follow-up. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?22/15/22776?source=see_link&amp;anchor=H7#H7\">",
"       \"Lumbar spinal stenosis: Treatment and prognosis\", section on 'Surgical treatment'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In patients with persistent symptoms related to isthmic spondylolisthesis, surgical fusion may result in early benefits compared to nonsurgical treatment. However, benefits do not persist with longer follow-up.",
"     </li>",
"     <li>",
"      Patients with intractable back pain, who are not surgical candidates or in whom surgery has not been successful, should be referred to chronic pain specialists, preferably in the setting of an interdisciplinary pain clinic. For patients with persistent disabling radicular pain following surgery, and following shared decision-making that includes a specific discussion regarding the relatively high rate of device-related complications, we suggest spinal cord stimulation as an option (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Intractable low back pain'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/5/34905/abstract/1\">",
"      Pengel LH, Herbert RD, Maher CG, Refshauge KM. Acute low back pain: systematic review of its prognosis. BMJ 2003; 327:323.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/5/34905/abstract/2\">",
"      Weinstein JN, Lurie JD, Olson PR, et al. United States' trends and regional variations in lumbar spine surgery: 1992-2003. Spine (Phila Pa 1976) 2006; 31:2707.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/5/34905/abstract/3\">",
"      Deyo RA, Rainville J, Kent DL. What can the history and physical examination tell us about low back pain? JAMA 1992; 268:760.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/5/34905/abstract/4\">",
"      Vroomen PC, de Krom MC, Knottnerus JA. Predicting the outcome of sciatica at short-term follow-up. Br J Gen Pract 2002; 52:119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/5/34905/abstract/5\">",
"      Weber H. Lumbar disc herniation. A controlled, prospective study with ten years of observation. Spine (Phila Pa 1976) 1983; 8:131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/5/34905/abstract/6\">",
"      van Tulder MW, Assendelft WJ, Koes BW, Bouter LM. Spinal radiographic findings and nonspecific low back pain. A systematic review of observational studies. Spine (Phila Pa 1976) 1997; 22:427.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/5/34905/abstract/7\">",
"      Mirza SK, Deyo RA. Systematic review of randomized trials comparing lumbar fusion surgery to nonoperative care for treatment of chronic back pain. Spine (Phila Pa 1976) 2007; 32:816.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/5/34905/abstract/8\">",
"      Fritzell P, H&auml;gg O, Wessberg P, et al. 2001 Volvo Award Winner in Clinical Studies: Lumbar fusion versus nonsurgical treatment for chronic low back pain: a multicenter randomized controlled trial from the Swedish Lumbar Spine Study Group. Spine (Phila Pa 1976) 2001; 26:2521.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/5/34905/abstract/9\">",
"      Brox JI, Reiker&aring;s O, Nygaard &Oslash;, et al. Lumbar instrumented fusion compared with cognitive intervention and exercises in patients with chronic back pain after previous surgery for disc herniation: a prospective randomized controlled study. Pain 2006; 122:145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/5/34905/abstract/10\">",
"      Brox JI, S&oslash;rensen R, Friis A, et al. Randomized clinical trial of lumbar instrumented fusion and cognitive intervention and exercises in patients with chronic low back pain and disc degeneration. Spine (Phila Pa 1976) 2003; 28:1913.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/5/34905/abstract/11\">",
"      Fairbank J, Frost H, Wilson-MacDonald J, et al. Randomised controlled trial to compare surgical stabilisation of the lumbar spine with an intensive rehabilitation programme for patients with chronic low back pain: the MRC spine stabilisation trial. BMJ 2005; 330:1233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/5/34905/abstract/12\">",
"      Brox JI, Nygaard &Oslash;P, Holm I, et al. Four-year follow-up of surgical versus non-surgical therapy for chronic low back pain. Ann Rheum Dis 2010; 69:1643.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/5/34905/abstract/13\">",
"      Chou R, Baisden J, Carragee EJ, et al. Surgery for low back pain: a review of the evidence for an American Pain Society Clinical Practice Guideline. Spine (Phila Pa 1976) 2009; 34:1094.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/5/34905/abstract/14\">",
"      Chou R, Loeser JD, Owens DK, et al. Interventional therapies, surgery, and interdisciplinary rehabilitation for low back pain: an evidence-based clinical practice guideline from the American Pain Society. Spine (Phila Pa 1976) 2009; 34:1066.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/5/34905/abstract/15\">",
"      Schafer J, O'Connor D, Feinglass S, Salive M. Medicare Evidence Development and Coverage Advisory Committee Meeting on lumbar fusion surgery for treatment of chronic back pain from degenerative disc disease. Spine (Phila Pa 1976) 2007; 32:2403.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/5/34905/abstract/16\">",
"      Ohtori S, Koshi T, Yamashita M, et al. Surgical versus nonsurgical treatment of selected patients with discogenic low back pain: a small-sized randomized trial. Spine (Phila Pa 1976) 2011; 36:347.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/5/34905/abstract/17\">",
"      Gibson JN, Waddell G. Surgery for degenerative lumbar spondylosis: updated Cochrane Review. Spine (Phila Pa 1976) 2005; 30:2312.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/5/34905/abstract/18\">",
"      Cahill KS, Chi JH, Day A, Claus EB. Prevalence, complications, and hospital charges associated with use of bone-morphogenetic proteins in spinal fusion procedures. JAMA 2009; 302:58.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/5/34905/abstract/19\">",
"      Carragee EJ, Hurwitz EL, Weiner BK. A critical review of recombinant human bone morphogenetic protein-2 trials in spinal surgery: emerging safety concerns and lessons learned. Spine J 2011; 11:471.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/5/34905/abstract/20\">",
"      Mitka M. Questions about spine fusion product prompt a new process for reviewing data. JAMA 2011; 306:1311.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/5/34905/abstract/21\">",
"      Turner JA, Ersek M, Herron L, et al. Patient outcomes after lumbar spinal fusions. JAMA 1992; 268:907.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/5/34905/abstract/22\">",
"      Fritzell P, H&auml;gg O, Nordwall A, Swedish Lumbar Spine Study Group. Complications in lumbar fusion surgery for chronic low back pain: comparison of three surgical techniques used in a prospective randomized study. A report from the Swedish Lumbar Spine Study Group. Eur Spine J 2003; 12:178.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/5/34905/abstract/23\">",
"      Jacobs WC, van der Gaag NA, Kruyt MC, et al. Total disc replacement for chronic discogenic low back pain: a cochrane review. Spine (Phila Pa 1976) 2013; 38:24.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/5/34905/abstract/24\">",
"      Blumenthal S, McAfee PC, Guyer RD, et al. A prospective, randomized, multicenter Food and Drug Administration investigational device exemptions study of lumbar total disc replacement with the CHARITE artificial disc versus lumbar fusion: part I: evaluation of clinical outcomes. Spine (Phila Pa 1976) 2005; 30:1565.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/5/34905/abstract/25\">",
"      Zigler J, Delamarter R, Spivak JM, et al. Results of the prospective, randomized, multicenter Food and Drug Administration investigational device exemption study of the ProDisc-L total disc replacement versus circumferential fusion for the treatment of 1-level degenerative disc disease. Spine (Phila Pa 1976) 2007; 32:1155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/5/34905/abstract/26\">",
"      Berg S, Tullberg T, Branth B, et al. Total disc replacement compared to lumbar fusion: a randomised controlled trial with 2-year follow-up. Eur Spine J 2009; 18:1512.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/5/34905/abstract/27\">",
"      Gornet MF, Burkus JK, Dryer RF, Peloza JH. Lumbar disc arthroplasty with MAVERICK disc versus stand-alone interbody fusion: a prospective, randomized, controlled, multicenter investigational device exemption trial. Spine (Phila Pa 1976) 2011; 36:E1600.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/5/34905/abstract/28\">",
"      Moreno P, Boulot J. [Comparative study of short-term results between total artificial disc prosthesis and anterior lumbar interbody fusion]. Rev Chir Orthop Reparatrice Appar Mot 2008; 94:282.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/5/34905/abstract/29\">",
"      Hellum C, Johnsen LG, Storheim K, et al. Surgery with disc prosthesis versus rehabilitation in patients with low back pain and degenerative disc: two year follow-up of randomised study. BMJ 2011; 342:d2786.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/5/34905/abstract/30\">",
"      Regan JJ, McAfee PC, Blumenthal SL, et al. Evaluation of surgical volume and the early experience with lumbar total disc replacement as part of the investigational device exemption study of the Charit&eacute; Artificial Disc. Spine (Phila Pa 1976) 2006; 31:2270.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/5/34905/abstract/31\">",
"      Maroon JC. Current concepts in minimally invasive discectomy. Neurosurgery 2002; 51:S137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/5/34905/abstract/32\">",
"      Arts MP, Brand R, van den Akker ME, et al. Tubular diskectomy vs conventional microdiskectomy for sciatica: a randomized controlled trial. JAMA 2009; 302:149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/5/34905/abstract/33\">",
"      Peul WC, van Houwelingen HC, van den Hout WB, et al. Surgery versus prolonged conservative treatment for sciatica. N Engl J Med 2007; 356:2245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/5/34905/abstract/34\">",
"      Weinstein JN, Tosteson TD, Lurie JD, et al. Surgical vs nonoperative treatment for lumbar disk herniation: the Spine Patient Outcomes Research Trial (SPORT): a randomized trial. JAMA 2006; 296:2441.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/5/34905/abstract/35\">",
"      Deen HG, Fenton DS, Lamer TJ. Minimally invasive procedures for disorders of the lumbar spine. Mayo Clin Proc 2003; 78:1249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/5/34905/abstract/36\">",
"      Atlas SJ, Keller RB, Wu YA, et al. Long-term outcomes of surgical and nonsurgical management of sciatica secondary to a lumbar disc herniation: 10 year results from the maine lumbar spine study. Spine (Phila Pa 1976) 2005; 30:927.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/5/34905/abstract/37\">",
"      Osterman H, Seitsalo S, Karppinen J, Malmivaara A. Effectiveness of microdiscectomy for lumbar disc herniation: a randomized controlled trial with 2 years of follow-up. Spine (Phila Pa 1976) 2006; 31:2409.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/5/34905/abstract/38\">",
"      Birkmeyer NJ, Weinstein JN, Tosteson AN, et al. Design of the Spine Patient outcomes Research Trial (SPORT). Spine (Phila Pa 1976) 2002; 27:1361.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/5/34905/abstract/39\">",
"      Weinstein JN, Lurie JD, Tosteson TD, et al. Surgical versus nonoperative treatment for lumbar disc herniation: four-year results for the Spine Patient Outcomes Research Trial (SPORT). Spine (Phila Pa 1976) 2008; 33:2789.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/5/34905/abstract/40\">",
"      Weinstein JN, Lurie JD, Tosteson TD, et al. Surgical vs nonoperative treatment for lumbar disk herniation: the Spine Patient Outcomes Research Trial (SPORT) observational cohort. JAMA 2006; 296:2451.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/5/34905/abstract/41\">",
"      Tosteson AN, Skinner JS, Tosteson TD, et al. The cost effectiveness of surgical versus nonoperative treatment for lumbar disc herniation over two years: evidence from the Spine Patient Outcomes Research Trial (SPORT). Spine (Phila Pa 1976) 2008; 33:2108.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/5/34905/abstract/42\">",
"      Tosteson AN, Tosteson TD, Lurie JD, et al. Comparative effectiveness evidence from the spine patient outcomes research trial: surgical versus nonoperative care for spinal stenosis, degenerative spondylolisthesis, and intervertebral disc herniation. Spine (Phila Pa 1976) 2011; 36:2061.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/5/34905/abstract/43\">",
"      van den Hout WB, Peul WC, Koes BW, et al. Prolonged conservative care versus early surgery in patients with sciatica from lumbar disc herniation: cost utility analysis alongside a randomised controlled trial. BMJ 2008; 336:1351.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/5/34905/abstract/44\">",
"      Peul WC, van den Hout WB, Brand R, et al. Prolonged conservative care versus early surgery in patients with sciatica caused by lumbar disc herniation: two year results of a randomised controlled trial. BMJ 2008; 336:1355.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/5/34905/abstract/45\">",
"      Henriksen L, Schmidt K, Eskesen V, Jantzen E. A controlled study of microsurgical versus standard lumbar discectomy. Br J Neurosurg 1996; 10:289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/5/34905/abstract/46\">",
"      Lagarrigue J, Chaynes P. [Comparative study of disk surgery with or without microscopy. A prospective study of 80 cases]. Neurochirurgie 1994; 40:116.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/5/34905/abstract/47\">",
"      Katayama Y, Matsuyama Y, Yoshihara H, et al. Comparison of surgical outcomes between macro discectomy and micro discectomy for lumbar disc herniation: a prospective randomized study with surgery performed by the same spine surgeon. J Spinal Disord Tech 2006; 19:344.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/5/34905/abstract/48\">",
"      Tullberg T, Isacson J, Weidenhielm L. Does microscopic removal of lumbar disc herniation lead to better results than the standard procedure? Results of a one-year randomized study. Spine (Phila Pa 1976) 1993; 18:24.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/5/34905/abstract/49\">",
"      Erginousakis D, Filippiadis DK, Malagari A, et al. Comparative prospective randomized study comparing conservative treatment and percutaneous disk decompression for treatment of intervertebral disk herniation. Radiology 2011; 260:487.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/5/34905/abstract/50\">",
"      Righesso O, Falavigna A, Avanzi O. Comparison of open discectomy with microendoscopic discectomy in lumbar disc herniations: results of a randomized controlled trial. Neurosurgery 2007; 61:545.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/5/34905/abstract/51\">",
"      Ryang YM, Oertel MF, Mayfrank L, et al. Standard open microdiscectomy versus minimal access trocar microdiscectomy: results of a prospective randomized study. Neurosurgery 2008; 62:174.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/5/34905/abstract/52\">",
"      Brock M, Kunkel P, Papavero L. Lumbar microdiscectomy: subperiosteal versus transmuscular approach and influence on the early postoperative analgesic consumption. Eur Spine J 2008; 17:518.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/5/34905/abstract/53\">",
"      Chatterjee S, Foy PM, Findlay GF. Report of a controlled clinical trial comparing automated percutaneous lumbar discectomy and microdiscectomy in the treatment of contained lumbar disc herniation. Spine (Phila Pa 1976) 1995; 20:734.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/5/34905/abstract/54\">",
"      Mayer HM, Brock M. Percutaneous endoscopic discectomy: surgical technique and preliminary results compared to microsurgical discectomy. J Neurosurg 1993; 78:216.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/5/34905/abstract/55\">",
"      Ruetten S, Komp M, Merk H, Godolias G. Full-endoscopic interlaminar and transforaminal lumbar discectomy versus conventional microsurgical technique: a prospective, randomized, controlled study. Spine (Phila Pa 1976) 2008; 33:931.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/5/34905/abstract/56\">",
"      Barth M, Weiss C, Thom&eacute; C. Two-year outcome after lumbar microdiscectomy versus microscopic sequestrectomy: part 1: evaluation of clinical outcome. Spine (Phila Pa 1976) 2008; 33:265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/5/34905/abstract/57\">",
"      Ostelo RW, de Vet HC, Waddell G, et al. Rehabilitation after lumbar disc surgery. Cochrane Database Syst Rev 2002; :CD003007.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/5/34905/abstract/58\">",
"      Erdogmus CB, Resch KL, Sabitzer R, et al. Physiotherapy-based rehabilitation following disc herniation operation: results of a randomized clinical trial. Spine (Phila Pa 1976) 2007; 32:2041.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/5/34905/abstract/59\">",
"      Sakai T, Sairyo K, Takao S, et al. Incidence of lumbar spondylolysis in the general population in Japan based on multidetector computed tomography scans from two thousand subjects. Spine (Phila Pa 1976) 2009; 34:2346.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/5/34905/abstract/60\">",
"      M&ouml;ller H, Hedlund R. Surgery versus conservative management in adult isthmic spondylolisthesis--a prospective randomized study: part 1. Spine (Phila Pa 1976) 2000; 25:1711.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/5/34905/abstract/61\">",
"      Ekman P, M&ouml;ller H, Hedlund R. The long-term effect of posterolateral fusion in adult isthmic spondylolisthesis: a randomized controlled study. Spine J 2005; 5:36.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/5/34905/abstract/62\">",
"      Carragee EJ. Single-level posterolateral arthrodesis, with or without posterior decompression, for the treatment of isthmic spondylolisthesis in adults. A prospective, randomized study. J Bone Joint Surg Am 1997; 79:1175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/5/34905/abstract/63\">",
"      M&ouml;ller H, Hedlund R. Instrumented and noninstrumented posterolateral fusion in adult spondylolisthesis--a prospective randomized study: part 2. Spine (Phila Pa 1976) 2000; 25:1716.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/5/34905/abstract/64\">",
"      North RB, Kidd DH, Farrokhi F, Piantadosi SA. Spinal cord stimulation versus repeated lumbosacral spine surgery for chronic pain: a randomized, controlled trial. Neurosurgery 2005; 56:98.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/5/34905/abstract/65\">",
"      Kumar K, Taylor RS, Jacques L, et al. Spinal cord stimulation versus conventional medical management for neuropathic pain: a multicentre randomised controlled trial in patients with failed back surgery syndrome. Pain 2007; 132:179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/5/34905/abstract/66\">",
"      Turner JA, Hollingworth W, Comstock BA, Deyo RA. Spinal cord stimulation for failed back surgery syndrome: outcomes in a workers' compensation setting. Pain 2010; 148:14.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/5/34905/abstract/67\">",
"      Hassenbusch SJ, Portenoy RK, Cousins M, et al. Polyanalgesic Consensus Conference 2003: an update on the management of pain by intraspinal drug delivery-- report of an expert panel. J Pain Symptom Manage 2004; 27:540.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7769 Version 14.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-125.39.66.147-7CC26F0507-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_5_34905=[""].join("\n");
var outline_f34_5_34905=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H15\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      INDICATIONS FOR SPINAL SURGERY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      NONSPECIFIC LOW BACK PAIN WITH DEGENERATIVE DISC CHANGES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Spinal fusion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Lumbar disc replacement",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      LUMBAR DISC PROLAPSE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Standard open discectomy or microdiscectomy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Compared to no surgery",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Comparing open discectomy to microdiscectomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Minimally invasive procedures",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Postoperative physiotherapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      SPINAL STENOSIS OR DEGENERATIVE SPONDYLOLISTHESIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      SPONDYLOLYSIS AND ISTHMIC SPONDYLOLISTHESIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      INTRACTABLE LOW BACK PAIN",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PC/7769\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PC/7769|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?27/40/28303\" title=\"figure 1\">",
"      Spondylolysis 2",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?22/15/22768\" title=\"figure 2\">",
"      Spondylolisthesis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PC/7769|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?7/38/7789\" title=\"table 1\">",
"      Meds for subacute LBP",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?38/46/39661\" title=\"table 2\">",
"      Nonpharm Rx subacute LBP",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?15/17/15646\" title=\"table 3\">",
"      Interventional Rx LBP",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?43/23/44412\" title=\"table 4\">",
"      Surg vs nonsurg Rx LBP",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/45/19162?source=related_link\">",
"      Back pain in children and adolescents: Overview of causes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/27/6585?source=related_link\">",
"      Clinical features and diagnosis of neoplastic epidural spinal cord compression, including cauda equina syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/15/22776?source=related_link\">",
"      Lumbar spinal stenosis: Treatment and prognosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/49/42778?source=related_link\">",
"      Overview of the treatment of chronic pain",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?8/47/8950?source=related_link\">",
"      Patient information: Low back pain in adults (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?36/7/36978?source=related_link\">",
"      Patient information: Low back pain in adults (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/52/39753?source=related_link\">",
"      Subacute and chronic low back pain: Nonsurgical interventional treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/24/19850?source=related_link\">",
"      Subacute and chronic low back pain: Pharmacologic and noninterventional treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/21/13658?source=related_link\">",
"      Treatment of acute low back pain",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f34_5_34906="Normal skeletal development and regulation of bone formation and resorption";
var content_f34_5_34906=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Normal skeletal development and regulation of bone formation and resorption",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?34/5/34906/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/5/34906/contributors\">",
"     Stavros C Manolagas, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?34/5/34906/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/5/34906/contributors\">",
"     Marc K Drezner, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?34/5/34906/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/5/34906/contributors\">",
"     Jean E Mulder, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?34/5/34906/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 27, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The skeleton is a highly dynamic organ that constantly undergoes changes and regeneration. It consists of specialized bone cells, mineralized and unmineralized connective tissue matrix, and spaces that include the bone marrow cavity, vascular canals, canaliculi, and lacunae containing osteocytes. Bone also contains water, which represents at least 25 percent of its wet weight and provides much of its unique strength and resilience.",
"   </p>",
"   <p>",
"    The skeleton has both structural and metabolic functions:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Its structural function is critical for locomotion, respiration, and protection of internal organs. The structural connection between the skeleton and the hematopoietic system is particularly intimate; these two systems share both cells and local regulatory factors.",
"     </li>",
"     <li>",
"      Its metabolic function is largely as a storehouse for calcium, phosphorus, and carbonate, and it can contribute to buffering changes in hydrogen ion concentration.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    This topic will review how the skeleton develops and how the processes of bone formation and resorption are regulated. The pathogenesis of osteoporosis is reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/53/3929?source=see_link\">",
"     \"Pathogenesis of osteoporosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H593789\">",
"    <span class=\"h1\">",
"     SKELETAL COMPONENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The vertebrate skeleton is subdivided into an axial and an appendicular component. The axial component comprises the skull, spine, sternum, and the ribs. The appendicular component comprises long bones and their appendices. There are two major types of bone in the adult skeleton (",
"    <a class=\"graphic graphic_figure graphicRef58348 \" href=\"mobipreview.htm?20/43/21174\">",
"     figure 1",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Cortical bone is dense and compact. It constitutes the outer part of all skeletal structures. The lamellae may be extensive (circumferential) or tightly packed in concentric circles in osteons. Cortical bone comprises 80 percent of the skeletal weight. Its major function is to provide mechanical strength and protection, but it can participate in metabolic responses, particularly when there is severe or prolonged mineral deficit.",
"     </li>",
"     <li>",
"      Trabecular (cancellous) bone is found inside the long bones, particularly at the ends, throughout the bodies of the vertebrae, and in the inner portions of the pelvis and other large flat bones. Trabecular bone is an important contributor to mechanical support, particularly in the vertebrae. It is also more metabolically active than cortical bone and provides the initial supplies of mineral in acute deficiency states.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1206084\">",
"    <span class=\"h1\">",
"     SKELETAL DEVELOPMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Flat bones, including the vault of the skull, most of the upper facial skeleton, parts of the mandible, clavicle, and the pelvis, as well as the collar of long bones, arise from the direct conversion of undifferentiated mesenchymal cells into bone in a process called intramembranous bone formation. The remaining axial and appendicular bone is formed by a multi-step process that requires the sequential formation and degradation of cartilaginous structures that serve as a template for the developing bones. Bone formation arising from a cartilaginous template is referred to as endochondral bone formation (",
"    <a class=\"graphic graphic_figure graphicRef68827 \" href=\"mobipreview.htm?40/49/41750\">",
"     figure 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Cartilage is unique among skeletal tissues in its capacity to grow interstitially, ie, by division of chondrocytes. Longitudinal bone growth occurs at the growth plates and involves elongation of the cartilaginous template as a result of the division of chondrocytes as well as increases in their size. The chondrocytes enlarge, form columns, and undergo apoptosis. Then marrow cells enter the space formerly occupied by these cells and the cartilage in between the columns becomes mineralized. Osteoblasts settle on the cartilaginous template and lay down extracellular matrix (osteoid) that calcifies into woven bone. With time, woven bone is resorbed by osteoclasts and replaced with mature trabecular bone made by osteoblasts. This process is responsible for the formation of the spongy honeycomb-like cancellous bone, and it allows for the formation and expansion of the bone marrow cavity simultaneously with the increase in bone size.",
"   </p>",
"   <p>",
"    Long bones, especially the femur and tibia, are subjected to most of the load during daily activities and they are crucial for skeletal mobility. They grow primarily by elongation of the diaphysis, with an epiphysis at the ends of the growing bone. The ends of epiphyses are covered with a hyaline cartilage (\"articular cartilage\"). The longitudinal growth of long bones is a result of endochondral ossification at the epiphyseal plate. Bone growth in length is stimulated by the production of a wide variety of hormones including growth hormone and IGF-I, sex steroids, thyroxine, and parathyroid hormone. (See",
"    <a class=\"local\" href=\"#H1207811\">",
"     'Systemic and local regulators of bone cells'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Skeletal development also requires the formation of blood vessels in the bone, and vascular endothelial growth factor (VEGF) signaling is critical for the conversion of avascular cartilage to highly vascular bone [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/5/34906/abstract/1,2\">",
"     1,2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1206092\">",
"    <span class=\"h2\">",
"     Cartilage proliferation and differentiation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The initial formation of the skeleton, first as cartilage and then as bone, requires the sequential activity of a large number of genes. Genes of the homeobox family (Hox, MSX, DLX) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/5/34906/abstract/3-6\">",
"     3-6",
"    </a>",
"    ] are responsible for the initial differentiation as well as the maintained growth of skeletal tissues. A complex interaction involving parathyroid hormone-related peptide (PTHrP) and the Indian hedgehog (IHH) genes is critical for the development and regulation of the cartilage growth plate [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/5/34906/abstract/7,8\">",
"     7,8",
"    </a>",
"    ]. Notch signaling is also involved in chondrocyte proliferation and differentiation into bone [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/5/34906/abstract/9,10\">",
"     9,10",
"    </a>",
"    ]. Bone morphogenetic proteins (BMPs) stimulate bone formation, but orderly growth requires that there also be periods when growth is inhibited or unwanted skeletal tissue is removed.",
"   </p>",
"   <p>",
"    Phosphate has long been known to play an important role in mineralization, but it also can affect cartilage proliferation and differentiation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/5/34906/abstract/11\">",
"     11",
"    </a>",
"    ]. The most important factor for phosphate regulation is probably fibroblast growth factor-23 (FGF-23) that possibly, along with other phosphatonins, plays a role in skeletal development as well as interacting with calcium regulatory hormones in phosphorus homeostasis in bone, kidney, and intestine [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/5/34906/abstract/12,13\">",
"     12,13",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H593737\">",
"    <span class=\"h2\">",
"     Osteoblasts",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5525058\">",
"    <span class=\"h3\">",
"     Differentiation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Osteoblasts form the connective tissue matrix, which mineralizes and becomes bone. The precursors of osteoblasts are multipotent mesenchymal stem cells, which also give rise to bone marrow stromal cells, chondrocytes, muscle cells, and adipocytes (",
"    <a class=\"graphic graphic_figure graphicRef79078 \" href=\"mobipreview.htm?1/39/1652\">",
"     figure 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/5/34906/abstract/14-16\">",
"     14-16",
"    </a>",
"    ]. Osteoblast progenitors may originate not only from stromal mesenchymal progenitors of the marrow, but also pericytes (mesenchymal cells adherent to the endothelial layer of vessels) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/5/34906/abstract/17\">",
"     17",
"    </a>",
"    ]. Mesenchymal stem cell progenitors of osteoblasts residing on the outer surface of blood vessels are critical for the formation of blood vessels as well [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/5/34906/abstract/18-20\">",
"     18-20",
"    </a>",
"    ]. The process of differentiation of these progenitors to mature osteoblasts, ie, the cells capable of synthesizing the bone matrix, is accomplished by a sequential progression from the least differentiated and most proliferative cell to terminally differentiated cell that can no longer undergo mitosis. At the beginning of the process, mesenchymal stem cells with unlimited self-renewal capacity undergo asymmetric divisions resulting in not only other stem cells, but also daughter cells with limited self-renewal and extensive proliferation capacity. Progressively, the proliferative capacity decreases as differentiation increases.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H593745\">",
"    <span class=\"h4\">",
"     Runx2",
"    </span>",
"    &nbsp;&mdash;&nbsp;Runx2, a member of the runt homology domain transcription factor family, is critical for the initiation of the osteoblast differentiation process and the commitment of multi-potential precursors to osteoprogenitors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/5/34906/abstract/21-23\">",
"     21-23",
"    </a>",
"    ]. Runx2 is the earliest differentiation marker of the osteoblast lineage. Together with Runx3, Runx2 is also required for the maturation of hypertrophic chondrocytes. Deletion of Runx2 results in the development of a complete cartilaginous skeleton, but no transformation to bone. Hence, the animals die at birth because their soft ribcage cannot support respiration. Heterozygous deletion of one Runx2 gene results in a human genetic disease called cleidocranial dysplasia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/5/34906/abstract/24,25\">",
"     24,25",
"    </a>",
"    ]. Osterix, another transcription factor and a zinc-finger protein, acts downstream of Runx2 and is responsible for the transition of osteoprogenitors to preosteoblasts [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/5/34906/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The nuclear receptor peroxisome proliferator-activated receptor (PPAR)&gamma; is a crucial cellular switch in the process of the commitment of the multi-potential mesenchymal osteoprogenitors. Activation of PPAR&gamma; by its natural ligands (eg, prostaglandin J2 or free fatty acids) or synthetic ligands, like the diabetes drug",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/26/2472?source=see_link\">",
"     rosiglitazone",
"    </a>",
"    , suppresses differentiation of the uncommitted progenitors toward the osteoblast lineage while simultaneously promoting differentiation toward the adipocyte lineage [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/5/34906/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Cultured preosteoblasts and osteoblasts have a reproducible temporal pattern of collagen and alkaline phosphatase synthesis followed by synthesis of osteocalcin, a protein containing gamma carboxylated glutamic acid that is produced by cells of osteoblast lineage [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/5/34906/abstract/28\">",
"     28",
"    </a>",
"    ]. In vivo, fully differentiated osteoblasts express the genes for all three of these proteins, and for other specialized proteins such as osteopontin and bone sialoprotein.",
"   </p>",
"   <p>",
"    Osteoblasts are functionally and morphologically heterogeneous [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/5/34906/abstract/29\">",
"     29",
"    </a>",
"    ]. During rapid phases of bone formation they may be columnar in shape, with abundant endoplasmic reticulum, and they synthesize collagen rapidly. When bone formation rates are slower, they are flatter and less metabolically active. Fully differentiated osteoblasts are oriented so that the collagen and noncollagen proteins are laid down on the bone surface in forms suitable for mineralization. Mineralization is delayed for several days, which allows time for collagen cross-linking and the development of large, strong fibers.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H593753\">",
"    <span class=\"h4\">",
"     Wnt signaling pathway",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Wnt signaling pathway is another critical regulator of skeletal development and mass, working in part through the stimulation of Runx-2 gene expression [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/5/34906/abstract/30\">",
"     30",
"    </a>",
"    ]. Activation of the canonical Wnt signaling involves the formation of a complex between Wnt proteins, Frizzled and low density lipoprotein receptor-related protein 5 (LRP5) or LRP6 receptors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/5/34906/abstract/31,32\">",
"     31,32",
"    </a>",
"    ]. This complex in turn leads to phosphorylation and inactivation of GSK-3&beta;, inhibition of &beta;-catenin degradation, and subsequent accumulation of &beta;-catenin in the nucleus [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/5/34906/abstract/33\">",
"     33",
"    </a>",
"    ]. Nuclear &beta;-catenin binds the",
"    <span class=\"nowrap\">",
"     TCF/Lef",
"    </span>",
"    family of transcription factors and induces target gene expression [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/5/34906/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Genetic studies in mice in which the activity of &beta;-catenin was manipulated have established that &beta;-catenin is indeed essential for the specification of osteoblasts from mesenchymal precursor cells through effects on both the proliferation and maturation of the precursor pool [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/5/34906/abstract/35-37\">",
"     35-37",
"    </a>",
"    ]. Moreover, it is now clear that &beta;-catenin suppresses the alternative chondrocyte fate of the precursor cells [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/5/34906/abstract/38\">",
"     38",
"    </a>",
"    ]. Besides its role in promoting osteoblastogenesis, deletion or activation of &beta;-catenin at a later stage of osteoblast differentiation leads to an increase or suppression of osteoclastogenesis, respectively, through regulation of osteoprotegerin (OPG) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/5/34906/abstract/39,40\">",
"     39,40",
"    </a>",
"    ]. Modulation of &beta;-catenin levels at this later stage of osteoblast differentiation had no apparent effect on osteoblast function.",
"   </p>",
"   <p>",
"    Osteocytes are the predominant cellular source of the Wnt antagonist sclerostin, a limiting factor for osteoblast generation and bone mass accrual that mediates the homeostatic adaptation of bone to mechanical loading [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/5/34906/abstract/41\">",
"     41",
"    </a>",
"    ]. Sclerostin is the product of the",
"    <em>",
"     Sost",
"    </em>",
"    gene and a negative regulator of Wnt signaling [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/5/34906/abstract/42\">",
"     42",
"    </a>",
"    ]. It binds to both LRP-5 and LRP-6 and prevents activation of the Wnt receptor complex [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/5/34906/abstract/43,44\">",
"     43,44",
"    </a>",
"    ]. This results in inhibition of bone formation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/5/34906/abstract/45\">",
"     45",
"    </a>",
"    ]. In addition to sclerostin, the DKK family members, particularly DKK-1 (Dickkopf-1), inhibit the Wnt pathway by binding to the",
"    <span class=\"nowrap\">",
"     LPR-5/6",
"    </span>",
"    receptor [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/5/34906/abstract/46\">",
"     46",
"    </a>",
"    ]. Wnt signaling can also be blocked by other proteins, such as soluble frizzled-related protein, that bind to Wnt ligands [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/5/34906/abstract/47\">",
"     47",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Disruption in the Wnt signaling pathway results in profound changes in skeletal homeostasis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/5/34906/abstract/48\">",
"     48",
"    </a>",
"    ]. As examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Loss or gain of function mutations in LRP5 causes osteoporosis-pseudoglioma syndrome [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/5/34906/abstract/49\">",
"       49",
"      </a>",
"      ] or the hereditary High Bone Mass trait, respectively [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/5/34906/abstract/50-52\">",
"       50-52",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Genetic disorders in which sclerostin production is decreased are associated with increased bone mass [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/5/34906/abstract/53\">",
"       53",
"      </a>",
"      ], and antibodies to sclerostin can increase bone formation [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/5/34906/abstract/54\">",
"       54",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The anabolic effects of PTH and mechanical loading may involve enhanced Wnt signaling via down-regulation of sclerostin activation of LRP-5 [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/5/34906/abstract/55-58\">",
"       55-58",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Inactivation of DKK family members can increase bone mass [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/5/34906/abstract/59\">",
"       59",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The Wnt pathway is also a major regulator of joint remodeling and TNF-alpha induction of DKK-1 results in the joint erosion characteristically seen in rheumatoid arthritis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/5/34906/abstract/46\">",
"       46",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H594350\">",
"    <span class=\"h3\">",
"     Apoptosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sixty to 80 percent of osteoblasts die by apoptosis. The remaining become either lining cells that spread out and cover quiescent bone surfaces or are entombed individually in lacunae of the mineralized matrix as osteocytes. The lining cells remain connected to the osteocytes, which may be necessary for transmitting the activation signal during remodeling.",
"   </p>",
"   <p>",
"    An increase in reactive oxygen species (ROS) has been implicated in the decreased bone formation associated with advancing age [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/5/34906/abstract/60\">",
"     60",
"    </a>",
"    ]. In line with this evidence, oxidative stress caused by increased ROS production in osteoblasts stimulates apoptosis and decreases bone formation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/5/34906/abstract/61-63\">",
"     61-63",
"    </a>",
"    ]. To protect against oxidative stress, organisms ranging from prokaryotes to mammals scavenge ROS by a network of overlapping mechanisms including various forms of superoxide dismutases (SODs) and catalase as well as thiol-containing oligopeptides with redox-active sulfhydryl moieties, the most abundant of which are glutathione and thioredoxin [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/5/34906/abstract/64\">",
"     64",
"    </a>",
"    ]. Reduction of these scavenging mechanisms, along with increased mitochondrial respiratory chain leakage and increased activity of membrane oxidases, are the three main mechanisms for oxidative stress.",
"   </p>",
"   <p>",
"    FoxO transcription factors are another important defense mechanism against oxidative stress, serving primarily to maintain the integrity of long lived cells including tissue stem cells. Consistent with this, global deletion of FoxOs recapitulates the effects of old age on the murine skeleton in young mice within five weeks, suggesting that FoxO-dependent oxidative defense provides a mechanism to handle the oxygen free radicals constantly generated by the aerobic metabolism of osteoblasts and is thereby indispensable for bone mass homeostasis throughout life. While defending against OS, FoxOs attenuate Wnt signaling and its potent influence on bone mass [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/5/34906/abstract/65,66\">",
"     65,66",
"    </a>",
"    ]. Indeed, in the setting of oxidative stress, the limited pool of &beta;-catenin in osteoblast progenitors is diverted from",
"    <span class=\"nowrap\">",
"     Wnt/Tcf-",
"    </span>",
"    to FoxO-mediated transcription [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/5/34906/abstract/65\">",
"     65",
"    </a>",
"    ]. This diversion leads to suppressed osteoblastogenesis and is associated with the old age-dependant decrease in osteoblast number and bone formation in the murine skeleton [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/5/34906/abstract/65,66\">",
"     65,66",
"    </a>",
"    ], and may contribute to several other age-related pathologies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/5/34906/abstract/67-71\">",
"     67-71",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H594407\">",
"    <span class=\"h2\">",
"     Osteocytes",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the process of their entombment within the mineralized matrix, osteocytes undergo a dramatic morphologic transformation that includes the development of an average of 50 slender cytoplasmic processes that radiate from the cell body and give osteocytes the resemblance of neuronal cells [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/5/34906/abstract/72\">",
"     72",
"    </a>",
"    ]. The processes run like buried cable along narrow canaliculi and are linked by gap junctions with the processes of neighboring osteocytes, as well as cells present on the bone surface, including the lining cells and cellular elements of the bone marrow and the endothelial cell of the bone marrow vasculature (",
"    <a class=\"graphic graphic_figure graphicRef73524 \" href=\"mobipreview.htm?26/52/27465\">",
"     figure 4",
"    </a>",
"    ). Unlike osteoclasts and osteoblasts, which are relatively short-lived and transiently present only on a small fraction of the bone surface, osteocytes are deployed throughout the skeleton, are long-lived, and are far more abundant than either osteoclasts (1000 times) or osteoblasts (10 times) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/5/34906/abstract/73\">",
"     73",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Osteocytes and their dendritic processes are surrounded by a gel-like matrix that is in continuity with the peripheral circulation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/5/34906/abstract/74,75\">",
"     74,75",
"    </a>",
"    ]. Transport of solutes through the lacunar-canalicular system is accommodated in part by hydraulic vascular pressure and in part by diffusion and convection induced by mechanical forces. Transmission of fluid shear stresses to the cytoskeleton by the matrix is essential for the ability of osteocytes to sense mechanical loading and choreograph the adaptation of bone to the prevailing mechanical forces. Cilia tether the osteocytes to the collagen, allowing them to sense fluid shifts. Osteocytes secrete growth factors that regulate bone formation. Mature osteocytes tonically secrete sclerostin to maintain an inhibition of bone formation, but when mechanical forces are applied to the bone, the osteocytes stop secreting sclerostin and bone formation is initiated on the bone surface.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H593827\">",
"    <span class=\"h2\">",
"     Osteoclasts",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3804263\">",
"    <span class=\"h3\">",
"     Development",
"    </span>",
"    &nbsp;&mdash;&nbsp;Osteoclasts are terminally differentiated multinucleated cells that are uniquely capable of digesting calcified bone matrix. They are formed by fusion of mononuclear precursors of the",
"    <span class=\"nowrap\">",
"     monocyte/macrophage",
"    </span>",
"    lineage (",
"    <a class=\"graphic graphic_figure graphicRef79078 \" href=\"mobipreview.htm?1/39/1652\">",
"     figure 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/5/34906/abstract/76,77\">",
"     76,77",
"    </a>",
"    ]. The receptor activator of nuclear factor kappa B (NF-&kappa;B) ligand (RANKL) and the macrophage colony-stimulating factor (M-CSF) are two cytokines that are essential for the development, function, and survival of osteoclasts [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/5/34906/abstract/78,79\">",
"     78,79",
"    </a>",
"    ], and NFATc1 is the master transcription factor responsible for osteoclast differentiation and function [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/5/34906/abstract/79,80\">",
"     79,80",
"    </a>",
"    ]. Osteocytes are the main cellular source of the RANKL that is required for osteoclast generation during bone remodeling [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/5/34906/abstract/81\">",
"     81",
"    </a>",
"    ]. However, it is currently unclear whether during remodeling RANKL is produced by apoptotic osteocytes or live osteocytes responding to the death of their neighbors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/5/34906/abstract/82\">",
"     82",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    RANKL interacts with a receptor on osteoclast precursors that is identical to the receptor involved in interaction of T-cells and dendritic cells called RANK (",
"    <a class=\"graphic graphic_figure graphicRef61626 \" href=\"mobipreview.htm?40/45/41681\">",
"     figure 5",
"    </a>",
"    ). NFATc1 is induced by RANKL and co-activated by immunoglobulin-like receptors and their associated adapter proteins. RANKL can also bind to a protein called osteoprotegerin (OPG) or osteoclastogenesis inhibitory factor [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/5/34906/abstract/83-87\">",
"     83-87",
"    </a>",
"    ]. Administration of a single dose of osteoprotegerin or an antibody to RANKL to postmenopausal women results in rapid reduction of biochemical markers of bone turnover and increase in BMD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/5/34906/abstract/88,89\">",
"     88,89",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Reactive oxygen species (ROS),",
"    <strong>",
"    </strong>",
"    in contrast to their negative effects on osteoblasts, are a critical requirement for RANKL-induced osteoclast generation, activation, and survival [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/5/34906/abstract/90-92\">",
"     90-92",
"    </a>",
"    ]. RANKL increases ROS through a cascade involving TRAF6, Rac1, and NADPH oxidase (",
"    <a class=\"graphic graphic_figure graphicRef61626 \" href=\"mobipreview.htm?40/45/41681\">",
"     figure 5",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/5/34906/abstract/90,93-97\">",
"     90,93-97",
"    </a>",
"    ]. ROS also play an important role in M-CSF-induced monocyte survival [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/5/34906/abstract/98\">",
"     98",
"    </a>",
"    ]. Conversely, decreased ROS levels caused by the administration of the antioxidant N-acetyl cysteine (NAC), inhibition of NADPH oxidase (Nox1), a dominant negative rac1, or overexpression of glutathione peroxidase (Gpx) prevents RANKL-induced JNK, p38, and ERKs activation and osteoclastogenesis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/5/34906/abstract/90,97\">",
"     90,97",
"    </a>",
"    ]. Several different antioxidants prevent the increased bone resorption that follows loss of sex steroids [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/5/34906/abstract/63,99\">",
"     63,99",
"    </a>",
"    ]. Moreover, mitochondrial biogenesis and ROS production coupled with iron uptake through TfR1 and iron supply to mitochondrial respiratory proteins are essential for the bone resorbing function of osteoclasts and the bone loss caused by estrogen deficiency [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/5/34906/abstract/100\">",
"     100",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3804381\">",
"    <span class=\"h3\">",
"     Function",
"    </span>",
"    &nbsp;&mdash;&nbsp;As they mature, osteoclasts undergo dramatic reorganization of their cytoskeleton. Filamentous actin (F-actin) is first organized into podosomes, highly dynamic structures that mediate cell adhesion and migration of osteoclasts. When osteoclasts adhere on bone, F-actin forms a ring-like structure (actin-ring) at the sealing zone, a tight adhesion structure where the osteoclast plasma membrane is juxtaposed to bone [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/5/34906/abstract/19\">",
"     19",
"    </a>",
"    ]. The sealing zone surrounds a specialized plasma membrane domain, the ruffled border, thus forming an isolated resorptive microenvironment between the osteoclast and the underlying bone matrix. The ruffled border is generated by the fusion of secretory vesicles with the bone apposing plasma membrane. During this process, protons and lysosomal enzymes (predominantly cathepsin K) are vectorially secreted into the resorption lacuna to dissolve bone mineral and digest organic matrix, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/5/34906/abstract/101\">",
"     101",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The functional differentiation of osteoclasts involves the expression of several genes. Deletion of the c-src, c-fos, and PU-1 genes results in an osteopetrotic phenotype associated with inadequate formation or activity of osteoclasts [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/5/34906/abstract/102\">",
"     102",
"    </a>",
"    ]. Critical functional proteins include: integrin receptors for sealing zone attachment, a hydrogen-potassium ATPase for hydrogen ion secretion, chloride channels, and cathepsin K. Mononuclear osteoclast precursors express the genes for these proteins and for calcitonin receptors during differentiation.",
"   </p>",
"   <p>",
"    The final activation step probably involves binding of integrins to proteins on the mineralized bone surface that are either already present or are secreted by the osteoclasts [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/5/34906/abstract/103\">",
"     103",
"    </a>",
"    ]. The life span of osteoclasts is probably limited because of programmed death of the nuclei (apoptosis). Estrogen and TGF-beta may decrease bone resorption by stimulating apoptosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/5/34906/abstract/104-106\">",
"     104-106",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Osteoclasts remove mineral and matrix to a limited depth on the trabecular surface or within cortical bone. It is unclear what stops this process, but high local concentrations of calcium or substances released from the matrix may be involved [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/5/34906/abstract/107,108\">",
"     107,108",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Among the stimulators of osteoclast generation (some of which act indirectly) are calcitriol, PTH, TNFalpha, prostaglandin E2, IL-1, IL-6, IL-11, and IL-17.",
"     </li>",
"     <li>",
"      Among the inhibitors of osteoclast generation are several interleukins (IL-4,-12,-13,-18). Interferon-gamma (IFNg) appears to have a direct inhibitory effect and an indirect stimulatory effect [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/5/34906/abstract/109,110\">",
"       109,110",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1206099\">",
"    <span class=\"h1\">",
"     BIOCHEMISTRY OF BONE MINERAL MATRIX",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bone is composed of an orderly collagen matrix on which calcium and phosphate are deposited in the form of hydroxyapatite. Collagen is deposited in a lamellar fashion and strengthened by multiple crosslinks, both within and between the triple-helical collagen molecules. These crosslinks are pyridinolines that are resistant to degradation and are released during bone resorption, either as free or peptide forms that can be measured in serum and urine. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/33/42519?source=see_link\">",
"     \"Bone physiology and biochemical markers of bone turnover\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The matrix also contains noncollagen proteins that are critical for regulating mineralization and strengthening the collagen backbone [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/5/34906/abstract/111\">",
"     111",
"    </a>",
"    ]. The calcium-binding proteins include osteocalcin (bone Gla protein) and matrix Gla protein, which contain gamma carboxyglutamic acid and are vitamin K-dependent, similar to many clotting factors. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/32/20999?source=see_link\">",
"     \"Vitamin K, gamma carboxyglutamic acid, and the function of coagulation and other proteins\"",
"    </a>",
"    .) These proteins may delay mineralization and allow bone matrix to mature. Even though osteocalcin is the most specific protein product of osteoblasts, knocking out the osteocalcin gene does not impair skeletal growth and mineralization [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/5/34906/abstract/112\">",
"     112",
"    </a>",
"    ]. To the contrary, skeletal mass is increased in osteocalcin knock-out mice due to increased bone formation. Bone sialoprotein and osteopontin bind both calcium and collagen and may play a role in the adherence of osteoclasts to the bone surface.",
"   </p>",
"   <p>",
"    The bone mineral is composed of complex, often incomplete, crystals of hydroxyapatite. The crystals may contain carbonate, fluoride, and a variety of trace minerals, depending on the environment in which the skeleton grows. They are relatively small, which is appropriate for a structure that can undergo strain with minimal microdamage. Mineralization is probably limited not only by the packing of the collagen fibers, but also by substances present on the bone crystal surface such as pyrophosphate.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1207796\">",
"    <span class=\"h1\">",
"     BONE MODELING AND REMODELING",
"    </span>",
"    &nbsp;&mdash;&nbsp;During development and growth, the skeleton is sculpted to achieve its shape and size by the removal of bone from one site and deposition at a different one; this process is called modeling. After the skeleton has reached maturity, regeneration continues in the form of a periodic replacement of old bone with new at the same location [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/5/34906/abstract/113\">",
"     113",
"    </a>",
"    ]. This process is called remodeling",
"    <strong>",
"    </strong>",
"    and is responsible for the complete regeneration of the adult skeleton every 10 years.",
"   </p>",
"   <p>",
"    Bone remodeling begins early in skeletal development. Endochondral remodeling in the primary spongiosa converts the relatively weak spicules of calcified cartilage into strong trabecular bone. Haversian remodeling in the cortex occurs in larger bones and is probably necessary to maintain the viability of cells far from the bone surface. Haversian remodeling is probably also important in repairing fatigue damage to the skeleton.",
"   </p>",
"   <p>",
"    Removal of bone (resorption) is the task of osteoclasts. Formation of new bone is the task of osteoblasts. Both of these processes are controlled by the osteocytes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/5/34906/abstract/73\">",
"     73",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1206106\">",
"    <span class=\"h2\">",
"     Modeling",
"    </span>",
"    &nbsp;&mdash;&nbsp;Growth of the skeleton and changes in bone shape are produced by modeling. Linear growth during childhood and adolescence occurs by growth of cartilage at the end plates, followed by endochondral bone formation (",
"    <a class=\"graphic graphic_figure graphicRef68827 \" href=\"mobipreview.htm?40/49/41750\">",
"     figure 2",
"    </a>",
"    ). The width of the bones increases by periosteal apposition. During childhood, this is accompanied by endosteal resorption. The endosteal (or inner) surface is in contact with the marrow; thus, endosteal resorption results in a concomitant enlargement of the marrow cavity.",
"   </p>",
"   <p>",
"    During puberty and early adult life, endosteal apposition and trabecular thickening provide maximum skeletal mass and strength (peak bone mass) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/5/34906/abstract/114\">",
"     114",
"    </a>",
"    ]. These processes are influenced by locally and systemically-produced factors and mechanical forces.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1206113\">",
"    <span class=\"h2\">",
"     Remodeling",
"    </span>",
"    &nbsp;&mdash;&nbsp;The purpose of remodeling in the adult skeleton is unclear but most likely it serves to remove dead osteocytes, maintain oxygen and nutrient supply and the appropriate level of matrix hydration, and repair fatigue damage, thus preventing excessive aging and its consequences. Remodeling, with positive balance, does occur in the growing skeleton as well. Its purpose, quite different from that proposed for the adult skeleton, is to expand the marrow cavity while increasing trabecular thickness [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/5/34906/abstract/115\">",
"     115",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The stages of the remodeling cycle (resorption, reversal, formation) have different lengths. Resorption probably continues for about two weeks. The reversal phase may last up to four or five weeks, while formation can continue for four months until the new bone structural unit is fully formed. Because bone resorption precedes and is faster than bone formation, when there is a sudden increase in the remodeling rate, there is always a temporary imbalance, termed the remodeling space.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3804279\">",
"    <span class=\"h3\">",
"     Bone multicellular unit",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most of the adult skeleton consists of bone that is remodeled periodically by temporal anatomic units comprising osteoclasts and osteoblasts, termed bone multicellular units (BMU) (",
"    <a class=\"graphic graphic_picture graphicRef75617 \" href=\"mobipreview.htm?12/28/12742\">",
"     picture 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/5/34906/abstract/115\">",
"     115",
"    </a>",
"    ]. All osteoclasts and osteoblasts belong to a BMU [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/5/34906/abstract/115\">",
"     115",
"    </a>",
"    ]. Although during modeling one cannot distinguish anatomical units analogous to BMU per se, sculpting of the growing skeleton requires spatial and temporal orchestration of the destination of osteoblasts and osteoclasts, albeit with different rules and coordinates to those operating in the BMU of the remodeling skeleton.",
"   </p>",
"   <p>",
"    The BMU, approximately 1 to 2 mm long and 0.2 to 0.4 mm wide, comprises a team of osteoclasts in the front, a team of osteoblasts in the rear, a central vascular capillary, a nerve supply, and associated connective tissue. In healthy human adults, three to four million BMUs are initiated per year and about one million are operating at any moment. Each BMU begins at a particular place and time (origination) and advances toward a target, which is a region of bone in need of replacement, and for a variable distance beyond its target (progression) and eventually comes to rest (termination) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/5/34906/abstract/116\">",
"     116",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In cortical bone, the BMU (also termed osteon) travels through the bone, excavating and replacing a tunnel (Haversian canal). In cancellous bone, the BMU moves across the trabecular surface, excavating and replacing a trench (Howship&rsquo;s lacunae). In both situations, the cellular components of the BMUs maintain a well orchestrated spatial and temporal relationship with each other. Osteoclasts adhere to bone and subsequently remove it by acidification and proteolytic digestion. As the BMU advances, osteoclasts leave the resorption site and osteoblasts move in to cover the excavated area and begin the process of new bone formation by secreting osteoid, which is eventually mineralized into new bone. In normal adults, bone resorption and bone formation are tightly balanced so that the amount of bone formed in new BMUs equals the amount of bone resorbed. Animated diagrams of bone remodeling can be viewed on the American Society of Bone and Mineral Research (ASBMR)",
"    <a class=\"external\" href=\"file://depts.washington.edu/bonebio/ASBMRed/growth.html\">",
"     bone curriculum website",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    One or more capillaries are always in close proximity to the teams of the osteoclasts and osteoblasts that remodel bone and are most likely the conduits by which osteoclast precursors reach the site that is targeted for remodeling [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/5/34906/abstract/19,117\">",
"     19,117",
"    </a>",
"    ]. In cancellous bone, blood vessels are juxtaposed to a canopy of flat cells that separates the BMU from the bone marrow [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/5/34906/abstract/118\">",
"     118",
"    </a>",
"    ]. Low oxygen tension, developed as the bone matrix expands, stimulates the expression of endothelial growth factors by osteoblasts and initiates a neovasculogenic program [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/5/34906/abstract/1,119,120\">",
"     1,119,120",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3804366\">",
"    <span class=\"h3\">",
"     Signaling pathways",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypertrophic chondrocytes and osteocytes are essential sources of the RANKL that controls mineralized cartilage resorption and bone remodeling, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/5/34906/abstract/81,121\">",
"     81,121",
"    </a>",
"    ].",
"    <strong>",
"    </strong>",
"    Newer studies of cultured cells show that osteocytes express a much higher amount of RANKL and have a greater capacity to support osteoclastogenesis in vitro than osteoblasts, and mice with deletion of the RANKL gene in osteocytes have increased bone mass. Contrary to the older paradigm, RANKL produced by mature osteoblasts or their progenitors does not seem to contribute to adult bone remodeling. The rate-limiting step of matrix resorption is controlled by cells embedded within the matrix itself. This evidence provides a mechanistic explanation for the view that at least some remodeling is a targeted (as opposed to stochastic) process in which cells that can sense mechanical strains [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/5/34906/abstract/122\">",
"     122",
"    </a>",
"    ] or matrix damage [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/5/34906/abstract/123\">",
"     123",
"    </a>",
"    ] act as beacons for excavation and repair of a specific region of bone. Similarly, hypertrophic chondrocytes may sense signals that initiate transformation of the cartilage scaffold into bony trabeculae. In both cases, the cells that can best detect the need for matrix removal directly control the process.",
"   </p>",
"   <p>",
"    During the last few years, it has become evident that osteocytes are the choreographers of the remodeling process on the bone surface by virtue of their ability to: sense worn-out bone, direct the homing of osteoclasts (and perhaps osteoblasts) to the site that is in need of remodeling, produce the RANKL and sclerostin that regulate osteoclast and osteoblast generation, respectively (",
"    <a class=\"graphic graphic_figure graphicRef50298 \" href=\"mobipreview.htm?22/7/22640\">",
"     figure 6",
"    </a>",
"    ), and control and modify the mineralization of the matrix produced by osteoblasts [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/5/34906/abstract/124\">",
"     124",
"    </a>",
"    ]. Mechanical forces sustain osteocyte survival. Conversely, diminished mechanical forces eliminate the necessary signals that sustain osteocyte survival, thereby leading to their apoptosis. Moreover, osteocytes are critical mediators of the homeostatic adaptation of bone to mechanical forces. On the other hand, disruption of the integrity of the osteocyte network leads to inappropriate remodeling and in and of itself compromises bone strength independently of changes in bone mass [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/5/34906/abstract/125\">",
"     125",
"    </a>",
"    ]. Furthermore, osteocytes control and modify the mineralization of the matrix produced by osteoblasts by secreting factors such as MEPE and the phosphaturic hormone FGF23 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/5/34906/abstract/124,126\">",
"     124,126",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1207804\">",
"    <span class=\"h3\">",
"     Resorption",
"    </span>",
"    &nbsp;&mdash;&nbsp;The bone remodeling cycle begins with osteoclast generation and recruitment to a particular site. Under physiologic conditions such site may be in need for repair while under pathologic conditions it may be randomly and inappropriately targeted.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1206120\">",
"    <span class=\"h3\">",
"     Reversal",
"    </span>",
"    &nbsp;&mdash;&nbsp;After osteoclastic resorption is completed, there is a reversal phase in which mononuclear cells, possibly of",
"    <span class=\"nowrap\">",
"     monocyte/macrophage",
"    </span>",
"    lineage, appear on the bone surface. These cells could prepare the surface for new osteoblasts to begin bone formation. A layer of glycoprotein-rich material is laid down on the resorbed surface, the so-called \"cement line,\" to which the new osteoblasts can adhere. Osteopontin may be a key protein in this process [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/5/34906/abstract/127\">",
"     127",
"    </a>",
"    ]. The cells at the reversal site may also provide signals for osteoblast differentiation and migration.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1206127\">",
"    <span class=\"h3\">",
"     Formation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The formation phase follows, with successive waves of osteoblasts laying down bone until the resorbed bone is completely replaced and a new bone structural unit is fully formed. When this phase is complete, the surface is covered with flattened lining cells, and there is a prolonged resting period with little cellular activity on the bone surface until a new remodeling cycle begins.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H244951\">",
"    <span class=\"h3\">",
"     Mineralization",
"    </span>",
"    &nbsp;&mdash;&nbsp;The newly formed osteoid begins to mineralize after about two weeks. This process involves accumulation of matrix molecules. Mineralization occurs rapidly at first, then more slowly. It takes several years for a bone structural unit to become fully mineralized.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1206134\">",
"    <span class=\"h1\">",
"     ABNORMAL BONE REMODELING",
"    </span>",
"    &nbsp;&mdash;&nbsp;In normal adults, bone resorption and bone formation are tightly balanced so that the amount of bone formed in new BMUs equals the amount of bone resorbed. The mechanism(s) of normal balancing is unknown but probably involves several factors released from the bone matrix during osteoclastic bone resorption, such as TGF-beta [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/5/34906/abstract/128-130\">",
"     128-130",
"    </a>",
"    ], factors produced by osteocytes, such as sclerostin, as well as mechanical needs or hormonal changes. High or low rates of remodeling with an imbalance between resorption and formation can be associated with decreased or increased bone mass.",
"   </p>",
"   <p>",
"    The rate of bone remodeling is very high during bone growth with total body bone formation exceeding resorption, but slows considerably thereafter and the volume of bone formed by each BMU declines with advancing age [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/5/34906/abstract/60\">",
"     60",
"    </a>",
"    ]. Normal parathyroid hormone production is an important determinant of the basal rate of remodeling, and patients with congenital, autoimmune, or surgical hypoparathyroidism have low remodeling rates [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/5/34906/abstract/131\">",
"     131",
"    </a>",
"    ]. Other hormonal changes such as menopause or loss of androgens in castrated males, hyperthyroidism, or primary hyperparathyroidism accelerate the rate of remodeling. In the case of the loss of sex steroid, the increased rate of remodeling is transient and returns to baseline within 5 to 10 years (unless there is vitamin D deficiency and secondary hyperparathyroidism), perhaps because of compensatory mechanisms. An oversupply of osteoclasts relative to the need for remodeling or an undersupply of osteoblasts relative to the need for cavity repair are the seminal pathophysiological cellular changes in the most common bone diseases, including osteoporosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/5/34906/abstract/132,133\">",
"     132,133",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3804447\">",
"    <span class=\"h2\">",
"     Low bone mass",
"    </span>",
"    &nbsp;&mdash;&nbsp;An oversupply of osteoclasts can result in excessive resorption depth, which can lead to complete loss of trabecular structures. The resulting perforations and discontinuities convert the normal plate-like trabecular architecture to a much weaker system of rods, some of which have free, disconnected ends (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef72620 \" href=\"mobipreview.htm?16/9/16529\">",
"     image 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef51633 \" href=\"mobipreview.htm?8/38/8808\">",
"     figure 7",
"    </a>",
"    ). There is no template for bone formation at the perforations and no formation occurs at the free ends of the trabeculae, perhaps because they are not subject to mechanical stress. Complete removal of template also occurs physiologically. As long bones grow, the metaphyseal trabecular bone area decreases as the secondary spongiosa is completely resorbed and the marrow space expands.",
"   </p>",
"   <p>",
"    Bone thinning can also occur without perforation when the extent of resorption or the number of resorbing sites is increased. Osteoblasts normally completely fill the resorption cavity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/5/34906/abstract/134\">",
"     134",
"    </a>",
"    ]; if this does not occur, the BMU is incomplete, which results in decreased \"wall thickness\" in trabecular bone. This is the histological hallmark of osteoporosis in elderly patients or patients treated with glucocorticoids [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/5/34906/abstract/135\">",
"     135",
"    </a>",
"    ], and it is the result of a decrease in the amount of bone formed by the team of osteoblasts within each BMU.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3804440\">",
"    <span class=\"h2\">",
"     High bone mass",
"    </span>",
"    &nbsp;&mdash;&nbsp;Remodeling imbalance can also occur because of failure of the resorptive process. This can result in dense bones (osteopetrosis or osteosclerosis) and impaired hematopoiesis. As described above, macrophage colony-stimulating factor (M-CSF, CSF-1) is required to initiate osteoclast differentiation. There are osteopetrotic mice that do not make M-CSF and the osteopetrotic gene locus maps to the same region of chromosome 3 as the M-CSF gene [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/5/34906/abstract/136\">",
"     136",
"    </a>",
"    ]. The applicability of this mechanism to osteopetrosis in humans is unknown. However, other genetic abnormalities have been identified that lead to osteosclerosis, including defects in the genes for ion transport in osteoclasts [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/5/34906/abstract/137-140\">",
"     137-140",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In humans, the most common mutation linked to osteopetrosis is a defect in the osteoclast-specific proton-pump subunit (TCIRG1); 60 percent of patients with severe autosomal recessive osteopetrosis have this mutation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/5/34906/abstract/141\">",
"     141",
"    </a>",
"    ]. Other clinically significant mutations have been identified in CLCN7, a gene that encodes an osteoclast-specific chloride channel; OSTM-1, a gene that may be involved in Wnt signaling; and in CAII, the carbonic anhydrase II gene. These mutations are associated with normal or elevated numbers of abnormally functioning osteoclasts [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/5/34906/abstract/141-143\">",
"     141-143",
"    </a>",
"    ]. In contrast, mutations in RANKL result in an osteoclast poor form of osteopetrosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/5/34906/abstract/144\">",
"     144",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In addition to increases in bone density due to impaired resorption, bone density can be increased by greater stimulation of bone formation or by a combination of the two. This probably is the mechanism for increased bone mass in so-called autosomal dominant type I osteopetrosis in which an activating mutation in the LRP5 gene leads to activation of the Wnt signaling pathway and promotion of osteoblastogenesis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/5/34906/abstract/51,145\">",
"     51,145",
"    </a>",
"    ]. Sclerostin is a major antagonist of the Wnt signaling pathway (see",
"    <a class=\"local\" href=\"#H593753\">",
"     'Wnt signaling pathway'",
"    </a>",
"    above). Loss of function mutations in the gene for sclerostin (SOST) have been described and are also associated with high bone mass [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/5/34906/abstract/146,147\">",
"     146,147",
"    </a>",
"    ]. The anabolic effect of intermittent PTH administration may also be due in part to suppression of sclerostin, decreased osteoblast and osteocyte apoptosis, and decreased oxidative stress [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/5/34906/abstract/148\">",
"     148",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1207811\">",
"    <span class=\"h1\">",
"     SYSTEMIC AND LOCAL REGULATORS OF BONE CELLS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many systemic hormones, cytokines, growth factors, and local signals influence the birth, death, and function of bone cells. The major systemic regulators are the calcium-regulating hormones, PTH, calcitriol, growth",
"    <span class=\"nowrap\">",
"     hormone/IGF-I,",
"    </span>",
"    glucocorticoids, thyroid hormones, and sex hormones. Other factors, such as IGFs, have both systemic and local effects, and some have mainly or solely local effects, particularly prostaglandins, TGF-beta, bone morphogenetic proteins, and cytokines.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1206142\">",
"    <span class=\"h2\">",
"     Parathyroid hormone",
"    </span>",
"    &nbsp;&mdash;&nbsp;PTH is the most important regulator of calcium homeostasis. It maintains serum calcium concentrations by stimulating bone resorption, increasing renal tubular calcium reabsorption, and increasing renal calcitriol production. PTH stimulates bone formation when given intermittently, but inhibits collagen synthesis at high concentrations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/5/34906/abstract/149,150\">",
"     149,150",
"    </a>",
"    ]. It stimulates bone resorption when given (or secreted) continuously, a process mediated by osteoclasts. It also stimulates gene expression in these cells and increases the production of several local factors, including IL-6, IGF-1 and an IGF-binding protein, IGF-BP-5, and prostaglandins. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/56/36744?source=see_link\">",
"     \"Parathyroid hormone secretion and action\"",
"    </a>",
"    .)",
"    <br/>",
"    <br/>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1206149\">",
"    <span class=\"h2\">",
"     Calcitriol",
"    </span>",
"    &nbsp;&mdash;&nbsp;Calcitriol increases intestinal calcium and phosphorus absorption, thereby promoting bone mineralization. At high concentrations, under conditions of calcium and phosphate deficiency, it also stimulates bone resorption, thereby helping to maintain the supply of these ions to other tissues. Calcitriol stimulates osteoclastogenesis in cell cultures, but animals lacking vitamin D have relatively normal bone growth and remodeling during development, as long as calcium and phosphate are maintained [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/5/34906/abstract/151\">",
"     151",
"    </a>",
"    ].",
"    <br/>",
"    <br/>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1206156\">",
"    <span class=\"h2\">",
"     Sex steroids",
"    </span>",
"    &nbsp;&mdash;&nbsp;Both estrogens and androgens have profound effects on bone homeostasis. Estrogen acts directly on cells of both the osteoblastic and osteoclastic lineage [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/5/34906/abstract/105,106,152\">",
"     105,106,152",
"    </a>",
"    ], and influences skeletal development in both sexes. In late puberty, estrogens decrease bone turnover by inhibiting bone resorption and they are necessary for epiphyseal closure in both females and males. Thus males with genetic loss of estrogen receptors or of the aromatase enzyme that converts androgen to estrogen have delayed bone age and decreased bone accrual and delayed epiphyseal closure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/5/34906/abstract/153\">",
"     153",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/53/3929?source=see_link\">",
"     \"Pathogenesis of osteoporosis\"",
"    </a>",
"    .)",
"    <br/>",
"    <br/>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1206163\">",
"    <span class=\"h2\">",
"     Calcitonin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Calcitonin inhibits osteoclasts and therefore bone resorption in pharmacologic doses. However, its physiologic role is minimal in the adult human skeleton. Its pharmacologic effects are transient, probably because of receptor downregulation. As a result, it is only transiently effective in treating hypercalcemia due to excessive bone resorption. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/42/16041?source=see_link\">",
"     \"Treatment of hypercalcemia\"",
"    </a>",
"    .)",
"    <br/>",
"    <br/>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1206170\">",
"    <span class=\"h2\">",
"     Growth hormone and IGFs",
"    </span>",
"    &nbsp;&mdash;&nbsp;The",
"    <span class=\"nowrap\">",
"     GH/IGF-1",
"    </span>",
"    system and IGF-2 are important for skeletal growth, especially growth at the cartilaginous end plates and endochondral bone formation. The actions of the IGFs are in part determined by the availability of the various IGF-BPs: IGF-BP-3 is the major determinant of serum IGF concentrations, while IGF-BP-5 may facilitate and IGF-BP-4 may inhibit the local actions of IGFs.",
"    <br/>",
"    <br/>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5525093\">",
"    <span class=\"h2\">",
"     TGF-beta",
"    </span>",
"    &nbsp;&mdash;&nbsp;TGF-beta and the bone morphogenetic protein family of proteins consist of at least 10 proteins that are produced by many different cells and that have multiple actions on growth and development [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/5/34906/abstract/154-156\">",
"     154-156",
"    </a>",
"    ]. TGF-beta can inhibit bone resorption and stimulate bone formation. Bone morphogenetic protein-2 and other members of this family increase osteoblast differentiation and bone formation when injected subcutaneously or intramuscularly.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1206177\">",
"    <span class=\"h2\">",
"     Glucocorticoids",
"    </span>",
"    &nbsp;&mdash;&nbsp;Inhibition of bone formation is the major cause of glucocorticoid-induced osteoporosis and may be due to accelerated apoptosis of osteoblasts and osteocytes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/5/34906/abstract/157\">",
"     157",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/54/42855?source=see_link\">",
"     \"Pathogenesis, clinical features, and evaluation of glucocorticoid-induced osteoporosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1206184\">",
"    <span class=\"h2\">",
"     Thyroid hormones",
"    </span>",
"    &nbsp;&mdash;&nbsp;Thyroid hormones stimulate both bone resorption and formation. Thus, bone turnover is increased in hyperthyroidism, and bone loss can occur. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/11/17593?source=see_link\">",
"     \"Bone disease with hyperthyroidism and thyroid hormone therapy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1206191\">",
"    <span class=\"h2\">",
"     Cytokines",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cytokines, produced by bone cells and adjacent hematopoietic and vascular cells, have multiple regulatory actions in the skeleton [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/5/34906/abstract/158-163\">",
"     158-163",
"    </a>",
"    ]. Many of these factors have been implicated in the bone loss associated with ovariectomy in rodents. Regulation may occur as a result of both varying production of agonists and of changes in the receptors or binding proteins (receptor antagonists) for these factors.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1206198\">",
"    <span class=\"h2\">",
"     Fibroblast growth factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fibroblast growth factors are another family of proteins involved in skeletal development. Mutations in the receptors for these factors result in abnormal skeletal phenotypes, such as achondroplasia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/5/34906/abstract/155\">",
"     155",
"    </a>",
"    ]. Other growth factors such as vascular-endothelial growth factor are produced in bone and may play a role in bone remodeling.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1206205\">",
"    <span class=\"h2\">",
"     Other",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of other factors play an important role in bone metabolism [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/5/34906/abstract/154,156,164-167\">",
"     154,156,164-167",
"    </a>",
"    ]. As examples: Prostaglandins, leukotrienes, and nitric oxide may be critical in the rapid responses of bone cells to inflammation and mechanical forces. Prostaglandins have biphasic effects on bone resorption and formation, but the dominant effects in vivo are stimulatory [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/5/34906/abstract/165\">",
"     165",
"    </a>",
"    ]. Prostaglandin production can be increased by impact loading and by inflammatory cytokines. Nitric oxide can inhibit osteoclast function [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/5/34906/abstract/168\">",
"     168",
"    </a>",
"    ], while leukotrienes stimulate bone resorption [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/5/34906/abstract/169\">",
"     169",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1207895\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The skeleton is a highly dynamic organ that constantly undergoes changes and regeneration. It consists of specialized bone cells, mineralized and unmineralized connective tissue matrix, and spaces that include the bone marrow cavity, vascular canals, canaliculi, and lacunae containing osteocytes. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Flat bones, including the vault of the skull, most of the upper facial skeleton, parts of the mandible, clavicle, and the pelvis, as well as the collar of long bones, arise from the direct conversion of undifferentiated mesenchymal cells into bone in a process called intramembranous bone formation. Axial and appendicular bone is formed from a cartilaginous template and is termed endochondral bone formation (",
"      <a class=\"graphic graphic_figure graphicRef68827 \" href=\"mobipreview.htm?40/49/41750\">",
"       figure 2",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H1206084\">",
"       'Skeletal development'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The precursors of osteoblasts are multipotent mesenchymal stem cells (",
"      <a class=\"graphic graphic_figure graphicRef79078 \" href=\"mobipreview.htm?1/39/1652\">",
"       figure 3",
"      </a>",
"      ). The process of differentiation of these progenitors to mature osteoblasts, ie, the cells capable of synthesizing the bone matrix, is accomplished by a sequential progression from the least differentiated and most proliferative cell to terminally differentiated cell that can no longer undergo mitosis. Runx2 and the Wnt signaling pathway are critical for the initiation of the osteoblast differentiation process and the commitment of multi-potential precursors to osteoprogenitors. (See",
"      <a class=\"local\" href=\"#H593737\">",
"       'Osteoblasts'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Osteoclasts remove mineral and matrix to a limited depth on the trabecular surface or within cortical bone. They are formed by fusion of mononuclear precursors of the",
"      <span class=\"nowrap\">",
"       monocyte/macrophage",
"      </span>",
"      lineage. The receptor activator of nuclear factor kappa B (NF-&kappa;B) ligand (RANKL) and the macrophage colony-stimulating factor (M-CSF) are two cytokines that are essential for the development, function, and survival of osteoclasts. (See",
"      <a class=\"local\" href=\"#H593827\">",
"       'Osteoclasts'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      During development and growth, the skeleton is sculpted to achieve its shape and size by the removal of bone from one site and deposition at a different one; this process is called modeling. After the skeleton has reached maturity, regeneration continues in the form of a periodic replacement of old bone with new at the same location, a process called remodeling. (See",
"      <a class=\"local\" href=\"#H1207796\">",
"       'Bone modeling and remodeling'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      All osteoclasts and osteoblasts belong to a unique temporary structure known as a bone multicellular unit (BMU) (",
"      <a class=\"graphic graphic_picture graphicRef75617 \" href=\"mobipreview.htm?12/28/12742\">",
"       picture 1",
"      </a>",
"      ). Osteoclasts adhere to bone and subsequently remove it by acidification and proteolytic digestion. As the BMU advances, osteoclasts leave the resorption site and osteoblasts move in to cover the excavated area and begin the process of new bone formation by secreting osteoid, which is eventually mineralized into new bone. In normal adults, bone resorption and bone formation are tightly balanced so that the amount of bone formed in new BMUs equals the amount of bone resorbed. (See",
"      <a class=\"local\" href=\"#H3804279\">",
"       'Bone multicellular unit'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      An oversupply of osteoclasts relative to the need for remodeling or an undersupply of osteoblasts relative to the need for cavity repair are the seminal pathophysiological cellular changes in the most common bone diseases, including osteoporosis (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef72620 \" href=\"mobipreview.htm?16/9/16529\">",
"       image 1",
"      </a>",
"      and",
"      <a class=\"graphic graphic_figure graphicRef51633 \" href=\"mobipreview.htm?8/38/8808\">",
"       figure 7",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H1206134\">",
"       'Abnormal bone remodeling'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Several systemic hormones, cytokines, growth factors, and local signals influence the birth, death, and function of bone cells. The major systemic regulators are the calcium-regulating hormones, PTH, calcitriol, growth",
"      <span class=\"nowrap\">",
"       hormone/IGF-I,",
"      </span>",
"      glucocorticoids, thyroid hormones, and sex hormones. Other factors, such as IGFs, have both systemic and local effects, and some have mainly or solely local effects, particularly prostaglandins, TGF-beta, bone morphogenetic proteins, and cytokines. (See",
"      <a class=\"local\" href=\"#H1207811\">",
"       'Systemic and local regulators of bone cells'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/5/34906/abstract/1\">",
"      Zelzer E, McLean W, Ng YS, et al. Skeletal defects in VEGF(120/120) mice reveal multiple roles for VEGF in skeletogenesis. Development 2002; 129:1893.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/5/34906/abstract/2\">",
"      Schipani E, Maes C, Carmeliet G, Semenza GL. Regulation of osteogenesis-angiogenesis coupling by HIFs and VEGF. J Bone Miner Res 2009; 24:1347.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/5/34906/abstract/3\">",
"      Blin-Wakkach C, Lezot F, Ghoul-Mazgar S, et al. Endogenous Msx1 antisense transcript: in vivo and in vitro evidences, structure, and potential involvement in skeleton development in mammals. Proc Natl Acad Sci U S A 2001; 98:7336.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/5/34906/abstract/4\">",
"      Wellik DM, Capecchi MR. Hox10 and Hox11 genes are required to globally pattern the mammalian skeleton. Science 2003; 301:363.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/5/34906/abstract/5\">",
"      Harris SE, Guo D, Harris MA, et al. Transcriptional regulation of BMP-2 activated genes in osteoblasts using gene expression microarray analysis: role of Dlx2 and Dlx5 transcription factors. Front Biosci 2003; 8:s1249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/5/34906/abstract/6\">",
"      Li H, Marijanovic I, Kronenberg MS, et al. Expression and function of Dlx genes in the osteoblast lineage. Dev Biol 2008; 316:458.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/5/34906/abstract/7\">",
"      Kronenberg HM. Developmental regulation of the growth plate. Nature 2003; 423:332.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/5/34906/abstract/8\">",
"      Kobayashi T, Chung UI, Schipani E, et al. PTHrP and Indian hedgehog control differentiation of growth plate chondrocytes at multiple steps. Development 2002; 129:2977.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/5/34906/abstract/9\">",
"      Mead TJ, Yutzey KE. Notch pathway regulation of chondrocyte differentiation and proliferation during appendicular and axial skeleton development. Proc Natl Acad Sci U S A 2009; 106:14420.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/5/34906/abstract/10\">",
"      Weber JM, Calvi LM. Notch signaling and the bone marrow hematopoietic stem cell niche. Bone 2010; 46:281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/5/34906/abstract/11\">",
"      Zalutskaya AA, Cox MK, Demay MB. Phosphate regulates embryonic endochondral bone development. J Cell Biochem 2009; 108:668.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/5/34906/abstract/12\">",
"      Berndt T, Kumar R. Novel mechanisms in the regulation of phosphorus homeostasis. Physiology (Bethesda) 2009; 24:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/5/34906/abstract/13\">",
"      Kiela PR, Ghishan FK. Recent advances in the renal-skeletal-gut axis that controls phosphate homeostasis. Lab Invest 2009; 89:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/5/34906/abstract/14\">",
"      Friedenstein AJ, Chailakhyan RK, Latsinik NV, et al. Stromal cells responsible for transferring the microenvironment of the hemopoietic tissues. Cloning in vitro and retransplantation in vivo. Transplantation 1974; 17:331.",
"     </a>",
"    </li>",
"    <li>",
"     Owen M. Lineage of osteogenic cells and their relationship to the stromal system. In: Bone and Mineral Research, Peck WA.  (Ed), Elsevier, Amsterdam 1985. Vol 3, p.1.",
"    </li>",
"    <li>",
"     Triffitt JT. The stem cell of the osteoblast. In: Principles of Bone Biology, Bilezikian JP, Raisz LG, Rodan GA.  (Eds), Academic Press, San Diego 1996. p.39.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/5/34906/abstract/17\">",
"      Schor AM, Canfield AE, Sutton AB, et al. Pericyte differentiation. Clin Orthop Relat Res 1995; :81.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/5/34906/abstract/18\">",
"      Pufe T, Scholz-Ahrens KE, Franke AT, et al. The role of vascular endothelial growth factor in glucocorticoid-induced bone loss: evaluation in a minipig model. Bone 2003; 33:869.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/5/34906/abstract/19\">",
"      Burkhardt R, Kettner G, B&ouml;hm W, et al. Changes in trabecular bone, hematopoiesis and bone marrow vessels in aplastic anemia, primary osteoporosis, and old age: a comparative histomorphometric study. Bone 1987; 8:157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/5/34906/abstract/20\">",
"      Sacchetti B, Funari A, Michienzi S, et al. Self-renewing osteoprogenitors in bone marrow sinusoids can organize a hematopoietic microenvironment. Cell 2007; 131:324.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/5/34906/abstract/21\">",
"      Komori T, Yagi H, Nomura S, et al. Targeted disruption of Cbfa1 results in a complete lack of bone formation owing to maturational arrest of osteoblasts. Cell 1997; 89:755.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/5/34906/abstract/22\">",
"      Otto F, Thornell AP, Crompton T, et al. Cbfa1, a candidate gene for cleidocranial dysplasia syndrome, is essential for osteoblast differentiation and bone development. Cell 1997; 89:765.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/5/34906/abstract/23\">",
"      Komori T. Regulation of bone development and extracellular matrix protein genes by RUNX2. Cell Tissue Res 2010; 339:189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/5/34906/abstract/24\">",
"      Mundlos S, Otto F, Mundlos C, et al. Mutations involving the transcription factor CBFA1 cause cleidocranial dysplasia. Cell 1997; 89:773.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/5/34906/abstract/25\">",
"      Lee B, Thirunavukkarasu K, Zhou L, et al. Missense mutations abolishing DNA binding of the osteoblast-specific transcription factor OSF2/CBFA1 in cleidocranial dysplasia. Nat Genet 1997; 16:307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/5/34906/abstract/26\">",
"      Nakashima K, Zhou X, Kunkel G, et al. The novel zinc finger-containing transcription factor osterix is required for osteoblast differentiation and bone formation. Cell 2002; 108:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/5/34906/abstract/27\">",
"      Kawai M, Rosen CJ. PPAR&gamma;: a circadian transcription factor in adipogenesis and osteogenesis. Nat Rev Endocrinol 2010; 6:629.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/5/34906/abstract/28\">",
"      Malaval L, Modrowski D, Gupta AK, Aubin JE. Cellular expression of bone-related proteins during in vitro osteogenesis in rat bone marrow stromal cell cultures. J Cell Physiol 1994; 158:555.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/5/34906/abstract/29\">",
"      Liu F, Malaval L, Aubin JE. The mature osteoblast phenotype is characterized by extensive plasticity. Exp Cell Res 1997; 232:97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/5/34906/abstract/30\">",
"      Gaur T, Lengner CJ, Hovhannisyan H, et al. Canonical WNT signaling promotes osteogenesis by directly stimulating Runx2 gene expression. J Biol Chem 2005; 280:33132.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/5/34906/abstract/31\">",
"      Tamai K, Semenov M, Kato Y, et al. LDL-receptor-related proteins in Wnt signal transduction. Nature 2000; 407:530.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/5/34906/abstract/32\">",
"      He X, Semenov M, Tamai K, Zeng X. LDL receptor-related proteins 5 and 6 in Wnt/beta-catenin signaling: arrows point the way. Development 2004; 131:1663.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/5/34906/abstract/33\">",
"      Liu C, Li Y, Semenov M, et al. Control of beta-catenin phosphorylation/degradation by a dual-kinase mechanism. Cell 2002; 108:837.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/5/34906/abstract/34\">",
"      Bienz M, Clevers H. Armadillo/beta-catenin signals in the nucleus--proof beyond a reasonable doubt? Nat Cell Biol 2003; 5:179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/5/34906/abstract/35\">",
"      Hu H, Hilton MJ, Tu X, et al. Sequential roles of Hedgehog and Wnt signaling in osteoblast development. Development 2005; 132:49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/5/34906/abstract/36\">",
"      Day TF, Guo X, Garrett-Beal L, Yang Y. Wnt/beta-catenin signaling in mesenchymal progenitors controls osteoblast and chondrocyte differentiation during vertebrate skeletogenesis. Dev Cell 2005; 8:739.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/5/34906/abstract/37\">",
"      Hill TP, Sp&auml;ter D, Taketo MM, et al. Canonical Wnt/beta-catenin signaling prevents osteoblasts from differentiating into chondrocytes. Dev Cell 2005; 8:727.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/5/34906/abstract/38\">",
"      Rodda SJ, McMahon AP. Distinct roles for Hedgehog and canonical Wnt signaling in specification, differentiation and maintenance of osteoblast progenitors. Development 2006; 133:3231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/5/34906/abstract/39\">",
"      Glass DA 2nd, Bialek P, Ahn JD, et al. Canonical Wnt signaling in differentiated osteoblasts controls osteoclast differentiation. Dev Cell 2005; 8:751.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/5/34906/abstract/40\">",
"      Holmen SL, Zylstra CR, Mukherjee A, et al. Essential role of beta-catenin in postnatal bone acquisition. J Biol Chem 2005; 280:21162.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/5/34906/abstract/41\">",
"      Winkler DG, Sutherland MK, Geoghegan JC, et al. Osteocyte control of bone formation via sclerostin, a novel BMP antagonist. EMBO J 2003; 22:6267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/5/34906/abstract/42\">",
"      Poole KE, van Bezooijen RL, Loveridge N, et al. Sclerostin is a delayed secreted product of osteocytes that inhibits bone formation. FASEB J 2005; 19:1842.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/5/34906/abstract/43\">",
"      Li X, Zhang Y, Kang H, et al. Sclerostin binds to LRP5/6 and antagonizes canonical Wnt signaling. J Biol Chem 2005; 280:19883.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/5/34906/abstract/44\">",
"      Ellies DL, Viviano B, McCarthy J, et al. Bone density ligand, Sclerostin, directly interacts with LRP5 but not LRP5G171V to modulate Wnt activity. J Bone Miner Res 2006; 21:1738.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/5/34906/abstract/45\">",
"      van Bezooijen RL, Svensson JP, Eefting D, et al. Wnt but not BMP signaling is involved in the inhibitory action of sclerostin on BMP-stimulated bone formation. J Bone Miner Res 2007; 22:19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/5/34906/abstract/46\">",
"      Diarra D, Stolina M, Polzer K, et al. Dickkopf-1 is a master regulator of joint remodeling. Nat Med 2007; 13:156.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/5/34906/abstract/47\">",
"      Bodine PV, Seestaller-Wehr L, Kharode YP, et al. Bone anabolic effects of parathyroid hormone are blunted by deletion of the Wnt antagonist secreted frizzled-related protein-1. J Cell Physiol 2007; 210:352.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/5/34906/abstract/48\">",
"      Ott SM. Sclerostin and Wnt signaling--the pathway to bone strength. J Clin Endocrinol Metab 2005; 90:6741.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/5/34906/abstract/49\">",
"      Gong Y, Slee RB, Fukai N, et al. LDL receptor-related protein 5 (LRP5) affects bone accrual and eye development. Cell 2001; 107:513.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/5/34906/abstract/50\">",
"      Little RD, Carulli JP, Del Mastro RG, et al. A mutation in the LDL receptor-related protein 5 gene results in the autosomal dominant high-bone-mass trait. Am J Hum Genet 2002; 70:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/5/34906/abstract/51\">",
"      Boyden LM, Mao J, Belsky J, et al. High bone density due to a mutation in LDL-receptor-related protein 5. N Engl J Med 2002; 346:1513.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/5/34906/abstract/52\">",
"      Mani A, Radhakrishnan J, Wang H, et al. LRP6 mutation in a family with early coronary disease and metabolic risk factors. Science 2007; 315:1278.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/5/34906/abstract/53\">",
"      Gardner JC, van Bezooijen RL, Mervis B, et al. Bone mineral density in sclerosteosis; affected individuals and gene carriers. J Clin Endocrinol Metab 2005; 90:6392.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/5/34906/abstract/54\">",
"      Shoback D. Update in osteoporosis and metabolic bone disorders. J Clin Endocrinol Metab 2007; 92:747.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/5/34906/abstract/55\">",
"      Keller H, Kneissel M. SOST is a target gene for PTH in bone. Bone 2005; 37:148.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/5/34906/abstract/56\">",
"      Sawakami K, Robling AG, Ai M, et al. The Wnt co-receptor LRP5 is essential for skeletal mechanotransduction but not for the anabolic bone response to parathyroid hormone treatment. J Biol Chem 2006; 281:23698.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/5/34906/abstract/57\">",
"      O'Brien CA, Plotkin LI, Galli C, et al. Control of bone mass and remodeling by PTH receptor signaling in osteocytes. PLoS One 2008; 3:e2942.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/5/34906/abstract/58\">",
"      Bellido T, Ali AA, Gubrij I, et al. Chronic elevation of parathyroid hormone in mice reduces expression of sclerostin by osteocytes: a novel mechanism for hormonal control of osteoblastogenesis. Endocrinology 2005; 146:4577.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/5/34906/abstract/59\">",
"      Fujita K, Janz S. Attenuation of WNT signaling by DKK-1 and -2 regulates BMP2-induced osteoblast differentiation and expression of OPG, RANKL and M-CSF. Mol Cancer 2007; 6:71.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/5/34906/abstract/60\">",
"      Manolagas SC. From estrogen-centric to aging and oxidative stress: a revised perspective of the pathogenesis of osteoporosis. Endocr Rev 2010; 31:266.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/5/34906/abstract/61\">",
"      Ambrogini E, Almeida M, Martin-Millan M, et al. FoxO-mediated defense against oxidative stress in osteoblasts is indispensable for skeletal homeostasis in mice. Cell Metab 2010; 11:136.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/5/34906/abstract/62\">",
"      Jilka RL, Almeida M, Ambrogini E, et al. Decreased oxidative stress and greater bone anabolism in the aged, when compared to the young, murine skeleton with parathyroid hormone administration. Aging Cell 2010; 9:851.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/5/34906/abstract/63\">",
"      Almeida M, Han L, Martin-Millan M, et al. Skeletal involution by age-associated oxidative stress and its acceleration by loss of sex steroids. J Biol Chem 2007; 282:27285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/5/34906/abstract/64\">",
"      Dickinson DA, Forman HJ. Glutathione in defense and signaling: lessons from a small thiol. Ann N Y Acad Sci 2002; 973:488.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/5/34906/abstract/65\">",
"      Almeida M, Han L, Martin-Millan M, et al. Oxidative stress antagonizes Wnt signaling in osteoblast precursors by diverting beta-catenin from T cell factor- to forkhead box O-mediated transcription. J Biol Chem 2007; 282:27298.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/5/34906/abstract/66\">",
"      Almeida M, Ambrogini E, Han L, et al. Increased lipid oxidation causes oxidative stress, increased peroxisome proliferator-activated receptor-gamma expression, and diminished pro-osteogenic Wnt signaling in the skeleton. J Biol Chem 2009; 284:27438.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/5/34906/abstract/67\">",
"      Manolagas SC, Almeida M. Gone with the Wnts: beta-catenin, T-cell factor, forkhead box O, and oxidative stress in age-dependent diseases of bone, lipid, and glucose metabolism. Mol Endocrinol 2007; 21:2605.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/5/34906/abstract/68\">",
"      van der Vos KE, Coffer PJ. FOXO-binding partners: it takes two to tango. Oncogene 2008; 27:2289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/5/34906/abstract/69\">",
"      Hoogeboom D, Burgering BM. Should I stay or should I go: beta-catenin decides under stress. Biochim Biophys Acta 2009; 1796:63.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/5/34906/abstract/70\">",
"      DeCarolis NA, Wharton KA Jr, Eisch AJ. Which way does the Wnt blow? Exploring the duality of canonical Wnt signaling on cellular aging. Bioessays 2008; 30:102.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/5/34906/abstract/71\">",
"      Jin T. The WNT signalling pathway and diabetes mellitus. Diabetologia 2008; 51:1771.",
"     </a>",
"    </li>",
"    <li>",
"     Marotti G, Cane V, Palazzini S, et al. Structure-function relationships in the osteocyte. Ital J Min Electro Metab 1990; 4:93.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/5/34906/abstract/73\">",
"      Manolagas SC, Parfitt AM. What old means to bone. Trends Endocrinol Metab 2010; 21:369.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/5/34906/abstract/74\">",
"      Knothe Tate ML, Niederer P, Knothe U. In vivo tracer transport through the lacunocanalicular system of rat bone in an environment devoid of mechanical loading. Bone 1998; 22:107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/5/34906/abstract/75\">",
"      Wang L, Wang Y, Han Y, et al. In situ measurement of solute transport in the bone lacunar-canalicular system. Proc Natl Acad Sci U S A 2005; 102:11911.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/5/34906/abstract/76\">",
"      Roodman GD. Advances in bone biology: the osteoclast. Endocr Rev 1996; 17:308.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/5/34906/abstract/77\">",
"      Suda T, Nakamura I, Jimi E, Takahashi N. Regulation of osteoclast function. J Bone Miner Res 1997; 12:869.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/5/34906/abstract/78\">",
"      Boyle WJ, Simonet WS, Lacey DL. Osteoclast differentiation and activation. Nature 2003; 423:337.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/5/34906/abstract/79\">",
"      Takayanagi H, Kim S, Koga T, et al. Induction and activation of the transcription factor NFATc1 (NFAT2) integrate RANKL signaling in terminal differentiation of osteoclasts. Dev Cell 2002; 3:889.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/5/34906/abstract/80\">",
"      Ishida N, Hayashi K, Hoshijima M, et al. Large scale gene expression analysis of osteoclastogenesis in vitro and elucidation of NFAT2 as a key regulator. J Biol Chem 2002; 277:41147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/5/34906/abstract/81\">",
"      Xiong J, Onal M, Jilka RL, et al. Matrix-embedded cells control osteoclast formation. Nat Med 2011; 17:1235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/5/34906/abstract/82\">",
"      Emerton KB, Hu B, Woo AA, et al. Osteocyte apoptosis and control of bone resorption following ovariectomy in mice. Bone 2010; 46:577.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/5/34906/abstract/83\">",
"      Yasuda H, Shima N, Nakagawa N, et al. Identity of osteoclastogenesis inhibitory factor (OCIF) and osteoprotegerin (OPG): a mechanism by which OPG/OCIF inhibits osteoclastogenesis in vitro. Endocrinology 1998; 139:1329.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/5/34906/abstract/84\">",
"      Fuller K, Wong B, Fox S, et al. TRANCE is necessary and sufficient for osteoblast-mediated activation of bone resorption in osteoclasts. J Exp Med 1998; 188:997.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/5/34906/abstract/85\">",
"      Simonet WS, Lacey DL, Dunstan CR, et al. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 1997; 89:309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/5/34906/abstract/86\">",
"      Hofbauer LC, Schoppet M. Osteoprotegerin: a link between osteoporosis and arterial calcification? Lancet 2001; 358:257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/5/34906/abstract/87\">",
"      Kearns AE, Khosla S, Kostenuik PJ. Receptor activator of nuclear factor kappaB ligand and osteoprotegerin regulation of bone remodeling in health and disease. Endocr Rev 2008; 29:155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/5/34906/abstract/88\">",
"      Bekker PJ, Holloway D, Nakanishi A, et al. The effect of a single dose of osteoprotegerin in postmenopausal women. J Bone Miner Res 2001; 16:348.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/5/34906/abstract/89\">",
"      Bekker PJ, Holloway DL, Rasmussen AS, et al. A single-dose placebo-controlled study of AMG 162, a fully human monoclonal antibody to RANKL, in postmenopausal women. J Bone Miner Res 2004; 19:1059.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/5/34906/abstract/90\">",
"      Lee NK, Choi YG, Baik JY, et al. A crucial role for reactive oxygen species in RANKL-induced osteoclast differentiation. Blood 2005; 106:852.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/5/34906/abstract/91\">",
"      Yang S, Madyastha P, Bingel S, et al. A new superoxide-generating oxidase in murine osteoclasts. J Biol Chem 2001; 276:5452.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/5/34906/abstract/92\">",
"      Kim MS, Yang YM, Son A, et al. RANKL-mediated reactive oxygen species pathway that induces long lasting Ca2+ oscillations essential for osteoclastogenesis. J Biol Chem 2010; 285:6913.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/5/34906/abstract/93\">",
"      Levasseur R, Barrios R, Elefteriou F, et al. Reversible skeletal abnormalities in gamma-glutamyl transpeptidase-deficient mice. Endocrinology 2003; 144:2761.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/5/34906/abstract/94\">",
"      Bai XC, Lu D, Liu AL, et al. Reactive oxygen species stimulates receptor activator of NF-kappaB ligand expression in osteoblast. J Biol Chem 2005; 280:17497.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/5/34906/abstract/95\">",
"      Lean JM, Jagger CJ, Kirstein B, et al. Hydrogen peroxide is essential for estrogen-deficiency bone loss and osteoclast formation. Endocrinology 2005; 146:728.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/5/34906/abstract/96\">",
"      Garrett IR, Boyce BF, Oreffo RO, et al. Oxygen-derived free radicals stimulate osteoclastic bone resorption in rodent bone in vitro and in vivo. J Clin Invest 1990; 85:632.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/5/34906/abstract/97\">",
"      Ha H, Kwak HB, Lee SW, et al. Reactive oxygen species mediate RANK signaling in osteoclasts. Exp Cell Res 2004; 301:119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/5/34906/abstract/98\">",
"      Bhatt NY, Kelley TW, Khramtsov VV, et al. Macrophage-colony-stimulating factor-induced activation of extracellular-regulated kinase involves phosphatidylinositol 3-kinase and reactive oxygen species in human monocytes. J Immunol 2002; 169:6427.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/5/34906/abstract/99\">",
"      Lean JM, Davies JT, Fuller K, et al. A crucial role for thiol antioxidants in estrogen-deficiency bone loss. J Clin Invest 2003; 112:915.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/5/34906/abstract/100\">",
"      Ishii KA, Fumoto T, Iwai K, et al. Coordination of PGC-1beta and iron uptake in mitochondrial biogenesis and osteoclast activation. Nat Med 2009; 15:259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/5/34906/abstract/101\">",
"      V&auml;&auml;n&auml;nen HK, Zhao H, Mulari M, Halleen JM. The cell biology of osteoclast function. J Cell Sci 2000; 113 ( Pt 3):377.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/5/34906/abstract/102\">",
"      Grigoriadis AE, Wang ZQ, Cecchini MG, et al. c-Fos: a key regulator of osteoclast-macrophage lineage determination and bone remodeling. Science 1994; 266:443.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/5/34906/abstract/103\">",
"      Rodan SB, Rodan GA. Integrin function in osteoclasts. J Endocrinol 1997; 154 Suppl:S47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/5/34906/abstract/104\">",
"      Hughes DE, Dai A, Tiffee JC, et al. Estrogen promotes apoptosis of murine osteoclasts mediated by TGF-beta. Nat Med 1996; 2:1132.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/5/34906/abstract/105\">",
"      Nakamura T, Imai Y, Matsumoto T, et al. Estrogen prevents bone loss via estrogen receptor alpha and induction of Fas ligand in osteoclasts. Cell 2007; 130:811.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/5/34906/abstract/106\">",
"      Martin-Millan M, Almeida M, Ambrogini E, et al. The estrogen receptor-alpha in osteoclasts mediates the protective effects of estrogens on cancellous but not cortical bone. Mol Endocrinol 2010; 24:323.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/5/34906/abstract/107\">",
"      Mentaverri R, Kamel S, Brazier M. Involvement of capacitive calcium entry and calcium store refilling in osteoclastic survival and bone resorption process. Cell Calcium 2003; 34:169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/5/34906/abstract/108\">",
"      Nielsen RH, Karsdal MA, S&oslash;rensen MG, et al. Dissolution of the inorganic phase of bone leading to release of calcium regulates osteoclast survival. Biochem Biophys Res Commun 2007; 360:834.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/5/34906/abstract/109\">",
"      Key LL Jr, Rodriguiz RM, Willi SM, et al. Long-term treatment of osteopetrosis with recombinant human interferon gamma. N Engl J Med 1995; 332:1594.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/5/34906/abstract/110\">",
"      Takayanagi H, Ogasawara K, Hida S, et al. T-cell-mediated regulation of osteoclastogenesis by signalling cross-talk between RANKL and IFN-gamma. Nature 2000; 408:600.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/5/34906/abstract/111\">",
"      Robey, PG. Vertebrate mineralized matrix proteins &mdash; structure and function. Connect Tissue Res 1996; 34-5:185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/5/34906/abstract/112\">",
"      Ducy P, Desbois C, Boyce B, et al. Increased bone formation in osteocalcin-deficient mice. Nature 1996; 382:448.",
"     </a>",
"    </li>",
"    <li>",
"     Frost HM. Bone remodeling and its relationship to metabolic bone diseases, Thomas, Springfield, Ill. 1973.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/5/34906/abstract/114\">",
"      Seeman E. The structural and biomechanical basis of the gain and loss of bone strength in women and men. Endocrinol Metab Clin North Am 2003; 32:25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/5/34906/abstract/115\">",
"      Parfitt AM. Osteonal and hemi-osteonal remodeling: the spatial and temporal framework for signal traffic in adult human bone. J Cell Biochem 1994; 55:273.",
"     </a>",
"    </li>",
"    <li>",
"     Parfitt AM. Skeletal heterogeneity and the purposes of bone remodeling: implications for the understanding of osteoporosis. In: Osteoporosis, Marcus R, Feldman D, Kelsey J.  (Eds), Academic Press, San Diego 1996. p.315.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/5/34906/abstract/117\">",
"      Michael Parfitt A. Misconceptions V--Activation of osteoclasts is the first step in the bone remodeling cycle. Bone 2006; 39:1170.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/5/34906/abstract/118\">",
"      Andersen TL, Sondergaard TE, Skorzynska KE, et al. A physical mechanism for coupling bone resorption and formation in adult human bone. Am J Pathol 2009; 174:239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/5/34906/abstract/119\">",
"      Wang Y, Wan C, Deng L, et al. The hypoxia-inducible factor alpha pathway couples angiogenesis to osteogenesis during skeletal development. J Clin Invest 2007; 117:1616.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/5/34906/abstract/120\">",
"      Wan C, Gilbert SR, Wang Y, et al. Activation of the hypoxia-inducible factor-1alpha pathway accelerates bone regeneration. Proc Natl Acad Sci U S A 2008; 105:686.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/5/34906/abstract/121\">",
"      Nakashima T, Hayashi M, Fukunaga T, et al. Evidence for osteocyte regulation of bone homeostasis through RANKL expression. Nat Med 2011; 17:1231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/5/34906/abstract/122\">",
"      Aguirre JI, Plotkin LI, Stewart SA, et al. Osteocyte apoptosis is induced by weightlessness in mice and precedes osteoclast recruitment and bone loss. J Bone Miner Res 2006; 21:605.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/5/34906/abstract/123\">",
"      Herman BC, Cardoso L, Majeska RJ, et al. Activation of bone remodeling after fatigue: differential response to linear microcracks and diffuse damage. Bone 2010; 47:766.",
"     </a>",
"    </li>",
"    <li>",
"     Manolagas SC. Perspective: Choreography from the tomb: an emerging role of dying osteocytes in the purposeful, and perhaps not so purposeful, targeting of bone remodeling. BoneKey-Osteovision 2006; 3:5.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/5/34906/abstract/125\">",
"      Weinstein RS, Wan C, Liu Q, et al. Endogenous glucocorticoids decrease skeletal angiogenesis, vascularity, hydration, and strength in aged mice. Aging Cell 2010; 9:147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/5/34906/abstract/126\">",
"      Bonewald LF. Osteocytes as dynamic multifunctional cells. Ann N Y Acad Sci 2007; 1116:281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/5/34906/abstract/127\">",
"      McKee MD, Nanci A. Osteopontin at mineralized tissue interfaces in bone, teeth, and osseointegrated implants: ultrastructural distribution and implications for mineralized tissue formation, turnover, and repair. Microsc Res Tech 1996; 33:141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/5/34906/abstract/128\">",
"      Tang Y, Wu X, Lei W, et al. TGF-beta1-induced migration of bone mesenchymal stem cells couples bone resorption with formation. Nat Med 2009; 15:757.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/5/34906/abstract/129\">",
"      Wu X, Pang L, Lei W, et al. Inhibition of Sca-1-positive skeletal stem cell recruitment by alendronate blunts the anabolic effects of parathyroid hormone on bone remodeling. Cell Stem Cell 2010; 7:571.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/5/34906/abstract/130\">",
"      Qiu T, Wu X, Zhang F, et al. TGF-beta type II receptor phosphorylates PTH receptor to integrate bone remodelling signalling. Nat Cell Biol 2010; 12:224.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/5/34906/abstract/131\">",
"      Bilezikian JP, Khan A, Potts JT Jr, et al. Hypoparathyroidism in the adult: epidemiology, diagnosis, pathophysiology, target-organ involvement, treatment, and challenges for future research. J Bone Miner Res 2011; 26:2317.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/5/34906/abstract/132\">",
"      Manolagas SC. Birth and death of bone cells: basic regulatory mechanisms and implications for the pathogenesis and treatment of osteoporosis. Endocr Rev 2000; 21:115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/5/34906/abstract/133\">",
"      Manolagas SC, Kousteni S, Jilka RL. Sex steroids and bone. Recent Prog Horm Res 2002; 57:385.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/5/34906/abstract/134\">",
"      Paddock C, Youngs T, Eriksen E, Boyce R. Validation of wall thickness estimates obtained with polarized light microscopy using multiple fluorochrome labels: correlation with erosion depth estimates obtained by lamellar counting. Bone 1995; 16:381.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/5/34906/abstract/135\">",
"      Dempster DW. Bone histomorphometry in glucocorticoid-induced osteoporosis. J Bone Miner Res 1989; 4:137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/5/34906/abstract/136\">",
"      Yoshida H, Hayashi S, Kunisada T, et al. The murine mutation osteopetrosis is in the coding region of the macrophage colony stimulating factor gene. Nature 1990; 345:442.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/5/34906/abstract/137\">",
"      Zelzer E, Olsen BR. The genetic basis for skeletal diseases. Nature 2003; 423:343.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/5/34906/abstract/138\">",
"      de Vernejoul MC, B&eacute;nichou O. Human osteopetrosis and other sclerosing disorders: recent genetic developments. Calcif Tissue Int 2001; 69:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/5/34906/abstract/139\">",
"      Scimeca JC, Quincey D, Parrinello H, et al. Novel mutations in the TCIRG1 gene encoding the a3 subunit of the vacuolar proton pump in patients affected by infantile malignant osteopetrosis. Hum Mutat 2003; 21:151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/5/34906/abstract/140\">",
"      Waguespack SG, Koller DL, White KE, et al. Chloride channel 7 (ClCN7) gene mutations and autosomal dominant osteopetrosis, type II. J Bone Miner Res 2003; 18:1513.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/5/34906/abstract/141\">",
"      Tolar J, Teitelbaum SL, Orchard PJ. Osteopetrosis. N Engl J Med 2004; 351:2839.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/5/34906/abstract/142\">",
"      Maranda B, Chabot G, D&eacute;carie JC, et al. Clinical and cellular manifestations of OSTM1-related infantile osteopetrosis. J Bone Miner Res 2008; 23:296.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/5/34906/abstract/143\">",
"      Feigin ME, Malbon CC. OSTM1 regulates beta-catenin/Lef1 interaction and is required for Wnt/beta-catenin signaling. Cell Signal 2008; 20:949.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/5/34906/abstract/144\">",
"      Sobacchi C, Frattini A, Guerrini MM, et al. Osteoclast-poor human osteopetrosis due to mutations in the gene encoding RANKL. Nat Genet 2007; 39:960.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/5/34906/abstract/145\">",
"      Henriksen K, Gram J, H&oslash;egh-Andersen P, et al. Osteoclasts from patients with autosomal dominant osteopetrosis type I caused by a T253I mutation in low-density lipoprotein receptor-related protein 5 are normal in vitro, but have decreased resorption capacity in vivo. Am J Pathol 2005; 167:1341.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/5/34906/abstract/146\">",
"      Brunkow ME, Gardner JC, Van Ness J, et al. Bone dysplasia sclerosteosis results from loss of the SOST gene product, a novel cystine knot-containing protein. Am J Hum Genet 2001; 68:577.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/5/34906/abstract/147\">",
"      Loots GG, Kneissel M, Keller H, et al. Genomic deletion of a long-range bone enhancer misregulates sclerostin in Van Buchem disease. Genome Res 2005; 15:928.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/5/34906/abstract/148\">",
"      Jilka RL. Molecular and cellular mechanisms of the anabolic effect of intermittent PTH. Bone 2007; 40:1434.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/5/34906/abstract/149\">",
"      Dempster DW, Cosman F, Parisien M, et al. Anabolic actions of parathyroid hormone on bone. Endocr Rev 1993; 14:690.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/5/34906/abstract/150\">",
"      Dobnig H, Turner RT. The effects of programmed administration of human parathyroid hormone fragment (1-34) on bone histomorphometry and serum chemistry in rats. Endocrinology 1997; 138:4607.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/5/34906/abstract/151\">",
"      Weinstein RS, Underwood JL, Hutson MS, DeLuca HF. Bone histomorphometry in vitamin D-deficient rats infused with calcium and phosphorus. Am J Physiol 1984; 246:E499.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/5/34906/abstract/152\">",
"      Taxel P, Kaneko H, Lee SK, et al. Estradiol rapidly inhibits osteoclastogenesis and RANKL expression in bone marrow cultures in postmenopausal women: a pilot study. Osteoporos Int 2008; 19:193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/5/34906/abstract/153\">",
"      Carani C, Qin K, Simoni M, et al. Effect of testosterone and estradiol in a man with aromatase deficiency. N Engl J Med 1997; 337:91.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/5/34906/abstract/154\">",
"      Lieberman JR, Daluiski A, Einhorn TA. The role of growth factors in the repair of bone. Biology and clinical applications. J Bone Joint Surg Am 2002; 84-A:1032.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/5/34906/abstract/155\">",
"      Chen L, Li C, Qiao W, et al. A Ser(365)--&gt;Cys mutation of fibroblast growth factor receptor 3 in mouse downregulates Ihh/PTHrP signals and causes severe achondroplasia. Hum Mol Genet 2001; 10:457.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/5/34906/abstract/156\">",
"      Chang H, Brown CW, Matzuk MM. Genetic analysis of the mammalian transforming growth factor-beta superfamily. Endocr Rev 2002; 23:787.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/5/34906/abstract/157\">",
"      Weinstein RS, Jilka RL, Parfitt AM, Manolagas SC. Inhibition of osteoblastogenesis and promotion of apoptosis of osteoblasts and osteocytes by glucocorticoids. Potential mechanisms of their deleterious effects on bone. J Clin Invest 1998; 102:274.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/5/34906/abstract/158\">",
"      Miyaura C, Onoe Y, Inada M, et al. Increased B-lymphopoiesis by interleukin 7 induces bone loss in mice with intact ovarian function: similarity to estrogen deficiency. Proc Natl Acad Sci U S A 1997; 94:9360.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/5/34906/abstract/159\">",
"      Kawaguchi H, Nemoto K, Raisz LG, et al. Interleukin-4 inhibits prostaglandin G/H synthase-2 and cytosolic phospholipase A2 induction in neonatal mouse parietal bone cultures. J Bone Miner Res 1996; 11:358.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/5/34906/abstract/160\">",
"      Horowitz MC. Cytokines and estrogen in bone: anti-osteoporotic effects. Science 1993; 260:626.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/5/34906/abstract/161\">",
"      Onoe Y, Miyaura C, Kaminakayashiki T, et al. IL-13 and IL-4 inhibit bone resorption by suppressing cyclooxygenase-2-dependent prostaglandin synthesis in osteoblasts. J Immunol 1996; 156:758.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/5/34906/abstract/162\">",
"      Lin SC, Yamate T, Taguchi Y, et al. Regulation of the gp80 and gp130 subunits of the IL-6 receptor by sex steroids in the murine bone marrow. J Clin Invest 1997; 100:1980.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/5/34906/abstract/163\">",
"      Kimble RB, Bain S, Pacifici R. The functional block of TNF but not of IL-6 prevents bone loss in ovariectomized mice. J Bone Miner Res 1997; 12:935.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/5/34906/abstract/164\">",
"      Baek K, Bloomfield SA. Beta-adrenergic blockade and leptin replacement effectively mitigate disuse bone loss. J Bone Miner Res 2009; 24:792.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/5/34906/abstract/165\">",
"      Kawaguchi H, Pilbeam CC, Harrison JR, Raisz LG. The role of prostaglandins in the regulation of bone metabolism. Clin Orthop Relat Res 1995; :36.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/5/34906/abstract/166\">",
"      M&ouml;dder UI, Achenbach SJ, Amin S, et al. Relation of serum serotonin levels to bone density and structural parameters in women. J Bone Miner Res 2010; 25:415.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/5/34906/abstract/167\">",
"      Bab I, Zimmer A, Melamed E. Cannabinoids and the skeleton: from marijuana to reversal of bone loss. Ann Med 2009; 41:560.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/5/34906/abstract/168\">",
"      Evans DM, Ralston SH. Nitric oxide and bone. J Bone Miner Res 1996; 11:300.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/5/34906/abstract/169\">",
"      Garcia C, Boyce BF, Gilles J, et al. Leukotriene B4 stimulates osteoclastic bone resorption both in vitro and in vivo. J Bone Miner Res 1996; 11:1619.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2053 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-79.122.249.114-59E8FFCE15-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_5_34906=[""].join("\n");
var outline_f34_5_34906=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H1207895\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H593789\">",
"      SKELETAL COMPONENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1206084\">",
"      SKELETAL DEVELOPMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1206092\">",
"      Cartilage proliferation and differentiation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H593737\">",
"      Osteoblasts",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5525058\">",
"      - Differentiation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H593745\">",
"      Runx2",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H593753\">",
"      Wnt signaling pathway",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H594350\">",
"      - Apoptosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H594407\">",
"      Osteocytes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H593827\">",
"      Osteoclasts",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H3804263\">",
"      - Development",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H3804381\">",
"      - Function",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1206099\">",
"      BIOCHEMISTRY OF BONE MINERAL MATRIX",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1207796\">",
"      BONE MODELING AND REMODELING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1206106\">",
"      Modeling",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1206113\">",
"      Remodeling",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H3804279\">",
"      - Bone multicellular unit",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H3804366\">",
"      - Signaling pathways",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1207804\">",
"      - Resorption",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1206120\">",
"      - Reversal",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1206127\">",
"      - Formation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H244951\">",
"      - Mineralization",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1206134\">",
"      ABNORMAL BONE REMODELING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3804447\">",
"      Low bone mass",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3804440\">",
"      High bone mass",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1207811\">",
"      SYSTEMIC AND LOCAL REGULATORS OF BONE CELLS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1206142\">",
"      Parathyroid hormone",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1206149\">",
"      Calcitriol",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1206156\">",
"      Sex steroids",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1206163\">",
"      Calcitonin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1206170\">",
"      Growth hormone and IGFs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5525093\">",
"      TGF-beta",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1206177\">",
"      Glucocorticoids",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1206184\">",
"      Thyroid hormones",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1206191\">",
"      Cytokines",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1206198\">",
"      Fibroblast growth factors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1206205\">",
"      Other",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1207895\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ENDO/2053\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ENDO/2053|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?16/9/16529\" title=\"diagnostic image 1\">",
"      CT image of cancellous bone",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ENDO/2053|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?20/43/21174\" title=\"figure 1\">",
"      Anatomy of cortical bone",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?40/49/41750\" title=\"figure 2\">",
"      Schematic representation of endochondral bone formation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?1/39/1652\" title=\"figure 3\">",
"      Role of the Wnt signaling pathway",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?26/52/27465\" title=\"figure 4\">",
"      Connection between osteocytes and blood vessels",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?40/45/41681\" title=\"figure 5\">",
"      RANKL and ROS-activated signals",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?22/7/22640\" title=\"figure 6\">",
"      Illustration of osteoblast and osteoclast formation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?8/38/8808\" title=\"figure 7\">",
"      Histological image of cortical and cancellous bone",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ENDO/2053|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?12/28/12742\" title=\"picture 1\">",
"      Photomicrograph of a BMU",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/11/17593?source=related_link\">",
"      Bone disease with hyperthyroidism and thyroid hormone therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/33/42519?source=related_link\">",
"      Bone physiology and biochemical markers of bone turnover",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/56/36744?source=related_link\">",
"      Parathyroid hormone secretion and action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/53/3929?source=related_link\">",
"      Pathogenesis of osteoporosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/54/42855?source=related_link\">",
"      Pathogenesis, clinical features, and evaluation of glucocorticoid-induced osteoporosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/42/16041?source=related_link\">",
"      Treatment of hypercalcemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/32/20999?source=related_link\">",
"      Vitamin K, gamma carboxyglutamic acid, and the function of coagulation and other proteins",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f34_5_34907="Prevalence of selected adverse reproductive outcomes in US";
var content_f34_5_34907=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F77872&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=12\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F77872&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=12\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Prevalence of selected adverse reproductive outcomes in the United States",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1\">",
"       Outcome",
"      </td>",
"      <td class=\"subtitle1\">",
"       Percent",
"      </td>",
"      <td class=\"subtitle1\">",
"       Unit of measure",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Infertility",
"      </td>",
"      <td>",
"       8-12",
"      </td>",
"      <td>",
"       Couples",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Recognized spontaneous abortion",
"      </td>",
"      <td>",
"       15-20",
"      </td>",
"      <td>",
"       Women or pregnancies",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Birth weight &lt;2500 g",
"      </td>",
"      <td>",
"       7-9",
"      </td>",
"      <td>",
"       Livebirths",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Preterm (&le;37 wks)",
"      </td>",
"      <td>",
"       11-13",
"      </td>",
"      <td>",
"       Livebirths",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Fetal death or stillbirth",
"      </td>",
"      <td>",
"       0.7-1",
"      </td>",
"      <td>",
"       Stillbirths and livebirths",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Infant death",
"      </td>",
"      <td>",
"       0.7",
"      </td>",
"      <td>",
"       Livebirths",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Birth defects (through 1 year of life)",
"      </td>",
"      <td>",
"       3",
"      </td>",
"      <td>",
"       Livebirths",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Chromosomal anomalies in livebirths",
"      </td>",
"      <td>",
"       0.2",
"      </td>",
"      <td>",
"       Livebirths",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Modified from: Windham, GC, Osorio, AMO. Female reproductive toxicology. Current Occupational &amp; Environmental Medicine, Lange Medical Books/ McGraw- Hill, New York, 2007. p. 387 and compiled from various sources.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_5_34907=[""].join("\n");
var outline_f34_5_34907=null;
var title_f34_5_34908="Clinical manifestations of CBD";
var content_f34_5_34908=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F55825&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F55825&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Clinical manifestations of corticobasal degeneration",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\" class=\"container\">",
"     <tbody>",
"      <tr>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Movement disorders",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Akinesia",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Rigidity",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Postural instability",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Falls",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Freezing of gait",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Postural-action tremor",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Limb dystonia",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Focal reflex myoclonus",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Orolingual dyskinesia",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Athetosis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Chorea",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Rest tremor",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Axial dystonia",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Cerebral cortical signs",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Cortical sensory loss",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Apraxia",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Alien limb phenomenon",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Frontal release reflexes",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Cognitive impairment",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Aphasia",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Behavioral change",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Other manifestations",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Hyperreflexia",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Babinski signs",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Impaired ocular motility",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Impaired eyelid motion",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Dysarthria",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Dysphagia",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Dysphonia",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Riley DE, Lang AE, Lewis A, et al. Cortical-basal ganglionic degeneration. Neurology 1990; 40:1203.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_5_34908=[""].join("\n");
var outline_f34_5_34908=null;
var title_f34_5_34909="Response PC02 increase";
var content_f34_5_34909=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F78945&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F78945&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Response to an increase in the PCO2",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 261px; height: 181px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Although these changes raise the pH toward normal, acid-base homeostasis will not be restored until ventilation is normalized.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_5_34909=[""].join("\n");
var outline_f34_5_34909=null;
var title_f34_5_34910="Metzenbaum dissecting scissors";
var content_f34_5_34910=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F58110&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F58110&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Metzenbaum dissecting scissors",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 180px; height: 454px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Blunt-blunt tips",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_5_34910=[""].join("\n");
var outline_f34_5_34910=null;
var title_f34_5_34911="Proper mechanics centering load";
var content_f34_5_34911=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F76812&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F76812&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Proper mechanics: Center the load when carrying an item",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 287px; height: 381px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Sharon Alzner, MPT.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_5_34911=[""].join("\n");
var outline_f34_5_34911=null;
